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INTRODUCTION
-. i
iANKYLOSING SPONDYLITIS (AS)
Ankylosing Spondylitis or Morbus Bechterew is a chronic inflammatory rheumatic disorder
that primarily effects the axial skeletal.
Sacroiliitis is the hallmark of the disease and causes the most common and characteristic
clinical symptom of AS: chronic inflammatory low back pain and stiffness. This back pain is
often of insidious onset and difficult to localize but most often felt in the sacroiliac region
or deep in the gluteal area. The pain can be quite severe, unilateral or bilateral and may
appear intermittent or more persistent. This inflammatory back pain and stiffness tend to
worsen after prolonged periods of inactivity and therefore pain may wake patients from
sleep. Exercise may improve symptoms of inflammatory back pain and stiffness.
Spondylitis is the process of inflammation of the vertebral ligaments and facet joints and may
lead to ossification of these structures. Pain, progressive loss of spinal mobility and
functional capacity in AS is caused by both spondylitis and ossification. Spinal ankylosis
appears most frequently in rather late stages of the disease and may not occur at all in
patients with mild disease'.
In approximately 25% of AS patients also the peripheral joints are affected in the disease
process especially the shoulders and the hips ('root'-joints)*. Patients may experience arthritis
which causes pain, swelling, stiffness and loss of mobility of the affected joints. Enthesitis is
also a frequent symptom.Typical localizations are at the achilles tendon, plantar fascia, pelvis
and thorax.
Besides these manifestations patients may experience extra-articular features such as acute
anterior uveitis, and inflammatory bowel disease. Clinical manifestations usually begin in late
adolescence or early adulthood and onset after age 45 is rare.
The prevalence of AS in the European population has been reported in several studies to be
approximately 0.1% but a recent study using magnetic resonance imaging techniques estimated
a much higher prevalence of 0.86%*. As many males as females suffer from AS but in female
patients the symptoms are often mild and the disease may not be detected'.Therefore often
three times as many males as females are included in most clinical AS studies.
AS is the most important disease of a specific group rheumatic disorders: the spondyl-
arthropathies (SpA). These rheumatic disorders are classified together because of several
common features such as inflammatory back pain (sacroiliitis, spondylitis), asymmetric
peripheral arthritis predominantly of the lower limbs and the absence of rheumatoid factor.
Other important extra-articular manifestations of SpA are acute anterior uveitis, inflammatory
bowel disease, psoriasis, carditis, conjunctivitis, dactylitis, inflammatory bowel disease,
balanitis and other genital inflammation. Furthermore there is a strong association of SpA
with the class-l molecule HLA-B27'*.The strongest association with the histocompatibility
antigen HLA-B27 is found for AS which is demonstrated in about 90% of cases.The prevalence
of HLA-B27 in the general European population is approximately 7 %. For a first degree
HLA-B27 positive relative of a HLA-B27 positive AS patient the chance to develop AS is up
to 30%*.
OUTCOME VS DISEASE ACTIVITY IN AS
Measuring disease activity and disease progression (outcome) in AS is quite challenging.
Progression of AS varies in rate and patterns, often independent of the degree in which
observed symptoms such as pain and stiffness appear.There is a lot of variety in the clinical
picture of AS therefore it is difficult to picture the whole spectrum of this disease in a
comprehensive way. In contrast to the situation in rheumatoid arthritis, laboratory indicators
of disease activity reflect neither clinical activity nor radiological progression and their use
in AS is controversial*. Furthermore different instruments are used to follow the disease
process in AS but often these instruments are not validated and therefore it is difficult to
compare clinical studies in AS. Because of lack of information on validation of these instruments
it is difficult to prefer one AS instrument over another.
In 1995 an international working group on Assessment in Ankylosing Spondylitis (ASAS)
was formed. In 1997,'core sets' for the following three settings were defined: disease
controlling anti-rheumatic therapy (DC-ART), symptom modifying anti-rheumatic drugs
(SM-ARD)/physical therapy and clinical record keeping'.The domains for all three core sets
are physical function, pain, spinal mobility, spinal stiffness and patient global assessment.The
core sets for clinical record keeping and DC-ART were extended with the domains acute
phase reactants, peripheral joints and entheses.The core set of DC-ART includes also in
addition spine and hip radiographs and fatigue. In a recent update of the core set, it was
decided that the domain fatigue should be included in all three core sets. In 1999 this ASAS
working group selected specific instruments for each core set according to the'OMERACT
(outcome measures in rheumatoid arthritis clinical trials) filter test' for relevance an
feasibility™. For each domain one or more instruments were selected. This selection
procedure was undertaken to diminish the large number of assessments to create uniformity
and comparability in AS clinical trials.There are several outstanding decisions on the optimal
instruments for each domain. This should be based on data of reliability and sensitivity to
change. To achieve this the remaining aspects of the 'OMERACT filter' should be used
concerning truth (validity) and discrimination (reproducibility and responsiveness)*.
n
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As a follow-up of the work of the ASAS working group the present study focuses on —
different aspects of the assessment of disease activity and outcome in AS. S
The objectives of this study were: (I) assess the validity of several widely used instruments a.
in the follow up of AS concerning physical function and laboratory tests focusing on the R
acute phase reaction, (2) develop and assess the reliability of self assessed joint counts in AS, 3(3) investigate on which criteria AS patients and rheumatologists base their opinion on disease '
•o
activity, (4) develop and validate a questionnaire designed to measure quality of life in AS and ^
(5) assess reliability and change over time of existing AS radiological scoring methods. ,o
To study these different objectives we started the Outcome in Ankylosing Spondylitis
International Study (OASIS) in October 1996 conducted in Maastricht/Sittard (the
Netherlands), Ghent (Belgium) and Paris (France). This multicenter open observational
study in AS patients included a total of 217 consecutive outpatients who satisfied the modified
New York criteria'. 137 of these AS patients were included in the Netherlands, 25 in Belgium
and 55 in France. This OASIS study population concerns a cross sectional cohort of AS
patients, followed longitudinally. During the first two years of the study an extended physical
examination and laboratory assessments were done every six months. During this period in
Belgium and the Netherlands the same physician and in France the same research nurse
performed all physical examinations of each individual patient. Furthermore patients were
asked to complete an extended package of self assessment questions concerning stiffness,
pain, disease activity and health status such as disability and impairment biannually.
Radiological assessments were based on yearly visits. Almost all manuscripts from this thesis
are based on data derived from this OASIS study.
The first part of the thesis (chapter 2-5) highlights aspects of disease activity in AS.
In Chapter 2 two widely applied specific physical function indexes used in the evaluation
of AS are compared. The Dougados Functional Index (D-FI) was developed in France and
the Bath Ankylosing Spondylitis Functional Index (BASFI) in the United Kingdom. These
indexes were published in 1988 and 1994 respectively'" "The BASFI consists of 10 questions
on a VAS, all questions deal with activities of daily living. The final score is the average
of the scores of the 10 items. The D-FI consists of twenty 5-point Likert response items,
assessing the ability to perform distinct daily activities.The total score (ranging from 0-40) is
calculated as the sum of the item scores. Physical function in patients with AS is both
related to disease activity and damage. In this study we compared the relation between
these two functional indexes specific for AS with both disease activity and damage
assessments specific for AS. The aim of the study was to investigate if one of these
instruments performed better with respect to the various aspects of validity and should
therefore be preferred.
Chapter 3 concerns the relative value of two laboratory assessments, erythrocyte
sedimentation rate (ESR, mm/h) and C-reactive Protein (CRP, mg/l) in the assessment of
disease activity in AS.The mean values of these two acute phase reactants are considerably
lower in AS than in rheumatoid arthritis". As there might exists differences with respect to
ESR and CRP in AS patients with only spinal involvement and those with active peripheral
arthritis and/or inflammatory bowel disease, we divided the patients into these two groups
for our analyses. Since there is no gold standard for disease activity in AS we studied the
relation of CRP and ESR with three substitute clinical variables; physician assessment of
disease activity and patient assessment of disease activity both on a Visual Analogue Scale
(VAS range: 0 = inactive, 10 = extremely active) and the Bath Ankylosing Spondylitis Disease
Activity Index (BASDAI)^.This index contains six VAS format questions on fatigue, pain of
the spine, pain and/or swelling of the peripheral joints, pain related to enthesitis, and duration
and severity of morning stiffness of the spine.The total score ranges from 0 to 10. Another
aim was to study if elevated CRP or ESR are predictive for active disease defined by the
three selected disease activity variables in AS.
Chapter 4 presents the reliability of patient self-assessment of swollen and painful joints
marked on a mannequin. In AS a minor part of the population has peripheral arthritis (±
25%).Traditionally, either a physician or a well-trained health care professional is involved in
the clinical assessment of arthritis. If joint counts assessed by a physician could be replaced
by self-assessed joint counts, this would lighten the task for rheumatologists in practice and
researchers in particular. This would also make it easier to collect these data more
frequently and even with postal questionnaires. The reliability of patient reported joint
counts for swelling and pain are frequently studied in the assessment of disease activity in
rheumatoid a r th r i t i s ' ' " ' * " " " "™. However the reliability of patient self-reported joint
counts in AS has never been reported.
Chapter 5 describes on which criteria AS patients and rheumatologists base their judgment
on disease activity. In AS it is especially difficult to define disease activity because there is
much variety in the clinical picture among different patients. Patients may only have axial
involvement in all degrees of severity, but may also have extraspinal manifestations.The clinical
diversity, both in severity and in localization, makes a high demand on the instruments that
are supposed to measure disease activity. Furthermore AS patients and rheumatologists
seem to have different understandings about active disease and at the moment no gold
standard is available for measuring disease activity in AS^'. Disease activity from the patient
perspective as well as from the physician perspective was analysed by dichotomising both
patient and physician global disease activity score on a VAS (VAS range: 0 not active and 10
extremely active) into 'high disease activity' and 'low disease activity'.Various AS instruments
selected by the ASAS working group were assessed every six months for two years. Data
reduction by principal components analysis (PCA) was performed to distinguish factors
capturing correlated instruments. Discriminant analysis with the factor loadings was
performed to discriminate between a low-and a high disease activity state for both patient
and physician perspective of disease activity. Multiple regression analysis on the discriminant
scores was performed to prioritise the instruments with respect to their contribution to
each disease activity perspective. Our aim was to explore differences between the
perspective of the patient and the perspective of the physician with respect to AS disease n
activity. ^
Chapter 6 and 7 focus on outcome measures in AS. *
Chapter 6 describes the development of the Ankylosing Spondylitis Quality of Life Z
questionnaire (ASQoL). There is a growing interest in the assessment of quality of life ?
(QoL), particularly in chronic disabling conditions and it is becoming relatively common to §"
measure QoL in studies designed to assess the impact of new pharmaceutical products or 5-
to compare different treatment regimes. AS instruments currently available focus predominantly
on physical impairment and/or physical functioning. Such instruments include: the Bath -g
Ankylosing Spondylitis Functional Index (BASFI)", the D-FI'°, a version of the Stanford §^
Health Assessment Questionnaire modified for the spondylarthropathies (HAQ-S)" and a Z
modified version of the Arthritis Impact Measurement Scales II specific to AS (AS-AIMSII)".
Generic health status instruments such as the Nottingham Health Profile, SF-36 and
EuroQoL*''"^ are available but no disease specific instrument exists for assessing quality of
life (QoL) in AS patients.The ASQoL is a quality of life instrument specific to AS and was
developed in parallel in the United Kingdom and the Netherlands and the content was
derived from interviews with patients in each country.The development methodology used
combines the theoretical strengths of the needs-based quality of life model" with the
statistical and diagnostic power of the Rasch modeP. Our aim was to produce a valid and
reliable AS-specific QoL measure that would be relevant and acceptable to respondents.
In chapter 7 available radiological scoring methods in AS are studied. Radiological damage
is considered an important outcome in AS^.The evaluation of radiological change proves to
be very difficult. Changes of the sacroiliac joints are most frequently scored using the 5
grade New York criteria" or the nearly similar SI score of the Stoke Ankylosing Spondylitis
Spine Score (SASSS)^'.To evaluate the lumbar and cervical spine in AS there are essentially
two different scoring methods.The Bath Ankylosing Spondylitis Radiology Index (BASRI) is
a global graded scoring method,quick and easy to per form"" ' ' ' and was also developed to
score the hips".The several BASRI scores are also combined in composite scores"'''.The
SASSS for the spine is a more detailed scoring method assessing different features such as
squaring, sclerosis and erosions at various locations of each vertebra"". Our aim was to
compare all these available AS radiological scoring methods for reliability and change over
one and two years.
Finally, this thesis ends with a summary and general discussion provided in English and Dutch
in chapter 8 and 9 respectively.
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A COMPARATIVE STUDY OF THE USEFULNESS OF THE
BATH ANKYLOSING SPONDYLITIS FUNCTIONAL INDEX
AND THE DOUGADOS FUNCTIONAL INDEX IN THE
ASSESSMENT OF ANKYLOSING SPONDYLITIS
Anneke Spoorenberg, Desiree van der Heijde, Erik de Klerk, Maxime Dougados, Kurt de Vlam, Herman
Mielants, Hille van deTempel, Sjef van der Linden. .<
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ABSTRACT
Objective: To determine whether the Bath Ankylosing Spondylitis Functional Index (BASFI,
score 0-10) or Dougados Functional Index (D-FI, score 0-40) is superior in measuring physical
function in Ankylosing Spondylitis (AS).
Methods: We studied 191 consecutive outpatients with AS in the Netherlands, France and
Belgium.The participating centers are secondary and tertiary referral centers.The external
criterion for disease activity (DA) was: both patient and physician assessment of disease
activity on a Visual Analogue Scale (VAS) and the Bath Ankylosing Spondylitis Disease
Activity Index (BASDAI).The external criterion for damage were 2 radiological scores of
the spine; BASRI-s (Bath Ankylosing Spondylitis Radiology Index-spine) and a modified
SASSS (Stoke Ankylosing Spondylitis Spine Score).
Results: Median scores for BASFI and D-FI were 2.5 (range: 0-10) and 8.5 (range: 0-35)
respectively. Spearman correlation coefficient between both indexes was 0.89. The average
correlation with disease activity variables was 0.42 for BASFI and 0.41 for D-FI. For both
BASFI and D-FI the correlation with BASRI-s was 0.42 and with SASSS 0.36.When distinguishing
between patients with high and low disease activity, sensitivity for both indexes was between
76% and 94% while specificity was between 66% and 87% for all three DA measures. Average
misclassification between BASFI, D-FI and DA was 23% and 27% respectively.
Conclusion: Both BASFI and D-FI correlate equally well with disease activity and damage.
INTRODUCTION
Two indexes are frequently used to evaluate physical function in ankylosing spondylitis (AS):
the Dougados Functional Index (D-FI) and the Bath Ankylosing Spondylitis Functional Index
(BASFI) published in 1988 and 1994 respectively'". As physical function is both related to
disease activity and damage, we compared the relation between these two functional indexes
and both disease activity and damage. The international Assessment in Ankylosing
Spondylitis (ASAS) working group has included physical function, assessed by D-FI or BASFI,
in the core sets for endpoints for all settings in AS*. Ruof and Stucki reviewed the literature
on the comparative usefulness of both indexes in this issue'. Based upon the literature data,
no definite preference could be identified, although there seemed to be a slight preference
for the BASFI. One problem in the evaluation of the D-FI was that data were only available
with the answers to the items on a three point scale, not on a five point Likert scale. In this
study we used a modification of the D-FI on the 5 point Likert scale.The goal of our cross-
sectional study was to determine whether one of the two functional indexes is superior.
PATIENTS AND METHODS
We included 191 consecutive AS outpatients of the University Hospital Maastricht (the
Netherlands), the Maasland Hospital Sittard (the Netherlands), the University Hospital
Ghent (Belgium) and the Hopital Cochin in Paris (France).These centers are secondary and
tertiary referral centers.
All patients fulfilled the modified New York criteria for AS*. Since physical function reflects
both disease activity and damage the indexes were compared with measures of clinical disease
activity and also with measures of damage.
Because there is no gold standard for disease activity in AS we used three clinical variables
as external criterion for disease activity; physician assessment of disease activity on a Visual
Analogue Scale (VAS, anchored 'no disease activity' at 0 cm and 'very severe activity' at 10
cm), patient assessment of disease activity (VAS, anchored 'no disease activity' at 0 cm and
'very severe activity' at 10 cm) and the Bath Ankylosing Spondylitis Disease Activity Index a-
(BASDAI)'.This index contains six VAS format questions, related to: fatigue, pain of the spine, «•
pain and/or swelling of the peripheral joints and duration and severity of morning stiffness JJ,
of the spine. The total score of the BASDAI ranges from 0 to 10. Three levels of disease •
activity were chosen, using the same cutoff values for all three disease activity variables: a $
score of s 4 meant no active disease, a score between 4 and 6 disease activity was labeled Jj
ambiguous, and a score of a 6 indicated definite disease activity. In our analysis we used only 9
the most contrasting groups where disease activity was defined as definite or no disease ~
activity. -o
Further, we used two radiological damage measures as external criterion for damage. ™
The Bath Ankylosing Spondylitis Radiology Index spine (BASRI-s) grades changes in the
sacroiliac (SI) joints, the lumbar spine and the cervical spine from 0-4, resulting in a scale
ranging from 2 to 12°. The Stoke Ankylosing Spondylitis Spine Score (SASSS) is used to
assess more detailed changes in the lumbar spine both at anterior and posterior sites
(range 0 to 72)'. Creemers et al developed a modified version that scores the anterior sites
of the lumbar and also of the cervical spine'". We used this modified SASSS as this has
shown the best reliability in another study".
The BASFI consists of 10 questions on aVAS, all questions deal with activities of daily living.
The final score is the average of the scores of the 10 items.The version of the D-FI we have
applied consists of twenty 5-point Likert response items, assessing the ability to perform
distinct daily activities.The total score (ranging from 0-40) is calculated as the sum of the
item scores.The BASFI and D-FI were completed by the patients in randomized order (half
of the patients completed BASFI first, other half completed D-FI first).
To deal efficiently with missing values of the D-FI, we assigned the average of the remaining
items to the missing values if no more than 3 items were missing, concordant with the
instructions of the D-FI authors. No corrections were applied to the BASFI.
Statistical analyses
Receiver Operator Curves (ROCs) were plotted for both functional indexes and the three
clinical measures of disease activity. A ROC is a curve of sensitivity (or true positivity) on
the vertical axis and I-specificity (or false positivity) on the horizontal axis '*. The cutoff
value of BASFI and D-FI will be the point on the curve with the highest sensitivity and
specificity, i.e., the highest point in the left upper corner of the graph. Further, the greater
the area under the curve, the greater the diagnostic accuracy of the BASFI or D-FI.
The percentage of patients incorrectly classified according to the cutoff values of the functional
indexes related to clinical disease activity were also computed. For correlations we used
Spearman correlation coefficients.
RESULTS
There were 191 AS patients in our study, two times more males then females. 7ob/e / shows
striking differences between duration of complaints and disease duration (defined as years
since diagnosis), indicating that AS patients have complaints long before the diagnosis is
made.
It is of interest that the median physician based disease activity is only 1.5, while the scores
for patient assessment of disease activity and BASDAI were somewhat higher: 3.6 and 3.9,
respectively. Furthermore the BASRI-s appears to give a relatively higher score for radiological
damage than the SASSS (Tab/e /).
A total of 7 BASFI questionnaires showed one or more missing answers versus 28 of the
D-FI questionnaires. After correction for missing values 24 D-FI questionnaires could be
calculated and analysed.
ob/e /. Study variables (median,
Demographics:
sex (M : F)
Age (years)
Duration of complaints (years)
Disease duration
Clinical Disease Activity (DA)
DA physician (0 - 10)
*4
4.1-5.9
26
missing
DA patient (0 - 10)
s4
4.1-5.9
missing
BASDAI ( 0 - 10)
s4
4.1-5.9
missing
Damage variables:
BASRI-s(2- 12)
Modified SASSS (0-72)
Functional Indexes:
BASFI score ( 0 - 10)
D-FI score (0 - 40)
range, 191 patients)
median (%)
2:1
43
17.9
9.4
variables:
1.7
147
22
10
12
3.9
100
45
44
2
3.7
106
53
26
6
7-0
120
2.5
8.5
(77%)
(12%)
(5%)
(6%)
(52%)
(24%)
(23%)
(1%)
(55%)
(28%)
(14%)
(3%)
range
18- 78
0.3 - 54.4
0.1 -41
0-9 .6
0 - 10.0
0-9 .4
3 - 12
3 - 6 5
0 - 10
0 - 35
As expected both functional indexes were highly correlated (Tob/e 2, see page 20). Correlation
coefficients for both functional indexes and clinical disease activity and damage measures were
comparable. Both showed a higher correlation with the BASDAI than with the other two
clinical disease activity measures.
figures / to 3 (see page 2 /) show the ROC of the two functional indexes and all three clinical
disease activity variables. Figure 3 shows the best curves with the highest sensitivity and
specificity values for both functional indexes and the BASDAI with no real difference between
the functional indexes.The plot lines of Figures / end 2, illustrating the two functional indexes
and the patient or physician assessment of disease activity, are similar. In these curves
Table 2. Spearman correlation coefficients
BASFl
D-FI
BASFl
****
0.89
D-FI
0.89
Clinical Disease Activity variables:
DA physician 0.33
DA patient 0.33
BASDAI 0.59
0.36
0.32
0.57
Damage variables:
BASRI-s 0.42
Modified SASSS 0.36
0.42
0.36
sensitivity and specificity values for the cutoff points are somewhat lower than for the
BASDAI versus the D-FI and the BASFl (ToWe 3).
The cutoff values found with the ROC are provided in ToWe 3.The cutoff values for BASFl
are consistently higher. Nevertheless, there are no real differences in specificity and sensitivity
values for the cutoff points for both BASFl and D-Fl.These values are uniformly rather high
but in most cases there is still a large proportion (12-30%) of patients who are misclassified
for disease activity by these two functional indexes.The proportion of misclassified patients
is lowest (12%) for the cutoff value of the BASFl and clinical disease activity measured with
the BASDAI.
Tob/e 3. Results of cutoff values from the ROCs
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Cutoff values specificity
DA physician
DA patient
BASDAI
BASFl 4.5
D-FI 10
BASFl 3.5
D-FI 8 " "
BASFl 4.5
D-FI 10
73%
70%
73%
" 66%
87%
79%
sensitivity
80%
80%
74%
77%
94%
93%
misclassified
patients
30%
30%
26%
31%
12%
19%
Figure /. Receiver Operator Curve of functional indexes: Bath Ankylosing Spondylitis
Functional Index (BASFI) and Dougados Functional Index (DFI) versus Bath
Ankylosing Spondylitis Disease Activity Index (BASDAI).
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Figure 2. Receiver Operator Curve of functional indexes: Bath Ankylosing Spondylitis
Functional Index (BASFI) and Dougados Functional Index (DFI) versus patient
assessment of disease activity
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Figure 3 . Receiver Operator Curve of functional indexes: Bath Ankylosing Spondylitis
Functional Index (BASFI) and Dougados Functional Index (DFI) versus physician
assessment of disease activity.
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DISCUSSION ^ ;, ,
Both BASFI and D-FI are validated and widely used instruments to assess physical function
in patients with AS.The differences between the two have been described in detail, but no
final choice could be made*. As physical function is a reflection of both disease activity and
damage, we correlated the BASFI and the D-FI with both clinical disease activity measures
and with radiographic damage measures. Because no gold standard is available to assess disease
activity, we used three disease activity variables: disease activity assessed by the physician,
disease activity assessed by the patient and using the BASDAI. A global grading system
including SI joints, cervical and lumbar spine (BASRI-s), and a detailed scoring system of the
lumbar and cervical spine (modified SASSS) were used to assess structural damage. Overall,
both functional indexes correlate highly with each other and correlate about equally with
the disease activity measures and the damage measures.The cutoff values to determine high
versus low disease activity were for the BASFI considerably higher (around 35-45% of the
full scale) compared to the D-FI (around 20% of the full scale). Using these cutoff values
shows that a considerable percentage of patients will be misclassified as having low or high
disease activity if solely based on their functional index scores.The whole scale was used
for BASFI, whereas 35 out of a maximum of 40 was the highest score for the D-FI. More D-FI
questionnaires (28) showed one or more question unanswered, compared to BASFI (7).
Our study has important limitations. Sensitivity to change is an important aspect of a disease
activity measure. This however, can not be analyzed with our cross-sectional data.
Therefore, longitudinal data are needed. Such data will be collected during long term follow
up of the patients in this ongoing observational study. Based upon the results of the present
study, no definite choice can be made between BASFI and D-FI neither for the assessment
of disease activity nor to approximate structural damage of the spine.
0)
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T H E RELATIVE VALUE OF ERYTHROCYTE
SEDIMENTATION RATE AND C-REACTIVE PROTEIN IN
THE ASSESSMENT OF DISEASE ACTIVITY IN ANKYLOSING
SPONDYLITIS
Anneke Spoorenberg, Desiree van der Heijde, Erik de Klerk, Maxime Dougados, Kurt deVlam, Herman
Mielants, Hille van deTempel, Sjef van der Linden.
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ABSTRACT
Objective: Our aim was to determine whether C-reactive protein (CRP) or erythrocyte
sedimentation rate (ESR) is more appropriate in measuring disease activity in ankylosing
spondylitis (AS).
Methods: We studied 191 consecutive outpatients with AS in the Netherlands, France and
Belgium. Patients were attending secondary and tertiary referral centers. The external
criterion for disease activity was: physician and patient assessment of disease activity on a
visual analoge scale (VAS) and the Bath Ankylosing Spondylitis Disease Activity Index
(BASDAI). In each measure we defined three levels of disease activity: no disease activity,
ambiguous activity, and definite disease activity. The patients with AS (modified New York
criteria) were divided into two groups: those with spinal involvement only (n=l49) and
those who also had peripheral arthritis and/or inflammatory bowel disease (IBD) (n=42).
For each criterion of disease activity, the patients with no activity and with definite activity
were included in receiver operator curves and used to determine cutoff values with the
highest sensitivity and specificity.We also calculated Spearman correlations.
Results: The median CRP and ESR were 16 mg/l and 13 mm/h, respectively, in the spinal
group and 25 mg/l and 21 mm/h, respectively, in the peripheral/IBD group. In both groups
the Spearman correlation coefficients between CRP and ESR were around 0.50.There was
moderate to poor correlation between CRP, ESR and the three disease activity variables
(0.06 - 0.48). Sensitivity for both ESR and CRP was 100% for physician assessment of disease
activity and between 44% and 78% for patient assessment of disease activity and the
BASDAI, while specificity was between 44% and 84% for all disease activity measures.The
positive predictive values of CRP and ESR in our setting were low (0.15 - 0.69).
Conclusion: We concluded that neither CRP nor ESR is superior to assess disease activity.
0.
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INTRODUCTION
Both erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) are frequently
used to evaluate patients with ankylosing spondylitis (AS). Assessment of an acute phase
reactant is also a recommended core set endpoint for disease controlling antirheumatic
therapy (DC-ART) and clinical record keeping in AS by the international Assessment in
Ankylosing Spondylitis (ASAS) Working Group'. ESR is usually measured with the
Westergren method. For CRP there is no formal consensus, but the nephelometric and
turbidimetric methods are the most widely used.
Cross-sectional data on the comparison of ESR and CRP show that they are highly correlated.
The mean values of these two acute phase reactants are considerably lower than in rheumatoid
arthritis (RA)*. Data on the correlation of ESR and CRP in the assessment of disease activity
in AS show ambiguous results. One important reason could be that there is no gold standard
for disease activity in AS. Longitudinal evaluations of ESR and CRP are primarily focused on
DC-ART clinical trials. In these proceedings Ruof and Stucki concluded, based on their literature
review, that insufficient data are available to favor either ESR or CRP^.The aim of our cross-
sectional study was to determine whether ESR or CRP is a more appropriate in measuring
disease activity in AS.
MATERIALS AND METHODS
We included 191 consecutive AS outpatients of the University Hospital Maastricht (the
Netherlands), the Maasland Ziekenhuis Sittard (the Netherlands), the University Hospital
Ghent (Belgium) and the Hopital Cochin in Paris (France), all secondary and tertiary referral
centers. All patients fulfilled the modified New York criteria for AS'. Ours was a longitudinal,
observational study with followup visits according to a fixed protocol. In this article only
baseline data are reported. As differences with respect to ESR and CRP in AS patients with
only spinal involvement and those with active peripheral arthritis and/or inflammatory
bowel disease (IBD) may exist, we divided the patients into these two groups. Active peripheral
arthritis was defined as synovitis of at least one large joint (wrist, elbow, shoulder, hip, knee,
ankle) or three or more small joints (hand- and feet joints, sternoclavicular joints). Because g"
there is no gold standard for disease activity in AS we used three substitute clinical variables. <j
Our first choice was physician assessment of disease activity on a 10 cm horizontal Visual w
Analogue Scale (VAS) anchored "no disease activity' at 0 cm and 'very severe activity" at 10 {JJ
cm.The two other clinical disease activity variables were patient assessment of disease activity <
on a VAS anchored 'no disease activity' at 0 cm and 'very severe activity' at 10 cm and the O
Bath Ankylosing Spondylitis Disease Activity Index (BASDAI)\This index contains six VAS ""
format questions on fatigue, pain of the spine, pain and/or swelling of the peripheral joints -o
and duration and severity of morning stiffness of the spine. The total score ranges from 0 *S
to 10.To define whether patients showed unambiguous disease activity or not, we subdivided -J
the continuous scale. We defined three levels of disease activity for all three disease activity
variables. A score of s 4 meant no active disease, a score between 4 and 6 disease activity
was ambiguous, and a score of a 6 meant that there was definite disease activity. In our
analysis we only used the two most contrasting groups where disease activity was defined
as definite or no disease activity.
ESR was assessed using the Westergren method (mm/h; normal range male 0-7, female 0-12)
and CRP by the turbidimetric method (mg/l; normal range 2-9).The lowest detection limit
for CRP was 2 and patients with undetectable levels were assigned 0.
Statistical analyses
To define cutoff values for ESR and CRP to measure disease activity with the best combination
of sensitivity and specificity values we calculated receiver operator curves (ROC) for both
acute phase reactants versus all three clinical disease activity variables in both the spinal and
in the peripheral/IBD group. For these analyses only those patients with no disease activity
and unambiguous disease activity were used as defined above.This was done in a similar way
as described by Wolfe for RA .^ A ROC is a curve of sensitivity (or true positivity) on the
vertical axis and I -specificity (or false positivity) on the horizontal axis. The best cutoff
values for ESR and CRP will be the point on the curve with the highest sensitivity and
specificity, i.e. the highest point in the left upper corner of the graph. Further, the greater
the area under the curve, the greater the diagnostic accuracy of the laboratory test.
We calculated Spearman correlations. Positive predictive values were also calculated for the
defined cutoff points for both ESR and CRP versus the three clinical disease activity variables
in the spinal only and peripheral/IBD groups.The percentages of patients incorrectly classified
according to the cutoff values of the acute phase reactants related to clinical disease activity
were also calculated.
RESULTS
I
a.
U
111
U
There were 149 AS patients with spinal involvement only and 42 patients with active
peripheral arthritis and/or IBD. In both groups the male/female ratio was 2:1.The median
duration of complaints and disease duration was higher in the peripheral group.There was
also a broad range of disease duration (Tob/e /). For the three clinical disease activity variables
the median disease activity was lowest for the assessment of activity by the physician: 1.5
for the spinal group and 2.5 for the peripheral arthritis/IBD group. The median ESR was
significantly higher in the peripheral arthritis/IBD group; 21 mm/h versus 13 mm/h. Although
CRP was also higher in the peripheral/IBD group, the difference was not statistically significant
(Tob/e/, see page 28). Also more patients in the spinal groups showed ESR and CRP values
in the normal range: 55% and 62% respectively, compared to the peripheral/IBD group (38%
and 39%, respectively).This was significantly different between the spinal and peripheral/IBD
Table /: Study variables (median, range)
Number
Demographics:
Sex (male: female)
Age
Duration of complaints
Disease duration
Clinical Disease Activity (
DA physician (0-10)
s4
4.1-5.9
£6
missing
DA patient (0-10)
<;4
4.1-5.9
26
missing
BASDAI (0-10)
s4
4.1-5.9
:>6
missing
Spinal group
149
2:1
40.4 yr.
(19-77)
16.9 yr.
(0.3 - 52.4)
9.4 yr.
(0.3 - 40.7)
DA) variables:
1.5
123
14
5
7
3.9
80
37
31
1
3.6
87
42
16
4
(0 - 9.6)
(83%)
(9%)
(3%)
(5%)
(0-10)
(54%)
(25%)
(21%)
(0%)
(0 - 9.4)
(58%)
(28%)
(11%)
(3%)
Laboratory Disease Activity variables:
ESR mm/hr
CRP mg/l
13* ( 1-118)
16 (0-125)
peripheral
2.5
24
8
5
5
4.1
20
8
13
1
4.3
19
I I
10
2
42
2:1
47.6 yr.
( 22 - 78)
24 yr.
(2 - 53.9)
10.8 yr.
(2.5 • 53.9)
(1-8.7)
(57%)
(19%)
(12%)
(12%)
(i - 10)
(48%)
(19%)
(31%)
(2%)
(3 - 9.4)
(45%)
(26%)
(24%)
(5%)
21* (3-80)
25(0-139)
* p<0.02 unpaired t-test w
s
groups for CRP but not for ESR (chi-squared, p=0.0l and p=0.06, respectively). In the spinal 9
group 18% of the patients showed an elevated ESR and a normal CRP and 12% an elevated
CRP and a normal ESR.These figures were 16% for both pairs in the peripheral/IBD group. "S
The Spearman correlations between ESR and CRP were similar in both groups, 0.50 and £,
0.48, respectively (Tob/e 2, see page JO). The correlations of the two acute phase reactants
Tob/e 2: Spearman correlation coefficients
i
i
ESR
CRP
DA physician
DA patient
BASDAI
spinal group
ESR
****
0.50
0.34
0.31
0.19
CRP
030
****
0.29
0.26
peripheral/IBD group
ESR
****
0.48
0.48
0.31
0.06
CRP
0.48
****
0.39
0.21
0.06
and the three clinical disease activity were considerably lower in both groups, range 0.48 for
ESR versus physician assessment of disease activity in the peripheral arthritis/IBD group to
0.06 for both ESR and CRP versus the BASDAI also in the peripheral arthritis/IBD group
(Tob/e 2).
Figure / shows the ROC of ESR versus CRP against physician assessment of disease activity
in the spinal group, with very low cutoff values for ESR and CRP; 15 mm/hr and 14 mg/l,
respectively.The figure also shows a very large area under the curve (AUC) especially for
ESR suggesting higher diagnostic accuracy of the test but the group considered to have
active disease by the physician comprised 5 patients only. In all other groups there were
more than 16 patients.The other ROC - ESR versus CRP against patient assessment of disease
Tob/e 3: Results of cutoff values from the ROCs
spinal group
positive
.^ . - . . . . misclassified
cutoff value specificity sensitivity predictive
patients
value
DA physician
DA patient
BASDAI
peripheral/IBD
DA physician
DA patient
BASDAI
ESR 15
CRP 14
ESR 15
CRP 10
ESR 6
CRP 12
group
ESR 25
CRP 15
ESR 14
CRP 10
ESR 17
CRP 10
77%
84%
83%
79%
52%
81%
83%
70%
60%
63%
58%
44%
100%
100%
55%
60%
63%
44%
100%
100%
62%
69%
70%
78%
15%
21%
56%
51%
19%
30%
55%
58%
50%
44%
46%
69%
22%
23%
24%
27%
47%
21%
14%
25%
39%
34%
34%
45^
Figure /. Receiver Operator Curve: ESR and CRP versus physician assessment of disease
activity.
—ESR
— CRP
Figure 2. Receiver Operator Curve: ESR and CRP versus patient assessment of disease
activity
— ESR
— CRP
Figure 3. Receiver Operator Curve: ESR and CRP versus Bath Ankylosing Spondylitis
Disease Activity Index (BASDAI).
70 80 90 100
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activity and BASDAI in the spinal group (Figure 2 and 3, see page 3/) - are more or less
identical with low cutoff values and no obvious difference between ESR and CRR However,
AUC are substantial smaller when compared with Figure / (see page 3/) suggesting lower
diagnostic accuracy.The ROC for the peripheral arthritis/IBD group are not shown, but they
express essentially the same trend as shown in the curves of the spinal group.
Tab/e 3 (see page 30) shows the cutoff values, sensitivity, specificity, positive predictive value and
percentage of misclassified patients for the three clinical disease activity variables in both
groups. Classifications of all three clinical disease activity measures in AS patients, with
either no disease activity or with definite disease activity, were compared with the
classification according to ESR or CRR based on the cutoff values of the ROC. In general,
the testcharacteristics sensitivity and specificity are reasonable, but the positive predictive
values - a relevant characteristic in clinical practice - are uniformly low, with large percentages
of misclassified patients.
DISCUSSION
In the spinal group the majority of the patients have normal values of ESR and CRR whereas
the majority of the patients in the peripheral/IBD group have elevated values of ESR and
CRR Also, the level of the ESR and CRP values is higher in the peripheral/IBD group compared
to the spinal group.Thirty percent of the patients in both disease subgroups show either an
elevated ESR with a normal CRP or vice versa.The large majority of these cases show values
just above normal in the acute phase reactant with a value outside the normal range.
Especially in the spinal group many AS patients have normal or slightly elevated values of
ESR and CRP which is in contrast to patients with rheumatoid arthritisMhese findings are
comparable with the results found in most other AS studies*. One reason could be that disease
activity in especially spinal AS is not well reflected in acute phase reactants such as ESR and CRR
The difference in the judgment of disease activity between the physician at one hand and
the patient and BASDAI (also patient based) on the other hand as reflected in quite different
mean values on the same (0-10) scale is quite striking. Physicians classified only 5 patients
as having definite disease activity (VAS a 6), contrasting with 31 and 16 according to the
*2 patients' judgment and BASDAI, respectively. Also the correlations between the disease
« activity defined by the physician and ESR and CRP are considerably higher than those
• between disease activity defined by the patient and BASDAI and ESR and CRP. In the
K peripheral/IBD group the correlations between ESR and CRP and BASDAI are virtually
M absent. It should be stressed that, when judging the DA, the physician was not aware of the
• j ESR or CRP value, because blood for these assessments was taken after the visit to the
JJJ physician.
fc The cut-off values based on the ROC, are only slightly higher for ESR for the peripheral/IBD
* group than for the spinal group for the classification according to the physician and the BASDAI.
O A problem in all this type of studies is that a gold standard for disease activity is lacking.
Most studies on the comparison of ESR and CRP in AS use different definitions of disease
activity*. The results depend heavily on the definition used, as illustrated by this study in
which three definitions for disease activity were applied. Also the disease spectrum in the
sample (i.e. patients with spinal disease only and patients with extraspinal involvement) can
influence the results greatly.
This cross-sectional study confirmed that there is no clear advantage to use either ESR or
CRP in the assessment of AS. Longitudinal data are needed to evaluate whether ESR or CRP
reflect fluctuation in disease activity better and whether one of the two is correlated better
to structural damage.There is a need for validated measures of disease activity in AS.
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ABSTRACT
Objective: To determine the reliability of self-reported joint counts to assess pain or
swelling in ankylosing spondylitis (AS).
Methods: 217 outpatients with AS fulfilling the modified New York criteria were asked to
mark painful and swollen joints on two mannequins presenting 44 and 40 joints respectively.
A doctor or research nurse assessed the same joints for pain and swelling at the same day,
after completion by the patient, without information on the results of the patient's assessment
Results: 21% of the patients reported a I swollen joint (mean number of swollen joints 0.5,
range 0-8); the doctor found a I swollen joint in 54 (25%) of the patients (mean number of
swollen joints 0.8, range 0-31). The overall agreement on the number of swollen joints
between patients and doctor was moderate (intraclass correlation coefficient (ICC) 0.53).
Agreement on individual swollen joints was poor to moderate (kappa 0.1-0.64).
128 (60%) reported tender joints (mean number of painful joints 2.4, range 0-26).The doctors
reported a I tender joint in 50% of the patients (mean number of tender joints 2.2, range 0-
34). The overall agreement was also moderate (ICC 0.71). The agreement on individual
tender joints was again poor to moderate (kappa 0.19-0.42).
There is only high concordance between physicians and patients on the absence of swollen
joints (82%).The concordance on the presence of monoarthritis, oligoarthritis or polyarthritis
is low (17-22%).
Conclusion: Owing to these discrepancies in assessment of individual joints and total
number of affected joints, joint counts in AS assessed by doctors cannot be replaced by joint
counts reported by the patient Patients are only able to judge if their joints are not swollen.
i
INTRODUCTION
In patients with ankylosing spondylitis (AS) a minor part of the population has peripheral
arthritis (± 20%). Traditionally, either a doctor or a well-trained health care professional is
involved in the clinical assessment of arthritis.The reliability of joint counts for swelling and
pain reported by the patients is often studied in the assessment of disease activity in
rheumatoid arthritis (RA).To evaluate these joint counts different methods have been used.
Some authors'-" used mannequins to mark painful or swollen joints, Hanly et al used a
questionnaire (modified version of the rapid assessment of disease activity in rheumatology
(RADAR) questionnaire)^ and some authors evaluated b o t h " " ' " " . T h e reported study
results were ambiguous but there were no differences in the results related to the method
used. Some authors reported good reliability and suggested that patients' self-reported joint
counts can be used to measure disease activity in R A ' " - ' ° " . Others found moderate to
poor reliability and suggested that joint counts derived by the patients can be used but are
not interchangeable with joint counts reported by doctors*-''-*-*. As far as we know reliability
of patient reported joint counts in AS has not been studied. Our aim was to determine the
reliability of self reported swollen joint counts and tender joint counts marked on a
mannequins by patients with AS.
PATIENTS AND METHODS
The study sample comprised consecutive outpatients with AS at the University Hospital
Maastricht.The Netherlands, the Maasland Ziekenhuis Sittard.The Netherlands, the University
Hospital Ghent, Belgium, and the Hopital Cochin, Paris, France. These hospitals are
secondary and tertiary referral centers. All patients fulfilled the modified New York criteria
for AS'* and are participating in a longitudinal, observational study with follow-up visits
according to a fixed protocol. The patients were asked to mark the painful joints on a
mannequin presenting 44 joints (F/'gure /, see page 38) and the swollen joints on a mannequin a*
presenting 40 joints (Figure /j.The mannequin diagram was designed after the method of j
Stewart et aP. Shoulder and hip joints were not represented on the swollen joint mannequin *,
because it is very difficult to see swelling of these joints, especially by untrained people. At rf
the same day but after the patient assessment, two doctors and one research nurse, one jj
person per participating center, assessed the joints for pain and swelling.These results were 5
reported on similar mannequins without knowledge of the patients' assessments. Data were 2.
collected at yearly intervals. In this paper the results of the baseline and one year data are 2.
presented. - £
Statistics *
Reliability was determined by the Intra Class Correlation Coefficient (ICC, type 3.1) and -o
kappa statistic. Kappa was used for between rater agreement on categorical data such as T?
the individual joints scores. ICC was used for overall agreement on linear data such as the »i
figure /. Joint figure
I. Please indicate with a mark on the picture
below all joints that are painfull at present.
2. Please indicate with a mark on the picture
below all joints that are swollen at present.
RIGHT
Sternal
clavicular joints
Hip joint
LEFT
Shoulder joint
RIGHT
Finger joints
LEFT
Sternal
'clavicular joints
Elbow joint
Toe joints
total number of tender and swollen joints.To visualise this overall agreement we plotted the
data using the method of Bland and Altman" and calculated the 95% limits of agreement.
This method is also designed as an absolute measure of agreement between two
instruments which are on the same scale of measurement. To visualize this, the difference
between two observations is plotted against the mean of the pairs of observations.
Furthermore Spearman's correlation coefficients were computed for data without a normal
distribution. All analyses were done with SPSS 10.0 for Windows.
RESULTS
There were 217 outpatients in our study, with a male to female ratio of 2:1. Tob/e / describes
the demographic and clinical features of all patients. Sixty one (28%) patients had finished
more than secondary school and 39 (18%) attended elementary school only. In 58 (27%)
patients peripheral arthritis was diagnosed by the treating rheumatologist. Psoriasis was
diagnosed in 10 (4.6%) of the patients and dactylitis in 20 (9.2%) during the whole course
of the disease. The mean score of Bath Ankylosing Spondylitis Disease Activity Index,
(BASDAiy and the Bath Ankylosing Spondylitis Functional Index (BASFI)", indicate an
Tab/e /. Characteristics of the patients (n = 217 ) presented as mean
(SD, min.-max.) or percentage
age (years)
male
disease duration since diagnosis(yrs)
reported peripheral arthritis*
reported psoriasis*
reported dactylitis*
formal education > 12 yrs
s6 yrs
BASRI t(patients with a 3
syndesmophytes at lumbar and /or cervical
spine)
BASDAI+t (range 0-10)
BASH w (range 0-10)
Mander enthesis index (range 0-90)
43 (12, 18-77)
67%
9.2 (8.6,0-42)
27%
4.6%
9.2%
28%
18%
43%
3.5(2.1,0-9.7)
3.4(2.6,0-10)
7.7(11.1,0-56)
* Diagnosed by treating rheumatologist, ever during the disease course
• Bath Ankylosing Spondylitis Radiology Index
•t Bath Ankylosing Spondyitis Disease Activity Index
™ Bath Ankylosing Spondylitis Functional Index . , ^ ,« , , , , ^ -> , , . v , * ^ . , - . - . .,v4'•,,,**.*£; .-•>,
overall mild disease activity and mild functional impairment of this group patients with AS.
The mean score of Bath Ankylosing Spondylitis Radiology Index (BASRI), of the lumbar and
cervical spine", was 1.9 (range 0-4) with 93 (43%) patients having at least 3 syndesmophytes
at the lumbar and /or cervical spine indicating moderate to severe damage. The enthesis
index according to Mander" was also computed with a mean score of 7.7 (range 0-90) at 3"
baseline (7ob/e/j "S
For baseline and one year data, both patients and doctors reported more tender than ^
swollen joints (Tob/e 2, see page 40).The average tender joint count and swollen joint count <f
were comparable between doctors and patients; however, there was a striking difference in g
the maximum number of swollen joints scored by the doctors (31) compared with the j *
number scored by the patients (8).The overall between observer agreement (ICC) between 2_
the patients and doctors for the total number of tender joints was moderate (0.71 and 0.54 1 !
for baseline and one year respectively) and was slightly worse on the total number of £
swollen joints (0.53 and 0.51 for baseline and one year respectively). There was no c
difference in agreement between patients and the two doctors and patients and research «
nurse for both swollen joint counts (0.53 and 0.54 respectively) and tender joint counts -o
(0.71 and 0.70 respectively). In general, the baseline and one year data were very similar. For ^
the remaining analyses we present baseline data only. By contrast with RA, most patients Io
Tobfe 2. Summary statistics of total number of tender and swollen joints (n=2l7)
physician patient inter-observer
mean mean agreement
(median, percentiles 10 (median, percentiles 10 (ICC)
and 90) and 90)
tender joints . ; > > • : > , , . .
baseline 2.2 (1.0,0.0-7.0) 2.4 (1.0,0.0-6.0)
I-year follow-up 2.1 (0.0,0.0-7.0) 3.1 (2.0.0.0-8.7)
0.71
0.54
swollen joints
baseline
I -year follow-up
0.8 (0.0,0.0-2.0)
0.5 (0.0,0.0-1.0)
0.5 (0.0,0.0-2.0) 0.53
0.5(0.0,0.0-2.0) 0.51
with AS have just a few inflamed joints. Therefore we analyzed the data also in a different
way: the number of patients with none, one, two or three, or more than three swollen joints
(Tob/e 3).The doctors found one or more swollen joints in 54 of 217 (25%) patients whereas
44 of 214 (21%) of the patients reported one or more swollen joint. These percentages
were very similar. However, this is misleading as there was low concordance on one or more
swollen joints between the patients and doctors (51 %). So the patients who judged that they
had one or more swollen joint were often different from those judged by the doctor to have
swollen joints. When the doctors' assessment was used as the gold standard, our results
indicate that AS patients can judge whether their joints are not swollen (specificity 93%) but
have difficulty judging one or more swollen joint (sensitivity 61%).
"S
tft
tfl
I
I
Tob/e 3. Number of painful and swollen joints, concordance and distribution of'root'-joints' ,J
Affected
joints
; ? * > < • . : .
0
I
Painful
physician
30
patient
86
26
Swollen
perfect 'root' physician
concordance joints
53%
12%
162
80% 22
patient
170
20
perfect 'root'
concordance joints
82%
17% 50%
mono-arthritis
2 or 3 30 patients 49 patients 23%
oligo-arthritis 70 joints I 15 joints
>3 47 patients 53 patients 47%
poly-arthritis 320 joints 372 joints
63% 20 patients 14 patients 17% 50%
48 joints 32 joints
27% 12 patients 10 patients 22% 0%
97 joints 54 joints
' 'root' joints are schoulders, hips and sternal-clavicular joints. Only sternal-clavicular joint were
scored at the swollen joint figure.The % of ' root ' joints are given of the concordant paires.
7bb/e 4. Levels of agreement on individual joints
sternoclavicular
shoulder
elbow
wrist
hand (mcp.pip)
hip
knee
ankle
foot (mtp)
left
0.38
0.42
0.43
0.37
0.73*
0.26
0.42
0.40
0.72*
tender joints
right
0.23
0.27
0.30
0.32
0.62*
0.19
0.34
0.27
0.57*
* Intra-class Correlation Coefficient (because of
(kappa)
left
0.53
-
0.1
0.48
0.05*
-
0.52
0.48
0.64
linear data)
swollen joints
right
0.36
-
0.1
0.48
0.25*
-
0.50
0.49
0.23
According to the doctors 50% of patients had one or more tender joint as opposed to 60%
according to the patients. Again the concordance on assessing one or more tender joint was
rather low (60%). Sensitivity of the patients' judgement on tender joints was rather high
(82%) but the specificity was low (62%).
Tab/e 3 shows the number of tender joints and swollen joints and concordance rate of
patients and doctors if the assessed joints were split into four categories: no arthritis,
monoarthritis.oligoarthritis.or polyarthritis.The only high concordance rate found was 82%
(category, non-affected swollen joints) again suggesting patients could only judge whether
their joints were not swollen. The other concordance rates were at best moderate but
overall they were low.
The distribution of monoarthritis and oligoarthritis according to the doctors gave more or
less the expected distribution in AS patients (Tab/e 3). In tender joints we found 53% and jj"
34% involvement of roo t joints (shoulders and hips) and mostly large joints were affected JJ
instead of small joints of hand and feet. *.
Analysis by kappa statistics showed moderate to poor and non-consistent agreement ».
between doctor and patients on individual joint counts for either pain o r swelling (Tab/e 4). jj»
Because there were only very few affected small joints in the hand and feet we clustered 2
these for statistical analysis using ICC instead of kappa statistics. 2.
Figure 2 (see page 42) shows the Bland and Al tman plot of the total number of tender joints. 1 .
There was a maximum difference of 25 joints between the doctors and the patients on the £
scoring range of 0 t o 40; the 95% limits of agreement of the difference is 6.2 (1.96*SD). It g
also shows that the doctors consistently scored somewhat lower as the patients (mean <•
difference -0.4). The Bland and Al tman plot of the total number of swollen joints showed -o
similar results (Figure 3, see page 42). However, now the doctors scored consistently TS
somewhat higher than the patients.There was one outlier, which showed a difference of 26 —
Figure 2. Bland and Altman: mean versus difference of patient and physician; total number of
tender joints.
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Figure 3. Bland and Altman: mean versus difference of patient and physician: total number of
swollen joints
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mean physician and patient swollen joints
I patient, every dash represents an extra patient
I .96*SD = 4.5
mean difference = 0.28
20
swollen joints between doctor and patient. Both Bland and Altman plots showed the
influence of the number of affected joints: by increasing number of affected joints, the .
disagreement between patient and physician was slightly larger although this is based on few
patients.
We also computed Spearmans' correlations of the total number of tender and swollen
joints judged by doctors and the patients with the enthesis index according to Mander et
al at baseline and dactylitis.The highest correlation found was 0.66 of physician painful joints
with the enthesis index.The correlations of swollen joints assessed by doctors and tender
and swollen joints assessed by the patient with the index of Mander et al were 0.38, 0.41
and 0.30 respectively. Correlations with dactylitis were low; 0.23 for both tender and
swollen joints assessed by the doctors and 0.27 and 0.23 for tender joints assessed by the
patients.
Discussion
Collecting accurate and reproducible information from patient in routine rheumatology
practice, epidemiological surveys, and clinical trials often is labour intensive and time
consuming.This is one of the reasons for an increased use of self administration forms such
as questionnaires on function, disease activity, and quality of life to assess the course and
outcome of the disease. If joint counts assessed by doctors could be replaced by joint
counts assessed by the patients, this would again lighten the task for rheumatologists in
practice and researchers in particular. It would also make it easier to collect these data more
often and even with postal questionnaires. However, to be able to replace joints derived by
doctors with joint counts derived by patients, the validity of the second needs to be
assessed. So far, studies comparing results from patients with those from doctors have only
been carried out on patients with RA. Five of these studies showed good reliability' *•'•'"•"
by contrast with four that showed only poor to moderate reliability"-".The authors from ="
the second group of studies concluded joint counts derived by patients could be used, but g
were not interchangeable with those derived by doctors. Furthermore, reliability for swollen *.
en tender joint counts were the same' " or slightly better for assessing tender joints". j f
As far as we know, this is the first study in AS to compare the patient's assessment of tender g>
and swollen jo int count w i th that o f the doc to r as a gold standard. A major difference between U
patient w i th RA and those w i th AS is the fact that in RA all patients' peripheral joints are 2.
affected, although to a different degree during the course of the disease. In AS patients only 2.
about 20 t o 30% of the patients have involvement o f peripheral joints. Roo t joints are involved £
in about 30% of patients and this is relatively more common in those w i th juvenile onset A S " . c
Moreover, if patients w i th AS have involvement of peripheral joints, this is often to a lesser «
extent than patients w i th RA and often a different pat tern of joints is involved. -o
O u r results show that, on a g roup level, there is a consistent difference between the number *S
of tender and swol len jo ints assessed by the patients o r by the doc to rs .The patients score w
consistently more tender joints, and the doctors more swollen joints. An explanation for
the first finding could be that it is difficult for patients to differentiate between a tender joint
and pain caused by enthesitis, although according to our data the enthesis index of Mander
et al was only significantly correlated with total number of tender joints assessed by the
doctor. This was possibly because both assessments use the same methodology and most
peripheral entheses are located near the joint. The second finding could be caused by the
fact that patients with AS are not educated as to what a swollen joint means. From the
group level results it could be concluded that absolute scores assessed by patients can not
replace those assessed by doctors. If we look on a patient level, the results are even worse.
The 95% limits of agreement were +/- 6.2 for tender joints indicating that there may be a
difference of 12 joints between the patient and doctor assessment, whereas there is no real
difference. For the swollen joints the 95% limits of agreement were +/- 4.5.
Although, actual joint counts assessed by a doctor cannot be replaced by self-assessed joint
counts, self assessment could still be valuable if the patients could differentiate between
absence of arthritis and presence of monoarthritis, oligoarthritis, or polyarthritis. Again the
concordance rates were very low for all groups of tender joints, and for the various levels
of swollen joints. The only good concordance rate was in the absence of swollen joints.
Consequently, patients are able to tell if they do not have swollen joints. However, if they
have swollen joints, they are unable to judge the extent of the swelling, even within rough
categories of monoarthritis, oligoarthritis and polyarthritis. Perhaps further studies could
investigate if training of the patients would make a difference.
A limitation of our study is that we did not assess test-retest reliability formally. However,
the results obtained at baseline and after one year of follow-up showed very similar results,
indicating good reliability.
Our study results show major discrepancy between the number of tender and swollen
joints assessed by a doctor or the patient. Therefore, joint scores derived by doctors can
not be replaced by self assessed joint scores in AS.The only reliable result is the judgment
of the patient that no joints are swollen.
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ABSTRACT
Introduction: There is no 'gold standard' to assess disease activity in patients with
ankylosing spondylitis (AS). It is known that patients and physicians have different opinions
about disease activity.
Objective: To investigate on which criteria patients with AS, and physicians base their
judgement on disease activity.
Patients and methods: A cohort of 203 AS outpatients fulfilling the modified New York
criteria included in the ongoing long-term follow-up was analysed. The Assessments in
Ankylosing Spondylitis working group (ASAS) has established different domains relevant for
outcome in AS. Each domain includes a number of instruments for making assessments, and
all these instruments are included in OASIS and were made every six months for two years.
Disease activity from the patient perspective as well as from the physician perspective was
analysed using the patient's- or the physician's global assessment of disease activity (Visual
analogue scale (VAS):0 (best)-10 (worst)) by dichotomising into'high disease activity' (VAS a 6.0)
and 'low disease activity' (VAS s 4.0). Data reduction by principal components analysis
(PCA) was performed to distinguish factors capturing correlated instruments. Discriminant
analysis with the factor loadings was performed to discriminate between a low disease and
a high disease activity state from both the patient- and the physician perspective. Multiple
regression analysis on the discriminant scores was performed to prioritise the instruments.
Results: PCA revealed four factors: spinal mobility, physician assessments, patient
assessments, and laboratory assessments (Cronbach's alpha: 0.52-0.80; explained variance:
61%). Discriminant function analysis showed that the factor 'patient assessments' was most
important (pooled correlation: 0.85) in discriminating between a low-and a high disease
activity state as defined by the patient.The other 3 factors contributed marginally (pooled
correlation: < 0.30). In contrast, the factors 'physician's assessments' (pooled correlation:
0.62), 'spinal mobility' (pooled correlation: 0.52) and 'laboratory assessments' (pooled
correlation: 0.48) contributed most to the physician perspective. The factor 'patients
assessment' did not contribute at all (pooled correlation: 0.05). Multivariate analysis showed
that the patient perspective of disease activity was best captured by the instruments 'pain
spine", 'BASFI', 'pain joints' and BASDAI fatigue'. The physician's perspective was best
captured by'cervical rotation','swollen joint count','CRP' and 'intermalleolar distance'.
Conclusion: AS patients rate disease activity on the basis of complaints while physicians
rate disease activity on the basis of instruments related to disease severity and inflammation.
INTRODUCTION
In most rheumatological disorders, disease activity and outcome cannot be measured by
one single variable. In clinical practice the opinion about disease activity and outcome is
based on different sources of information, such as patient complaints, clinical variables,
laboratory variables (acute phase reactants) and imaging. All this information is compiled
into an overall impression of disease activity.
Patients and physicians may think differently about how to define disease activity. In judging
whether their disease is active or not, patients may rate their complaints higher than eg
abnormal laboratory results, or rapidly progressive damage on X-rays, whereas physicians
will tend to give weight to the latter observations, irrespective of patient complaints.
In ankylosing spondylitis (AS) it is especially difficult to define disease activity because there
is much variety in the clinical picture among different patients. Patients may only have axial
involvement in all degrees of severity, but they may also have extraspinal manifestations,
such as enthesitis and joint inflammation or inflammation of the gastrointestinal tract. The
clinical diversity, both in severity and in localization, makes a high demand on the
instruments that are supposed to measure disease activity and outcome in AS. Since there
is no gold standard available for measuring disease activity and outcome, many different
instruments have been developed to assess a variety of signs and symptoms in AS. Some of
these instruments emphasize the patient perspective of disease activity or disease outcome,
whereas others represent the physician's point of view. Acute phase reactants such as C-
reactive protein (CRP) and erythrocyte sedimentation rate (ESR) are considered more
objective. In AS their value in determining whether the disease is active or not is rather
limited. Elevated CRP-levels and ESR are frequently absent in AS and do not correlate well
with clinical activity and radiological progression'-*. ^
In 1999, a core set to assess outcome in AS was selected by the 'Assessment in Ankylosing w
Spondylitis' (ASAS) working group.This AS outcome core set consists of different domains »
with specific instruments for each domain^. It includes instruments that are supposed to "•
primarily measure the patient's perspective as well as the physician's perspective regarding 2j
disease activity and outcome. "S
The objective of this study was to explore differences between the perspective of the 5'
re
patient and the perspective of the physician with respect to disease activity. We £
hypothesized that patients with AS will rate the activity of their disease primarily on the o.
basis of their complaints, whereas the treating physicians will use other parameters on g
which to base their judgment. *
PATIENTS AND METHODS
For this study data derived from the OASIS cohort (Outcome in Ankylosing Spondylitis
International Study) were used. The OASIS project is an international longitudinal
observational multicenter study performed at the rheumatology outpatient department of
the University hospital in Maastricht (the Netherlands), the Maasland hospital in Sittard (the
Netherlands), Hopital Cochin in Paris (France) and the University hospital in Ghent
(Belgium). In total, 203 AS outpatients who satisfied the modified New York criteria'' were
included in this study. 73% of patients were male, a distribution usually found in AS
populations. The mean age at baseline was 43 (SD: 13) years. The mean duration of disease
since diagnosis is I I (SD: 8) years. 27% of the patients had a history of peripheral arthritis
diagnosed by their treating rheumatologist. At each institution the same trained person (2
rheumatologists, I research nurse) assessed all patients every six months according to a
pre-specified protocol. All patients were followed by their rheumatologists, independent of
the evaluations of the researchers.
Assessments
The following assessments were made every 6 months for the first two years of the OASIS
study: physician spinal pain assessment (0= no pain on firm palpation, percussion and on
extreme motion of complete spine. No spasm, 1= slight pain on firm palpation, percussion
or motion of complete spine and no more than slight limitation of motion, 2= moderate
pain on moderate palpation, percussion or motion of complete spine and no more than
slight limitation of motion, 3= moderate to severe pain on light palpation, percussion or
slight motion of complete spine and moderate to severe limitation of motion, 4= extreme
pain with inability to withstand even light palpation or percussion and essentially no mobility
of spine) (FDA guidelines).The best of two tries was documented in case of: chest expansion
(cm)', finger to floor (cm)', occiput to wall (cm)(FDA guidelines), tragus to wall (cm)',
modified Schober test (cm)*, cervical rotation (d°)', lateral spinal flexion (cm)'" and
intermalleolar distance (cm)"Tragus to wall, modified Schober test,cervical rotation, lateral
spinal flexion and intermalleolar distance were combined to compute the Bath Ankylosing
Spondylitis Metrology Index (BASMI)'l Other physician derived assessments were: the
articular index according to Dougados (range 0-30)'^, enthesis index according to Mander
(0-90)''', Maastricht Ankylosing Spondylitis Enthesis Score (MASES) (range 0-13)", physician
assessment of disease activity on a visual analogue scale of 10 cm (VAS, 0 = not active, 10 =
extremely active), physician assessment of the number of tender joint (range 0-44) and
swollen joints (0-40)*.
Patient derived assessments were: duration of morning stiffness of the spine (min), duration
of morning stiffness of the peripheral joints (min), pain of the spine (VAS, 0 = no pain, 10 =
unbearable pain), pain of the peripheral (VAS, 0 = no pain, 10 = unbearable pain), patient
assessment of disease activity (VAS, 0 = not active, 10 = extremely active), fatigue (VAS,
0=not at all, IO=extremely), Bath Ankylosing Spondylitis patient Global Score (BASG) (VAS,
0 = no influence of AS on global wellbeing during the past week, 10 = global wellbeing
ij completely influenced by AS during the past week)", patient assessment of night pain (range
9" 0 = no pain, 4 = extremely painful during the whole night), Bath Ankylosing Spondylitis
O Disease Activity Index (BASDAI) (range 0-10)", Bath Ankylosing Spondylitis Functional
Index (BASFI) (range 0-10)" and Dougados Functional Index (D-FI) (range 0-40)". The
fatigue question of the BASDAI was used as a single variable for further analysis of the
domain fatigue. The laboratory assessments were: erythrocyte sedimentation rate (ESR,
mm/h)) and C-reactive protein (CRP, mg/l).
All measurements were obtained to follow the course of ankylosing spondylitis.
Analysis
First, all selected variables were assessed for their suitability for parametric statistical
analysis.Variables with a skewness statistic a I were logarithmically transformed in order to
obtain a reasonably normal distribution.
If mutual correlation of the selected instruments was high (Pearson correlation coefficient
> 0.6), it was assumed that these variables assess the same process (collinearity)To diminish
collinearity we chose one of the two variables with high Pearson correlation for further
analyses.
Data reduction
In order to structure the large number of instruments and to identify underlying constructs
(factors), principal components analysis (PCA) (SPSS 10.0.7 factor analysis, rotation-
varimax) was performed on two subsets of all patients: those with active disease from the
patient perspective (I) and those with active disease from the physician perspective (2).
Active disease from the patient and physician perspective was defined as a score of a 6.0
(VAS) and low disease activity was defined as s 4.0 (VAS) on the instruments 'patient's global
assessment of disease activity' and 'physician's global assessment of disease activity' respectively
(VAS range: 0 = not active to 10 = extremely active). Factor loadings were saved in order
to use in further statistical analysis. Internal consistency of the resulting factors was
calculated using Cronbach's alpha. nI
Discriminant function analysis and linear regression analysis "*
To investigate whether and how the constructs (factors) could discriminate between low 2j
and high disease activity from patient and physician point of view, discriminant function »
analyses using the factor loadings were performed for both perspectives. Pooled 5"
correlations were used to judge the relative contribution of each factor to the discriminant £
function.To test the robustness of the observations, the same analyses were performed for o.
different time points of the study . 2
Subsequently, linear regression analysis with stepwise selection of the variables was *
performed, in order to rate the relative contribution of every single instrument to the §.
variability in individual discriminant scores. ,$'
Tbb/e /: Mean, standard deviation (SD), median, inter quantile range (IQR),
minimum, maximum and skewness before and after transformation of
baseline data from OASIS population (patients n=203).
mean, SD median, IQR min.-max.
chest expansion (cm) 4.7,2.2 4.4, 3.0 - 6.0 0.4 - 12.5
finger to floor (cm) 14.6, 13.8 12.9, 1.0 - 22.7 0.0 - 56.5
cervical rotation (d°) 63.9,23.2 68.0,50.3-80.8 3.3-107.0
lateral spinal flexion
(cm)
intermalleolar
distance (cm)
occiput to wall (cm)
physician spinal pain
assessment (0-4)
ph/sician swollen
joints (0-40
physician painful
joints(0-44)
physician assessment
of disease activity
(VAS0-I0)
Articular Index
Dougados (0-20)
pain spine patient
(VAS0-I0)
pain joints patient
(VAS0-I0)
patient night pain
(0-4)
BASFI (0-10)
BASDAI fatigue
(VAS0-I0)
patient assessment
of disease activity
(VASO-10)
ESR mm/h
CRP mg/l
10.9,5.9 10.8,6.8-15.2 0.0-26.1
104.5,21.7 106.0,93.0-118.0 15.2-150.0
3.8, 5.6
0.9,0.9
0.8, 2.6
3.3,5.0
2.1, 1.5
2.7, 3.3
3.5,2.4
3.0.2.6
1.2,0.8
3.4, 2.9
4.5, 2.9
3.8,2.8
14.3, 16.0
17.8,24.9
BASDAI total (0-10) 3.5,2.1
0.0, 0.0 - 5.8
1.0,0.0- 1.0
0.0, 0.0 - 1.0
1.0,0.0-5.0
1.3,0.5-3.0
2.0, 0.0 - 4.0
3.2.1.7-5.2
2.6, 0.5 - 4.9
1.0. 1.0-2.0
3.3, 1.0-5.2
4.6, 1.8-7.0
3.5, 1.3-5.7
10.0,4.0- 18.0
7.0,6.0- 19.0
3.2,1.6-5.3
0.0-26.1
0-4.0
0.0 - 31.0
0.0 - 41.0
0.0 - 9.6
0.0 - 20.0
0.0 - 9.5
0.0- 10.0
0-3.0
0.0 - 10.0
0.0 - 10.0
0.8 - 10.0
0.0- 118.0
0.0- 139.0
0.6 - 9.7
skewness skewness after
before LN
transformation transformation
0.63
•047
0,17
-0.62
I J7
!Q0
108
0.36
0.71
0.27
0.51
0,03
0.48
196
173
0.39
0.18
0.20
2.1
0.56
-0.42
0.22
-0.06
-0.18
RESULTS
Selection of variables
The descriptive statistics of all assessments at baseline are presented in Tob/e /.Variables not
normally distributed (skewness a I) were In-transformed. A Pearson correlation matrix of
all variables from the OASIS data set at baseline was constructed to trace collinearity
(r>0.6).We chose one of the two variables with high inter-variable correlation for further
analysis. BASFI was selected instead of D-FI; occiput-to-wall distance was selected instead
of tragus-to-wall distance; lateral spinal flexion was selected instead of the modified Schober
test; pain spine was selected instead of BASG-week ; physician assessment of painful joints
was selected instead of MASES and Mander enthesis index.
Finally, the following instruments were selected for further analysis: physician spinal pain
assessment (In-transformed), physician assessment of painful peripheral joints (In-
transformed), physician assessment of swollen peripheral joints (In-transformed), chest
expansion, finger-to-floor distance, occiput-to-wall distance (In-transformed), lateral spinal
flexion, cervical rotation, intermalleolar distance, physician's assessment of disease activity
(In-transformed), Dougados articular index, patient assessment of disease activity, patient
night pain, patient pain joints, patient pain spine, BASFI, the BASDAI fatigue question, and
ESR (In-transformed) and CRP (In-transformed).
Patients available for analysis
In all, 203 OASIS records with baseline data were available. In case of the patient perspective
a total of 158 OASIS records fulfilled the criteria for low (n= I 12) or for high (n=46) disease
activity. The 45 records with an intermediate level of disease activity were not used for
further analyses. For the physician perspective of disease activity 145 OASIS records were ^
available for further analyses; 128 with low disease activity and 17 with high disease activity. 2"
The 58 records with an intermediate level of disease activity according to the physician !?
were neglected.
Factor analyses
Factor analysis (SPSS-factor analysis (PCA) with varimax rotation for the final solution) on
the OASIS baseline data of the above-described variables was performed to structure the j?
high number of variables. For both patient and physician perspectives of disease activity 4 a
factors were extracted with Eigen-values > I, and a cumulative percentage of explained <g
variance o f 61 %. Tab/e 2 (see page 54) shows the d i s t r i bu t ion o f the selected OASIS baseline »
variables in a four - fac to r mode l f o r each perspect ive o f disease activity. Bo th perspect ives ft
gave the same factors that consisted of variables reflecting spinal mobility and function (I), , j
variables reflecting assessments by the physician (2), variables reflecting assessments by the '
•o
patient (3) and variables reflecting laboratory acute phase reactants (4).The order in which «
the factors appear slightly differed across the perspectives.The internal consistency of the tn
factors was moderate to good (Cronbach's a ranging from 0.52 to 0.80) (Tob/e 2).
Table 2: Four factor models with explained variance and internal consistency
(Cronbach's a) of all selected OASIS baseline data reflecting the
patient perspective and the physician perspective of disease activity
Perspective: patient assessment of disease
activity
factor I factor 2 factor 3 factor 4
'mobility 'physician 'patient 'lab'
and assess- assess-
function' ments' merits'
chest spinal pain
expansion assessment
fingers to number of
floor painful joints
cervical
rotation
number of
swollen
joints
physician
lateral spinal assessment
flexion of disease
activity
intemnalleolar
distance
occiput to
wall
articular
index of
Dougados
pain spine
pain joints
night pain
BASFI
BASDAI
fatigue
ESR
CRP
Perspective: physician assessment of disease
activity
factor I factor 2 factor 3 factor 4
'patient 'mobility 'physician ' lab '
assess- and assess-
ments' function' ments'
pain spine
pain joints
night pain
chest spinal pain
expansion assessment
fingers to number of
floor painful joints
cervical
rotation
number of
swollen
joints
patient . .
, , . , articular
assessment lateral spinal
, ,. . . index of
of disease flexion
. . Dougados
activity *
BASDAI intermalleolar
fatigue distance
BASFI occiput to
wall
ESR
CRP
i
aO.S2 a 0.80 a 0.73 a 0.71
explained variance: 61%
a 0.80 a 0.52 a 0.75 a 0.71
explained variance: 61 %
Discriminant analyses
The factor values of the four factors of both disease activity perspectives were used
separately (as independent variables) in the discriminant function analyses. We performed
discriminant function analyses on the baseline data, and subsequently on data of 6, 12, 18
and 24 months follow up. The factor values (dependent variables) were restricted to the
groups of patients with defined high and low disease activity for both perspectives. Table 3
shows the pooled- and canonical correlation coefficients for all 4 factors for each
perspective of disease activity.
Factor 3 (patients assessments) and to a far less extent factor 2 (physicians assessments)
contributed most to the discriminant score describing disease activity from the patients
perspective, for all time periods analysed.The other 2 factors were not contributive at all.
The pooled correlation for factor 3 remained high if tested at other time points. Factor 3
TaWe 3: Pooled correlation of discriminant functions of four factors according
to the patient's perspective and the physician's perspective of disease
' activity in AS at baseline, 6, 12, 18,24 months follow up.
" . , baseline 6 months 12 months 18 months 24 months
discriminating factor
Patient assessment of disease activity
Factor I'mobility and function' 0.13 0.12 0.24 0.04 0.14
Factor 2 'physician'
Factor 3 'patient'
Factor 4 'lab'
Canonical correlation
Correctly classified (%)
Physician assessment of disease
Factor 1 'patient'
Factor 2 'mobility and function'
Factor 3 'physician'
Factor 4 'lab'
Canonical correlation
Correctly classified (%)
0.27
0.85
0.23
0.63
79
activity
0.05
0.52
0.62
0.48
0.39
77
0.43
0.84
0.04
0.49
69
0.41
0.47
0.72
0.21
0.44
78
0.42
0.79
-0.01
0.49
72
0.07
0.55
0.74
0.41
0.35
80
0.34
0.81
-0.14
0.59
77
-0.14
0.99
-0.05
-0.14
0.22
67
0.43
0.80
0.06
0.65
78
0.37
0.81
0.38
0.18
0.25
72
" : - ; • : •
(physicians assessments) contr ibuted most to the discriminant score describing disease
activity f rom the physicians perspective, but factor 2 (spinal mobility and function) as well
as factor 4 (laboratory acute phase reactants) also contr ibuted significantly. Interestingly,
factor I (patients assessments) was far less important. The contr ibut ion of factor 2 to the
discriminant score was very consistent over t ime; the contr ibut ion of the factors 1, 3 and 4
was somewhat less consistent over t ime.
Regression analysis «
Both discriminant functions (one for the patient perspective and one for the physician a.
perspective) contain 4 factor values, which are each composed of several clinical variables. S
In order to get insight in which variables explain the discriminant scores best, we performed ™
stepwise forward multiple linear regression analyses for each disease activity perspective. s.
These regression analyses were performed on the baseline OASIS records, wi th the two ^
discriminant functions (individual discriminant scores) as dependent variables, and all
selected assessments as explanatory variables. <&
Tob/e 4 shows the relative contr ibut ion of the variables as a result of this stepwise analysis. JJJ
Disease activity from the patient perspective was best captured by the instrument 'pain
Tob/e 4: Relative contribution of individual variables explaining disease
activity from the perspective of the patient, as well as from the
K perspective of the physician.
variable
perspective: patient's
pain spine
BASFI
pain joints
BASDAI fatigue
Physician disease
activity LN
variance (R square)
perspective: physician
cervical rotation
swollen joints LN
CRPLN
intermalleolar distance
finger to floor
variance (R square)
corresponding
factor
assessment of AS
3
3
3
3
2
1
mode
standardized coefficient Beta
2 3
• disease activity
.76
.58
.55
.52
.81
.44
.42
.30
.86
's assessment of AS disease activity
2
3
4
2
2
-.74
•54
-.59
.46
•73
-.54
.35
.33
.83
4
.37
.36
.29
.22
.90
-.44
.37
.34
-.25
.88
5
.34
.31
.29
.22
.18
.93
-.37
.38
.30
.24
.18
.91
spine', followed by BASFI, the instrument "pain joints', the BASDAI 'fatigue' question and the
instrument 'physician global assessment of disease activity'. Disease activity from the
physician's perspective was best captured by the instrument 'cervical rotation', followed by
the instruments 'number of swollen joints', CRP,'intermalleolar distance' and 'finger-to-floor
distance'.The combination of these 5 instruments explained more than 90% of variance in
discriminant scores for each perspective of disease activity.The standardized coefficients of
the end solution reveal that 'pain spine', BASFI and 'pain joints' contribute approximately
similarly to explaining disease activity from the patient perspective.The instruments'cervical
rotation' and 'swollen joint count' and to a somewhat lesser extent CRP, contribute almost
similarly to explaining disease activity from the physician perspective.
DISCUSSION
The most important conclusion from this study is that patients with AS and physicians have
different views on what active AS means.
Patients base their judgment primarily on the presence and severity of complaints related
to AS, which are registered by self-administered questionnaires. The impact of spinal
mobility, the assessments made by the physician and the acute phase reactants can almost
be neglected. Instruments measuring pain (pain spine, pain joints) contribute more to
explaining disease activity from the patient perspective than instruments measuring stiffness,
fatigue and genera/ we// being. An explanation may be that measuring pain already captures
the latter. Apart from these pain instruments the BASFI, an index primarily designed to
assess function also contributes to disease activity from the patient perspective. Apparently,
patients base part of their estimation of disease activity on what they are able to (physically)
perform.This is a phenomenon that we know from rheumatoid arthritis patients in whom
function measured by the health assessment questionnaire (HAQ) is often strongly
correlated with disease activity".
A few more conclusions can be derived from the observations regarding the patient
perspective. First, patients appear to properly distinguish disease activity (defined by them as
complaints) from disease severity (spinal mobility). Second, measuring acute phase reactants
does not capture disease activity from the patient perspective: laboratory assessments do
not contribute to disease activity as perceived by the patients.
The physician judgment about disease activity rests on a combination of constructs:
assessments made by the physician are particularly important, and patient-derived scores
were far less contributive. Looking at the combination of instruments that best explains the
physician's judgment, it is remarkable that 3 of the 5 variables include measures combining
information on disease activity and severity (cervical rotation, intermalleolar distance and
finger-to-floor distance) rather than pure activity (swollen joints and CRP). In a separate
study designed to investigate on which criteria physicians judge whether a patient with AS
should be treated with TNF-blocking drugs, we also found that physicians rated disease
severity at least as important as disease activity (personal communication). ^
The disease activity markers that emerged from the multivariate analysis (CRP and swollen w
joint count) are known to be insensitive to trace disease activity from the patient »
perspective. CRP is poorly correlated with BASDAI, a patient-derived index of disease *"
activity, and the swollen joint count is an insensitive marker for active disease, because only 5
a subset of patients actually has swollen joints. "S
It is rather intriguing that we, as physicians, now commonly use patient-derived instruments 5*
(such os BASDAI) as a gold standard for measuring disease activity, both for including £
patients in clinical trials as well as establishing drug effects, whereas there is no appropriate o.
evidence that patients and physicians perceive disease activity similarly. Another important j *
consideration is the lack of evidence that either patient derived assessments or physician *
derived assessments of disease activity are somehow associated with long term outcome in ft
AS (long-term function, structural damage, loss of participation etc). Since the options for ,3
drug therapy in AS are steadily increasing it becomes more and more important to define
measures assessing a uniform construct of disease activity and long-term outcome to be M
used in clinical trials. wi
One may question the validity of this study with respect to extrapolation of the findings.
The OASIS cohort is an observational cohort with consecutive patients with AS from three
different countries, from university hospitals as well as non-university general hospitals.
Patients were included irrespective of age, gender, disease duration, severity or activity of
their disease, and may therefore be considered an appropriate reflection of the average
patient with AS. As shown in Tob/e /, the OASIS patients cover the entire range of activity-
and severity variables scores, which may further add to this conclusion .
In order to be able to truly discriminate between active and inactive disease, we defined
inactive disease at a value of s 4.0 and active disease at a value of a 6.0 (VAS from 0 to 10)
for both patient and physician perspectives. By doing this, we may limit the interpretability
of the findings in case of an indifferent' level of disease activity. The goal of this study,
however, was to investigate how patients and physicians define inactive and active disease
(which asks for a clear distinction), rather than classifying patients as active or inactive.
However, the number of patients with high disease activity was rather low, especially in case
of the physician perspective.The analyses at other time points revealed similar information
as compared to the analyses performed at baseline data, which adds to the validity. These
analyses are based on the same patient group and therefore do not contain independent
information. Furthermore the patient perspective of disease activity is based on the opinion
of a large number of patients, on the other hand the physician perspective is based on the
opinion of three investigators only. Another remark is that one of the investigators assessing
'physician global disease activity' (in less than 25% of patients) is not a rheumatologist, but
a very experienced research nurse trained to assess patients in many AS studies. Strictly
spoken this is not a physician assessment and as a research nurse she lacks the experience
of treating AS patients. The similarity in results over the entire two year follow up might
serve as an external validation for the consistency in assessing disease activity by the
involved assessors. Probably most important is that the treating physicians of the Dutch
5 OASIS patients based their decisions on starting TNF-blocking agents more on spinal
6 mobility and other disease severity measures than on disease activity measures (unpublished
data), which is in consistence with the results of the physician perspective in this study.
•fl In summary, in this study we showed that patients with AS perceive disease activity
* differently in comparison with physicians. Patients rate complaints and to a lesser extent
a function as important values of defining disease activity. Physicians rate variables reflecting
^ inflammation and severity such as their own assessments and acute phase reactants as most
important in assessing disease activity instead of patient perception.
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ABSTRACT
Objective: Although disease-specific health status measures are available for ankylosing
spondylitis (AS), no instrument exists for assessing quality of life (QoL) in the condition.The
aim was to produce an AS-specific QoL measure that would be relevant and acceptable to
respondents, valid, and reliable.
Methods: The ASQoL employs the needs-based model of QoL and was developed in
parallel in the UK and the Netherlands (NL). Content was derived from interviews with
patients in each country. Face and content validity were assessed via patient field-test
interviews (UK and NL). A postal survey in the UK produced a more efficient version of
the ASQoL, which was tested for scaling properties, reliability, internal consistency and
validity in a further postal survey in each country.
Results: A 41-item questionnaire was derived from interview transcripts. Field-testing
interviews confirmed acceptability. Rasch analysis of data from the first survey (n= 121)
produced a 26-item questionnaire. Rasch analysis of data from the second survey (UK:
n=l64; NL: n= 154) showed some item misfit, but that items formed an hierarchical order
and were stable over time. Problematic items were removed giving an 18-item scale. Both
language versions had excellent internal consistency (alpha 0.89 to 0.91), test-retest
reliability (Spearman 0.92 UK and 0.91 NL) and validity.
Conclusions: The ASQoL provides a valuable tool for assessing the impact of interventions
for AS and for evaluating models of service delivery. It is well accepted by patients, taking
approximately 4 minutes to complete, and has excellent scaling and psychometric
properties.
INTRODUCTION
Ankylosing spondylitis (AS) is a chronic inflammatory rheumatic condition affecting the
sacroiliac joints, to a varying degree the spinal column and to a smaller extent the peripheral
joints. Patients have pain, morning stiffness and disability which increases with duration of
disease. A number of patients also experience extra-spinal and extra-articular
manifestations as acute anterior uveitis and inflammatory bowel disease'. Population studies
report a prevalence of AS of between 0.5% and 1.6% and it is more commonly found in men
than w o m e n " The pattern and rate of disease progression are variable but may be
independent of disease duration''. Although major advances in the understanding of the
disease pathogenesis have occurred in recent years, the optimal strategy for treatment is
still unknown. Disease onset is generally in late adolescence or early adulthood and,
consequently, the effects are present for a majority of the patient's life. Progression may
continue through what should be economically active years^. Chamberlain' reported that
two-thirds of male patients experience difficulty at work, one third have social problems and
up to two thirds report having difficulty with sexual activity. Reactive depression and
frustration are noted together with impaired self-esteem and social skills'. Energy related
problems are also widely reported'. All these features denote significant effects of the
disease on lifestyle.
There is a growing interest in the assessment of quality of life (QoL), particularly in chronic
disabling conditions. It is becoming relatively common to measure QoL in studies designed
to assess the impact of new pharmaceutical products or to compare different treatment
regimes. Although the concept has existed for many years, it is only within the last few
decades that attempts have been made to operationalise QoL into a construct that can be
measured in a meaningful way'.
Instruments currently available for use with AS patients focus predominantly on symptoms
(impairment) or functioning (disability, or both, and are used to assess the presence or
absence of disease and its consequences in these terms. Such instruments include: the Bath
Ankylosing Spondylitis Functional Index (BASFI)®, the Leeds Disability Questionnaire
(LDQ)', the Ankylosing Spondylitis Assessment Questionnaire (ASAQ)'°, the Dougados
Functional Index (DFI)", a version of the Stanford Health Assessment Questionnaire O
modified for the spondylarthropathies (HAQ-S)'*, and, a modified version of the Arthritis •§
Impact Measurement Scales II specific to AS (AS-AIMS II) ' \ Although such measures provide *
important information on the level of impairment and disability experienced by patients, ~
they do not inform on the impact of the condition on QoL. The construct of QoL differs v
from impairment and disability in so far as it concerns the impact of disease from the «3
patient's (rather than a clinical) perspective. By investigating how patient's lives are affected ^
by impairment, disability and other influences it provides an outcome that is complementary »
to the traditionally assessed impacts of disease'*'^. Generic health status instruments such -o
as the Nottingham Health Profile, SF-36 and EuroQoL also concentrate on impairment and T?
disability rather than QoL. Furthermore, they have been shown to lack the responsiveness w
necessary to detect real changes in health status associated with effective treatment'".
There is a clear need for a valid and reliable disease-specific instrument for assessing the
impact of AS on QoL that is suitable for use in clinical practice. This paper describes the
development of such a measure, the Ankylosing Spondylitis Quality of Life Questionnaire
(ASQoL). The instrument was required to be suitable for monitoring patients, evaluating
alternative treatment regimes, new pharmaceutical products and/or models of service delivery
from the patient's perception. The development methodology employed is based on recent
advances in the recognition and understanding of the conceptual and practical basis of
measurement. The process combines the theoretical strengths of the needs-based quality of
life model'^ with the statistical and diagnostic power of the Rasch model'*. The needs-based
model of quality of life postulates that life gains its quality from the ability and capacity of the
individual to satisfy his or her needs. QoL is high when these needs are fulfilled and low when
few needs are satisfied.The model is well-established and has been applied successfully in the
development of a large number of disease-specific QoL instruments, se-veral of which have
become established as the outcome instrument of choice for clinical trials and
s t u d i e s " " ^ ' " " " " * ' . The application of the Rasch model ensures that the fundamental
scaling properties of the instrument (for example, unidimensionality and level of
measurement) are assessed in addition to the traditional psychometric assessments of
reliability and construct validity. Such basic measurement properties were considered at each
stage of the development of the ASQoL.
PATIENTS AND METHODS
Figure / sets out the stages involved in the development of the ASQoL. The intention was
to produce an instrument that would be equivalent for both the UK and the Netherlands
(NL). Consequently, all stages were conducted simultaneously in both countries, with the
exception of stage 4, which took place in the UK only. The purpose of stage 4 was to
produce a more efficient instrument for final testing, by removing clearly problematic items.
^ Patient Samples
Sj The study was approved by ethics committees in both countries and participants gave their
"• written informed consent. All participating patients fulfilled the modified New York criteria
,» for AS"'™. Patients with significant co-morbidity such as psychiatric disorders, cancer or
^ fibromyalgia were excluded. To ensure that a wide spectrum of clinical features were
5" represented, each sample included patients with both axial and peripheral disease, a range
§ of disease duration and patients with uveitis or inflammatory bowel disease, or both.
^ Patients were recruited from three hospitals in the north of England and from three in the
a south of the Netherlands. In both countries, different patients participated at each stage of
S" the study.
x
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figure /: Stages in the production of the ASQoL
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Stage I: Interviews with patients
Deriving the content of a measure from individuals who are representative of the target
population ensures that only relevant topics are included and that areas important to QoL
are not omitted. For the ASQoL, the content of the questionnaire was derived from •
unstructured, qualitative interviews with relevant patients in both countries, conducted by -j
experienced qualitative researchers. The interviews, took the form of informal, focused
conversations. They were designed to explore the impact of AS on the patient, with
emphasis on the persons's ability to fulfil his or her needs. For example, where interviewees
indicated functional limitations associated with AS they were prompted to consider how
such restrictions impacted on their lives - particularly, how they prevented the fulfilment of
their needs. The interviews were audio recorded with the permission of the interviewee.
Transcripts were produced from the tapes, which were then wiped clean. All traces of the
interviewee's identity were omitted from the transcripts to maintain anonymity.
Stage 2: Selection of items and response format for the draft questionnaire
In both countries, the interview transcripts were subjected to independent content analysis
to identify statements relating to need satisfaction. As far as possible, the actual words used
by interviewees were selected for the questionnaire. Duplicate and idiosyncratic items were
removed and the list was subjected to further scrutiny, with items retained if they were
applicable to all potential respondents, reflected a single idea, were unambiguous and were
short and simple. The item lists from each country were then compared at a meeting
between the English and Dutch researchers.The purpose of this meeting was to decide on
the content for the first draft of the questionnaire and to identify a response system that
would be suitable for both languages.
A yes/no response system was selected for the draft measure as previous experience had
indicated that this maximises language equivalence and ease of scoring and minimises
respondent burden. In the development of the rheumatoid arthritis-specific instrument (the
RAQoL) it was shown that a yes/no response format was more sensitive to change than a
four-response Likert-type format".
Stage 3: Field testing for face and content validity
The purpose of this exercise was to test the applicability, comprehensibility, relevance and
comprehensiveness of the ASQoL with patients with AS. Participants completed the
questionnaire in the presence of an interviewer.They were then asked to comment on its
ease of completion and on the appropriateness of the instructions, items and response
format. Items found to be problematic in either country were removed. Items were
considered problematic if respondents found them ambiguous or difficult to understand.
Results from this stage were used to compile a second draft version of the measure.
Stage 4: Postal Survey I (UK)
The new draft ASQoL was administered by post to patients in the UK. Analyses were
performed on the resulting data in order to identify items that failed to fit onto the
underlying measurement construct and/or that worked differently by age (above or below
the median), gender, AS diagnosis (axial only or axial with peripheral involvement), or
disease duration (above or below the median). Such differential item functioning (DIF)
would indicate that an item is valued differently by subgroups of the patient population. For
example, in a disability measure it might be hypothesised that an item such as / am unob/e
to trove/ to my workp/oce would be affirmed less often by respondents who have reached
retirement age.Therefore, regardless of their level of disability, this item would appear to be
less severe for younger respondents. DIF was identified though the application of the one
parameter logistic item response theory model - the Rasch model'*. In the context of a QoL
scale, the Rasch model applies the premise that the likelihood of a person affirming a
particular item depends on the level of QoL of the person and on the level of QoL
represented by that item. The analysis provides estimates for the item and person
parameters in log-odds units (logits). Such estimates are based on the assumption that the
scale is indeed measuring a single underlying construct - that is, that the items form a
unidimensional scale.The extent to which this assumption is justified is indicated by item fit
statistics. For the present analysis, Rasch mean square (MNSQ) item fit statistics were
identified through application of the computer program WINSTEPS".Two MNSQ statistics
are given; an information-weighted fit statistic (INFIT) and an outlier-sensitive fit statistic
(OUTFIT). OUTFIT is more sensitive to inconsistencies in the extreme responses, that is
those made to items far removed from the individual's level of QoL. The INFIT statistic is
weighted so that these outliers have less impact and is, thus, more sensitive to non-extreme
responses.Taken together, these two MNSQ fit statistics inform on the extent to which the
individual items map onto the underlying measurement construct, in this case, the QoL.
Given the present sample sizes, MNSQ values between 0.7 and 1.3 were taken to reflect
adequate fit to the modeP. As no Dutch data were included in Stage 4, only those items
that were clearly problematic were removed. The third draft of the questionnaire was
produced on the basis of these analyses and used in the subsequent postal survey in both
countries.
Stage 5: Postal Survey 2 (UK and NL) Q
The purpose of the final postal survey was to assess the scaling properties, reliability, - |
internal consistency and construct validity of the ASQoL in each country. Patients in both *
countries were sent a package consisting of the ASQoL, a demographic questionnaire, ^
additional comparator measures and a reply paid envelope. Patients who completed and |_
returned the first pack were sent a similar package timed to arrive two weeks later. The -3
demographic questionnaire, which was consistent across countries, included questions on ^
patient perceived disease activity and severity of illness. The Nottingham Health Profile «
(NHP)*' and the BASFI were used as comparator measures in both countries. In addition, -o
the LDQ was used in the UK and the Dougados Functional Index (DFI)" was selected in *
the Netherlands. The NHP is a measure of perceived distress and provides a profile of -J
scores in six sections; physical mobility, energy level, pain, emotional reactions, social
isolation and sleep. It is scored out of a maximum of 100 for each of the sections, with a
higher score indicating greater distress.The BASFI, the LDQ and the DFI each yield a single
score. Scores on the BASFI can range from 0-100, on the LDQ, from 0-48 and on the DFI
from 0-40. For each of these scales, a high score indicates greater disability. Each item on
the ASQoL is given a score o f I' or '0 ' . A score o f I' is given where the item is affirmed,
indicating adverse QoL. All item scores are summed to give a total score or index, with a
high score indicating a worse QoL. Questionnaires with missing data were omitted from the
analysis.The following properties of the two versions of the ASQoL were assessed: scaling
properties, reliability, internal consistency and construct validity.
Scaling properties
Rasch analyses were conducted to confirm that items mapped onto the same underlying
construct (unidimensionality), that they represented different amounts of the construct
(hierarchical ordering) and that they worked in same way across different patient groups
(differential item functioning). The level of measurement (that is, ordinal or interval level)
provided by the measure was also examined.
Reliability
The reliability of the ASQoL was assessed using the test-retest method.This is an estimate
of the instrument's reproducibility over time, assuming that no change in condition has taken
place. For each country, ASQoL scores from each administration were correlated. Patients
were excluded from these analyses if they reported significant changes to their perceived
general health, severity of illness or perceived disease activity (that is, whether or not the
patients considered their disease to be active at the time of completing the questionnaire)
between administrations. Where an instrument is required for use in a clinical trial or for
monitoring individual patients, a correlation coefficient of at least 0.85 is required". Due to
the ordinal nature of the data, Spearman rank correlation coefficients were produced (intra-
class correlation coefficients are also reported for information only).
<g Internal consistency
gL Internal consistency was assessed by Cronbach's alpha coefficients. This statistic indicates
*• the degree of relatedness between items. A value of 0.70 or above was taken as reflecting
^ adequate internal consistency".
i
£ Construct validity
J ASQoL scores were related to the comparator instruments and to patient perceived
^ general health and severity of illness and patient-perceived disease activity (that is, whether
h or not the patients considered their disease to be active at the time of completing the
y questionnaire). Patients describe disease activity in terms of whether they are having a'good
O day' or a 'bad day'.This terminology is used throughout the results section. It was predicted
that there would be a moderate association between the ASQoL and the comparator
measures indicating that they assess different but related constructs. It was also
hypothesised that QoL would be worse for respondents experiencing a bad day (active
disease), those reporting poorer general health or those describing their AS as severe.
RESULTS
Findings from the interviews (stage I )
Thirty patients were interviewed in the UK and 25 in the Netherlands. Patient samples were
comparable in each country. Approximately two thirds of those interviewed were male and
a third reported having peripheral arthritis.The age of those interviewed ranged from 18 to
78 years, with disease duration ranging from 1.5 to 44 years. Interviews lasted for between
30 minutes and two hours with a median length of one hour and 10 minutes. All
respondents chose to be interviewed in their own homes and all gave consent for the
interview to be audio recorded.
Similar findings emerged from the Dutch and UK interviews. Respondents commented on
the impact of pain and its effect on sleep, mood, motivation and ability to cope with the day
ahead. One of the greatest fears expressed was that of losing independence. Many reported
that they required some degree of assistance with everyday tasks such as dressing, washing
and shopping (particularly for foodstuffs). In addition, many reported feeling that they were
no longer in control of their own personal hygiene or grooming. A particular concern was
about the future, particularly in relation to uncertainties surrounding disease progression.
The AS had a major impact on interviewees' ability to meet their needs for stimulation and
exploration, gender role fulfilment and feelings of worth. Major impacts were also reported
on self image and self esteem, resulting from concerns over appearing slouched or slovenly.
AS had a profound impact on relationships with family members and friends and social life
was severely limited. For example, several interviewees commented that they chose places
they could visit on the basis of how tolerable they found the seating. The condition was
often cited as a major source of family tension and some interviewees reported taking out
their frustration and anger on those closest to them. O
Development of the draft questionnaire (stage 2) !?
Items for the questionnaire consisted of actual quotations from the transcripts in a majority —
of cases. However, it was necessary to change the actual words used by interviewees for gj_
some of the items. For example, some were shortened, had the word order altered, or were -5
changed so that they were expressed in the first person and/or in the present tense.The ^
item pool from each country was compared and items selected for the draft questionnaire 3"
that covered issues raised in both countries. Fourty-one items were selected that best -o
expressed the issues raised by the interviewees. T?
Tob/e /. Demographic and disease information (postal surveys). Results are
shown as No (%)
i
£
Demographic details
Males (%)
Females (%)
Age range (years)
Mean age (SD) (years)
Married or living as married (%)
Disease information
Range of duration of illness (years)
Median (mean) duration of illness in years
No. reporting peripheral involvement (%)
No. reporting uveitis (%)
No. reporting IBD (%)
Perceived AS severity
Mild (%)
Moderate (%)
Quite severe (%)
Very severe (%)
Perceived general health status
Excellent / very good (%)
Good (%)
Fair (%)
Poor (%)
Perception of today
Very good (%)
Good (%)
Bad (%)
Very bad (%)
First postal
survey
(stage 4)
UK
n=l2l
92 (76)
29 (24)
21-77
47.6(12.4)
85 (72)
1.5-50
15 (16.3)
85 (70)
30 (25)
14(12)
18(15)
50 (42)
45 (38)
5(4)
12(10)
48 (40)
43 (36)
18(15)
I I (9)
71 (61)
34 (29)
1 (1)
Second postal
(stage 5)
UK
n=2IO
150(71)
59 (28)
19-82
46.1 (12.4)
144(68)
1-62
18(19.6)
174(83)
48 (23)
31 (15)
22(11)
76 (37)
93 (45)
16(8)
10(5)
58 (28)
100(49)
38(18)
11(5)
101 (50)
83 (41)
8(4)
survey
The
Netherlands
n=l54
110(71)
44 (28)
20-79
47.6(11.8)
126 (82)
3-51
19(20.8)
112(71)
36 (23)
22(14)
36 (25)
69 (47)
35 (24)
6(4)
7 (4.6)
48(31.6)
83 (54.6)
14(9.2)
13(8)
95 (62)
42 (27)
4(3)
Field-testing for face and content validity (stage 3)
In the UK 10 patients were interviewed in clinic and 5 in their home. In the Netherlands all
15 patients were interviewed in clinic. The ASQoL took between 2 and 16 minutes to
complete (median 4 minutes in both the UK and NL).The measure was well accepted by
interviewees in both countries, who generally found the items to be easily understood and
relevant. Field testing of the questionnaire resulted in minor changes to the wording of two
items and the removal of five more from both language versions. Items were removed
because they were found to be problematic or were considered inappropriate by a number
of respondents. For example, the item / find it difficu/t to get moving in the morning was among
those deleted, as it was interpreted in different ways by UK respondents.The item / often
hove to rest when doing jobs around the house was removed due to gender bias. Although the
item was intended to cover a range of household tasks such as cooking, cleaning, decorating
or home maintenance, it was generally construed by patients in the UK to be solely related
to housework. Many male respondents in the UK commented that they never undertook
such tasks and, consequently, could not answer the question. Following these changes, a 36-
item version of the ASQoL was produced for use in the first postal survey.
Testing the psychometric and scaling properties of the ASQoL
For both versions of the measure, a high score indicates worse QoL. For all tables in the
following sections, n values deviating from the overall number are due to individual missing
responses.
Results of the first postal survey (UK) (Stage 4)
Questionnaire packs were distributed to 180 people and returned by 121, a response rate
of 67%. Tab/e / shows the demographic details of the sample. Rasch analyses were
performed on the data to identify items that were problematic in terms of misfit or DIF.
While a number of items were found to misfit, DIF was minimal. As a result of these
analyses, 10 items were removed from the measure, leaving a 26 item version of the ASQoL.
This version was taken forward for further testing in each country.
Results of the second postal survey (Stage 5) ft
In the UK, 288 questionnaires were distributed at time I and 210 were returned, a response •§
rate of 73%. Of these, 157 (75%) were returned at time 2. In the NL, 180 questionnaires ?
were distributed at time I and 158 were returned, giving a response rate of 88%. Of these, ^
139 (88%) were returned at time 2. Four questionnaire sets from the Dutch sample were £_
returned too late to be included in the analyses. Tob/e / shows demographic details of the •?
samples at time I in the UK and the NL. It can be seen from the table that the samples ^
included in the postal surveys were similar demographically. Demographic characteristics of <*"
respondents at time 2 were also comparable. Tob/e / also provides information on the -o
respondents' perceived health status.The table shows that the UK respondents rated their T?
health status worse than the Dutch participants. Respondents' scores on the comparator —
N instruments showed that, with the exception of social isolation, perceived distress (as shown
X by NHP section scores) is high for this patient sample and higher in the UK than in the NL.
i Rasch analyses were conducted on the data from each country. Eight items were removed
as they were shown to misfit in one or both countries.The fit of the final 18 item ASQoL
was good in both countries, with most MNSQ values within the required 0.7 to 1.3 range
(tob/e 2). Item stability over time was excellent in both countries, with Rasch item parameter
estimates similar at times I and 2 (within 95% confidence intervals). Items were not equally
spaced along the measurement continuum, indicating that the 18 item ASQoL produces raw
scores at the ordinal level of measurement.
Scores on the 18-item ASQoL can range from 0-18. Median scores for the UK were 10.0
(Inter-quartile range (IQR) 5.0-14.0; mean 9.5, standard deviation (SD) 5.3) at time I and 9.0
(IQR 4.0-14.0; mean 8.8, SD 5.7) at time 2. For the NL, median scores were 6.0 (IQR 2.0-10.0;
mean 6.7, SD 4.8) at time I and 6.0 (IQR 1.5-9.0; mean 6.2, SD 4.8) at time 2. Relatively few
respondents scored at the extremes, although the basement effect was greater in the NL.
Tobfe 2. Rasch item statistics for the 18-item ASQoL in the UK and the"
Netherlands
Mean square fit statistic (MNSQ)
Item number
1
2
3
4
5
6
7
8
9
10
II
12
13
14
15
16
17
18
UK
Infit
.90
1.21
.95
.79
1.02
.88
/.36
.83
.99
1.13
.86
1.20
.99
.88
.98
1.16
1.11
.87
Netherlands
Outfit
.74
1.22
.87
.77
.70
.75
/.87
.65
.96
.84
.71
r.40
.90
.92
.90
1.06
1.02
.73
Infit
.91
.93
.97
.84
1.25
.87
1.00
.93
.99
1.08
1.20
1.06
.89
1.37
.90
.98
.76
1.19
Outfit
.78
.84
.88
.63
1.23
.71
1.06
.68
.91
1.25
1.15
1.12
.76
1.16
.74
1.08
.76
1.16
Bo/d ita/ics, MNSQ values above 1.3; /to//cs, MNSQ values below 0.7
Association with additional factors
ASQoL scores were not related to duration of illness or to the presence of uveitis. Patients
with IBD scored higher on the measure (indicating worse QoL) than those without (UK
p<0.0l, NL p<0.005; Mann-Whitney U test).
Reliability and internal consistency of the ASQoL
The Spearman rank correlation coefficients for the test-retest reliability of the 18-item
ASQoL was 0.92 in the UK (n= 129) and 0.91 (n= I 19) in the NL, indicating that the measure
has excellent reliability, producing low levels of random measurement error. Identical
intraclass correlation coefficients were obtained (0.92 in the UK and 0.91 in the NL).Very
few patients (two in the UK and one in the NL) reported any significant change in perceived
general health, severity of illness or perceived disease activity. Therefore, removing such
patients made little difference to the results obtained. The ASQoL also has good internal
consistency in both countries (0.91 at time I and 0.92 at time 2 in the UK and 0.89 at time
I and 0.90 at time 2 in the NL).
Tob/e 3. Correlations* between scores on the 18-item ASQoL and those on
the comparator measures
Netherlands Time IComparator measure
NHP sections
Physical Mobility
Energy
Pain
Emotional reactions
Sleep
Social isolation
BASFI
LDQ
DFI
UKTime 1
.78
.74
.81
.72
.54
.53
.72
.70
.
e
.79
.73
.79
.73
.59
.50
.75
-
.80
* Spearman rank correlation coefficients ^1
Validity of the ASQoL £
Evidence of construct validity was provided by examining the levels of association between 5
the ASQoL and the comparator instruments. Moderate to high correlations were found •?
between the ASQoL and all the comparator instruments (tob/e 3).The pattern of association ^
between the NHP section scores and the ASQoL was as expected, with the highest •»
correlations being with the physical mobility, pain and energy level sections.The correlations -o
with the emotional reactions section were also high. Further evidence of the validity of the °S
ASQoL was gained through investigating the measure's ability to distinguish between w
TaWe 4. ASQoL scores by specified groups
Grouping factor
Disease Activity (good
day / bad day)
Very good / good
Very bad / bad
Perceived general health
Excellent / good
Fair
Poor
Perceived AS severity
Mild
Moderate
Quite / very severe
UK
n
p<.00l*
102
81
p<00 l * *
61
91
34
p<.00l**
19
73
95
Median
p<.00l*
7.0
13.0
p<.00l**
3.0
11.0
15.0
p<00 l * *
3.0
7.0
13.0
IQR
3.0-11.3
10.0-15.5
1.0-7.0
8.0-13.0
14.0-17.0
1.0-5.0
3.0-10.0
11.0-16.0
Netherlands
n
101
40
52
76
12
34
61
39
Median
5.0
10.0
2.0
9.0
13.5
1.5
6.0
9.0
IQR
1.5-9.0
8.0-12.7
0-4.0
6.0-10.7
12.0-14.7
0-4.2
4.0-10.0
8.0-12.0
* Mann-Whitney UTest;** Kruskal-Wallis one-way analysis of variance.
specified groups of patients (known groups validity). Tob/e 4 shows that ASQoL scores
differed significantly by whether the respondent was having a good or a bad day (disease
activity); self perceived general health status, and self perceived AS severity.
Discussion
The efficient and cost effective management of any disease requires competing treatment
regimes to be evaluated in terms of their ability both to control the disease and improve
the QoL of patients. Existing instruments for use with subjects with AS focus on symptoms
and functioning. Although these provide important information they do not provide
information about the overall impact of the condition and its treatment on the patient's
QoL. The ASQoL is based on a clear, conceptual model of QoL that has been
successfully employed in the development of several other disease-specific QoL
i n s t r u m e n t s " ' " ' " ' " " * ' " " . T h e development process was conducted in parallel in the UK
and the NL. Consequently, it was possible to remove items that were problematic in one or
other language version of the instrument at each stage of the testing procedure. This
method of development is preferable to the standard one in which an instrument is
produced in one country and then adapted for use in other languages. Such sequential
development cannot overcome cultural and linguistic differences between countries.
The content of the measure was derived from interviews with individuals diagnosed with
AS in the UK and the NL. For each language version, the items are expressed (as far as
possible) in the original words of the patients. Consequently, respondents find the
instrument acceptable, comprehensive and relevant to their condit ion.The ASQoL is quick
and easy to complete (taking less than five minutes), making it suitable for use in clinical
settings.
Application of item response theory in the form of the one parameter Rasch model showed
the ASQoL to be unidimensional.had good item stability over t ime, and to have minimal DIF.
The reliability of each language version of the measure has been shown to be excellent -
the test-retest reliability coefficients obtained indicate that the ASQoL is suitable for use in
routine clinical practice or for monitor ing the progress of individual patients. Internal
consistency was also adequate. It is essential to establish that a new instrument has
construct validity, that is, that it is measuring the intended construct. Two prerequisites of
this are; that the instrument is based on a model of the construct assessed and that it has
good reliabil ity". These requirements were met in both countries and hence, it is possible
to infer that the ASQoL provides a valid assessment of the construct defined in the model.
However, it is also necessary to determine construct validity formally through association
with instruments measuring related constructs (convergent validity) and by comparing
scores of patients at different stages of disease activity o r wi th different disease severity
(known groups validity). For the ASQoL, formal assessment was undertaken by correlating
scores on the ASQoL wi th those on the NHP and the BASFI. ASQoL scores in the UK were
also correlated wi th the L D Q and in the NL wi th the DFI.These comparator instruments
measure a range of constructs; the NHP assesses perceived distress, while the BASFI, L D Q
and DFI measure AS-specific disability.The relatively high levels of association between the
ASQoL and these different constructs reflects the multifaceted nature of the impact of the
disease on the patient. For example, pain, being a prominent feature of AS, would be
expected to have a major influence on the QoL of the patient and, indeed, the correlation
between these two measurements indicates approximately 66% shared variance. Similarly,
QoL was moderately highly correlated wi th physical disability, energy and emotional
reactions sections of the NHP.The results obtained show that the ASQoL and comparator
instruments measure different though related constructs. Taken together, they provide a
more complete picture of the impact of AS than any single measure can give alone.
The psychometric and scaling properties of the ASQoL suggest that researchers and n
clinicians can have confidence in the scores obtained by respondents on the measure. •§
Further assessments of the instrument's validity will be possible as it is used in clinical 3
studies. In addition, it is recommended that future studies are carried out to assess —
responsiveness, the instruments ability to detect meaningful changes in QoL. £
The decision to adopt a dichotomous response system for the instrument was driven by -5
practical issues related to language equivalence and ease of completion and scoring. There ^
is often an assumption that such simplification is at the cost of some loss of sensitivity •»
because it is presumed that multiple response items are able to provide more detailed -o
information about the variable of interest. However, this assumption is not necessarily T8
correct" . The ASQoL comprises 18 dichotomous items that have been shown through m
Rasch analysis to form a single scale. Furthermore, the results from the assessment of
known groups validity suggest that this scale is able to measure the QoL associated with a
wide range of perceived disease severity and activity.
The ASQoL will serve as a valuable tool for assessing the impact of AS and its treatment
on QoL in clinical settings and research studies. Such an instrument will allow accurate
assessment of the effectiveness of interventions from the patient's perspective.
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Chapter 7
RADIOLOGICAL SCORING METHODS IN ANKYLOSING
SPONDYLITIS: RELIABILITY AND CHANGE OVER ONE AND
TWO YEARS
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ABSTRACT
Objective: To compare reliability and change over time of radiological scoring methods in
AS.
Methods: Two trained observers scored 217 sets of radiographs from baseline, one and
two years follow up. The sacroiliac (SI) joints were grade 0-4 by the New York method and
SASSS (Stoke Ankylosing Spondylitis Spine Score). Hips, cervical and lumbar spine were
graded 0-4 (Bath Ankylosing Spondylitis Radiological Index, BASRI). BASRI spinal scores, and
New York SI are combined in BASRI-spine (2-12) and with the addition of BASRI-hips in
BASRI-total (2-16). Cervical and lumbar spine were also scored in detail (SASSS, 0-36 each)
and combined in SASSS-total or 'modified' SASSS (both range 0-72). To assess change a
smallest detectable difference (SDD) was estimated for data on a quasi interval scale.
Results: The SI scoring methods showed intra- and interobserver kappas between 0.36 and
0.70.The BASRI-hip reached kappa's between 0.59-0.84. Combined SASSS scores were most
reliable, with intra- and interobserver ICC's between 0.90 and 0.96. The ICC's of the
combined BASRI scores were also very good, ranging from 0.85 to 0.95. For SI New York,
SI SASSS and BASRI-hip 0.3-1.2% of patients deteriorated a I grade. 7.5% deteriorated
a I grade (6.3% of maximum score) in BASRI-spine and BASRI-total and observers agreed in
up to 48% of the cases that no change occurred.The SDD was lowest (7.5; 10% of maximum
score) for 'modified' SASSS. Only 0.8% of patients deteriorated more than the SDD and
observers agreed in up to 92% of the cases that no change occurred.
Conclusion: Radiological scoring methods for AS are moderately to excellently reliable.
Under the selected scoring conditions (concealed time order, average of two observers,
SDD based on interobserver data, unselected patient population) there was too little
change over two years to be picked up reliably by the scoring methods.
0)
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INTRODUCTION
Radiological damage is considered an important outcome in Ankylosing Spondylitis (AS)'.
The evaluation of radiological change proves to be very difficult.There are several reasons
for this. Radiological sacroiliitis can easily be missed because of the complex anatomy of the
sacroiliac joints. The undulating articular surfaces make it hard to image these joints on
conventional radiographs. Squaring, erosions and sclerosis appear in different stages of the
disease" and syndesmophytes must be differentiated from osteophytes and disorders such
as diffuse idiopathic skeletal hyperostosis (DISH). Usually AS is a slowly progressive disease
and radiological change appears gradually: evaluation of radiographs with an interval of one
year does not seem to be useful*-*. However, a detailed scoring method showed some
change after a period of one year* and change after two years of follow up could also be
detected by a graded scoring method*.
Changes of the sacroiliac joints are most frequently scored using the 5 grade New York
criteria"' or the nearly similar Stoke Ankylosing Spondylitis Spine Score (SASSS)^.To evaluate
the spine in AS there are essentially two different scoring methods. The Bath Ankylosing
Spondylitis Radiology Index (BASRI) is a global graded scoring method, quick and easy to
perform®'-'°.The first version of this BASRI was described in 1995^ and a modified version was
published in 1998. Several BASRI scores are also combined in composite scores"iThe SASSS
for the spine is a more detailed scoring method assessing different features such as squaring,
sclerosis and erosions at various locations of each vertebra"". In an earlier study we
compared the reliability and change over time over one year of these scoring methods. We
concluded that both the SASSS method for the spine and BASRI reached good reliability. All
other scoring showed moderate reliability at best. No method showed change over a period of
one year in a considerable number of patients*. At the time of our first study no scoring method
was available to evaluate the hip in AS.Therefore the Larsen scoring method designed to score a-
the hips in rheumatoid arthritis was used. Recently a new graded scoring method was developed "S
to evaluate the hip in AS, the BASRI-hip'. In this second study we used the BASRI-hip. ^,
The objective of this follow-up study was to compare all available AS radiological scoring *
methods for reliability and change over 2 years time. 5'
MATERIALS A N D METHODS g
Patients. A total of 217 consecutive outpatients who satisfied the modified New York 3
criteria'* were included in our study. Our study population concerns a cross sectional g.
cohort of AS patients, followed longitudinally. 69% of patients were male, a distribution g.
usually found in AS populations. The median age at baseline was 42.2 year (range: 18-78).
There is a striking difference between median duration of complaints (17.0 year, range: 0.3- £j
54) and duration of disease since diagnosis (9.4 year, range:0.1-41), indicating AS patients 00
have compla in ts long before the diagnosis is made.
Scoring methods SI joints. The SI joints were scored according to the New York (NY)
method (0-4) and the Stoke Ankylosing Spondylitis Spine Score (SASSS; 0-4). Both methods
score the lower half of the Sl-joints and are graded from 0 to 4"- ' . The main difference
between these methods is grade 4 (complete ankylosis), where the New York method does
not allow residual sclerosis. Both SI joints are scored separately, and thereafter the score is
summed.
Scoring method hips. The hips were scored according to BASRI-hips, graded: 0= normal,
1= suspicious (possible focal joint space narrowing), 2= minimal (definite narrowing, leaving
a circumferential joint space > 2mm), 3= moderate (narrowing with circumferential joint
space s 2mm or bone-on-bone apposition of < 2cm), 4= severe (bone deformity or bone-
on-bone apposition a 2cm or total hip replacement)'". Both hips are scored separately, and
thereafter the score is averaged.
Scoring methods spine. The Bath Ankylosing Spondylitis Radiology Index (BASRI) was
developed for the AP and lateral view of the lumbar spine and the lateral view of the
cervical spine and is graded 0 to 4 for each view'. The BASRI-spine (BASRI-s) is the
composite score of the BASRI scored on the lumbar spine, the cervical spine and the Sl-
joints (NY method), with scores ranging from 2 to 12'.The highest score of the two views
of the lumbar spine is applied in this BASRI-s. In case of absence of one of the lumbar spine
radiographs, the score of the available view was taken into account.The BASRI-total (BASRI-
t) is a composite score of the BASRI-s and de BASRI-hips, with scores ranging from 2 to 16'°.
The SASSS is scored from the lower border of 12^ thoracic vertebra down to and including
the upper border of the sacrum. This scoring method is used on both the anterior and
posterior site of the vertebrae with a score ranging from 0 to 36 for each site, so the total
score will range from 0 to 72" .
The 'modified' SASSS is scored from the lower border of the 2™* cervical vertebra until the
upper border of the I" thoracic vertebra and the lower border of the 12^ thoracic vertebra
until the upper border of the sacrum".This scoring method is only used on the anterior site
of the vertebrae, with a score ranging from 0 to 36 for the cervical spine and 0-36 for the
lumbar spine.Therefore the total score of the modified version will also range from 0 to 72.
Missing scoring sites for the SASSS were handled as follows: when up to 3 scoring sites for
each view could not be scored, the mean of the other scoring sites was applied; when more
than 3 scoring sites could not be scored the whole SASSS score for that particular view was
scored missing.
In case of all 'spine' scoring methods syndesmophytes were differentiated from osteophytes
using the following description; an osteophyte was defined as a bony deformity on the edge
of the vertebra projecting more than 0.5 cm horizontally. Osteophytes were not included
in the analyses.The scoring methods for the SI joint and spine are described in more detail
in our first study*.
Inter- and intraobserver reliability. To obtain inter- and intra observer reliability of the
scoring method for the hips (BASRI-hip) two experienced observers (AS and KV) scored
30 randomly selected baseline radiographs from the 217 consecutive outpatients with AS.
The University Hospital Maastricht, the University Hospital Gent and the Hopital Cochin in
Paris each provided 10 blinded radiographs of anterior-posterior view of the pelvis to score
the hips. The two observers had a training session to gain experience with the scoring
method. All abnormalities present on the radiographs were discussed in detail. After this
training session the observers scored a set of radiographs independently and discussed the
results with each other and this session was followed by a consensus meeting with the two
observers and two other experts in AS.The study on BASRI-hip reliability was started when
few (s 5) discrepancies existed between the two observers. Two different sets of 30
radiographs were used for training and again a different set of 30 radiographs was used for
assessment of reliability of BASRI-hip In case of BASRI-hip interobserver reliability was
calculated and in addition intra observer reliability based on the scores of the radiographs
scored a second time after 2 weeks.
For all other scoring methods of the sacroiliac joints and the spine inter-and intraobserver
reliability was assessed in our first study"*. Baseline and I year radiographs were scored
during our first study and again in this present study. Intraobserver reliability could be
computed also using data from baseline and I year of our first study and this present study
except for BASRI-total because the BASRI-hip scoring method which is part of BASRI-total
was not available at the time of our first study
This second intraobserver reliability was based on an interval of 2 years between the first
and the second read. Interobserver reliability could also be calculated for baseline, I year
and 2 year data of this study.
Change over t ime over two years. We included 217 consecutive outpatients who
satisfied the modified New York criteria for AS'*; 137 patients from the University Hospital
Maastricht and Maasland Hospital Sittard (the Netherlands), 55 patients from the Hopital
Cochin, Paris (France) and 25 patients from the University Hospital Gent (Belgium). These
hospitals are secondary and tertiary referral centers. Of these 217 patients we studied 3
sets of radiographs taken with an interval of one year. All three sets of radiographs were
scored viewing the radiographs simultaneously (paired) without knowledge on the
chronology of the radiographs in a random order by the same two experienced observers
independently (AS and KVJ.The scoring methods were also scored in random order. As a
result sacroiliac joints were scored separately from the hip joints. We used the scoring
methods as described in the previous section.
Statistics. Inter- and intra- observer agreement of the different scoring methods was analyzed
for categorical data by the linear weighted Kappa (k) statistic and for continuous data by the
random effects, average measure Intraclass Correlation Coefficient (ICC, type 3.1) with
observer as fixed facet'*. Joint pairs (hips and SI- joints) were regarded as independent units,
i.e., their possible correlation was ignored.To visualize the observer agreement we plotted the
continuous data using the'Bland & Altman' method'"*. Change over time of the scoring methods
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Tob/e /: Inter- and Intra-observer reliability of all scoring methods with lower
and upper border of the 95% confidence interval (baseline,! year and 2 year)
Method: interobserver
agreement
observer I and 2
TO TI2 T24
Intra-observer agreement
the radiographs are scored with a
' ' 2 year interval
observer I observer 2
TO T I 2 TO T I 2
Sl-joints N-York k=0.68 k=0.69 k=0.66 k=0.63 k=0.55 k=0.40 k=0.40
0-4 0.61-0.72 0.62-0.74 0.62-0.72 0.56-0.69 0.47-0.63 0.32-0.48 0.32-0.48
N=400 N=388 N=365 N=348 N=342 N=348 N=339
Sl-joints SASSS k=0.68 k=0.69 k=0.70 k=0.67 k=0.62 k=0.42 k=0.36
0-4 0.63-0.72 0.64-0.74 0.64-0.74 0.63-0.74 0.56-0.64 0.34-0.49 0.28-0.43
N=400 N=388 N=365 N=352 N=344 N=348 N=339
BASRI-hip k=0.60 k=0 .59 k=0 .60 - , ^ : . .
0 - 4 0.54-0.67 0.52-0.66 0.52-0.67 .,,_,... , . : . • .
N = 3 0 N = 3 0 N = 3 0
S
BASRI-s ICC=0.92 ICC=0.94 ICC=0.93 ICC=0.89 ICC=0.90 ICC=0.85 ICC=0.86
2-12 0.90-0.94 0.93-0.96 0.91-0.95 0.84-0.92 0.86-0.92 0.79-0.89 0.80-0.89
N=I92 N=I9O N=I76 N=I54 N=I63 N=I44 N=I6I
BASRI-t ICC=0.94 ICC=0.96 ICC=0.95 A
2-16 0.92-0.95 0.94-0.97 0.93-0.96 •
N=I92 N=I9O N=I76 :
SASSS modified
0-72
ICC=0.98 ICC=0.97 ICC=0.97 ICC=0.96 ICC=0.96 ICC=0.96 ICO0.95
0.97-0.98 0.96-0.98 0.96-0.98 0.95-0.97 0.95-0.97 0.95-0.97 0.94-0.97
N=I62 N=I72 N=I53 N=I54 N=I64 N=I36 N=I55
SASSS total ICC=0.98 ICC=0.98 ICC=0.98 ICC=0.93 ICC=0.96 ICC=0.92 ICC=0.95
0-72 0.97-0.98 0.97-0.98 0.97-0.98 0.92-0.94 0.95-0.97 0.91-0.93 0.94-0.96
N=I6I N=I63 N=I57 N=I52 N=I62 N=I4O N=I56
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was assessed by a cut-off value based on interobserver reliability of change. For grading scales,
such as all BASRI methods and the New York and SASSS method for the sacroiliac joints, a
change of one grade was defined as the minimum detectable difference. For data on a semi-
continuous scale, such as the SASSS methods for the spine, a smallest detectable difference
(SDD) was estimated in the situation of 2 fixed observers yielding a mean change".The SDD
is the smallest change that can be detected apart from measurement error. In case of the BASRI
scores and the SI scores, these are categorical scales, which do not allow to calculate a SDD.
RESULTS
Inter- and intra-observer reliability of BASRI-hip (single radiographs).
BASRI-h (0-4) scores of 30 baseline radiographs showed good to very good reliability with
intraobserver kappa's of 0.73 and 0.84 and interobserver kappa 0.63 and 0.66.
Inter- and intra-observer reliability of all scoring methods (baseline, I and 2 years).
SI scoring methods (New-York and SASSS, 0-4) showed moderate to good intraobserver
reliability with kappa ranging from 0.36 to 0.67. For both scoring methods interobserver
reliability was good with kappa's between 0.66 and 0.70 (7bb/e/).
The BASRI grading scores of the various parts of the spine (0-4) showed moderate to good
reliability. For BASRI scores of the lumbar spine the intraobserver kappa with two year
interval between the scoring sessions ranged from 0.61 to 0.65 and interobserver kappa's
from 0.58-0.78. BASRI of the cervical spine showed intraobserver kappa's ranging from 0.41
to 0.56 and interobserver kappa's from 0.61 to 0.62. BASRI-h (0-4) scores again showed
good interobserver reliability, kappa's ranging from 0.59 to 0.60 (Tob/e /). Intraobserver
reliability could not be calculated because at the time our first study was performed the
scoring method for BASRI-h was not available. g-
The combined BASRI scores showed good to excellent reliability. For the BASRI-spine (2- S
12) the intraobserver ICC ranged from 0.85 to 0.90 and the interobserver ICC from 0.92 ^,
to 0.94.This was even slightly better for BASRI-total (0-16) with ICC's ranging from 0.94 to *
0.96 for interobserver reliability (Tob/e /). Intraobserver reliability could not be computed 5j
because the BASRI-hip scoring method which is part of BASRI-total was not available at the «_
time of our first study. 6L
The SASSS scores also showed excel lent rel iabi l i ty.The SASSS scored on the anter io r and g
posterior site of the lateral view of the lumbar spine (both 0-36) showed intraobserver ICC 5'
0.94-0.95 and interobserver ICC ranging from 0.94-0.98. P
The combined score, SASSS-total (0-72), showed intra- and interobserver ICC's of 0.92- g.
0.96 and 0.98 respectively (Tob/e /).The SASSS score applied on the anterior site of the a
lateral view of the cervical spine showed intra- and interobserver ICC's of 0.92-0.96 and
0.95-0.96 respectively.The combined score of the anterior sites of both the lateral view of <&
the lumbar and cervical spine ('modified' SASSS, 0-72) showed good intra- and inter g>
obse rve r ICC's o f 0 .95-0.96 and 0.97-0.98 respect ive ly (Tob/e / ) .
Tob/e 2: Concordance rate (%) observer I and 2
i SI SASSS SI New BASRI- BASRI- BASRI- SASSS- 'modified'York hip spine total total SASSSIwk ant and Iwk ant and
post cwk ant
N=434 N=434 N=434 N=2I7 N=2I7 N=2I7 N=2I7
range 0-4 range 0-4 range 0-4 range 2-12 range 2-16 range 0-72 range 0-72
35% 22%
78% 78%
33% 23%
80% 77%
27% 21%
77% 71%
'perfect agreement
< 2 grades difference
< 6 points difference
1 year
•perfect agreement
< 2 grades difference
< 6 points difference
2 years
*perfect agreement
< 2 grades difference
< 6 points difference
* perfect agreement:
70%
71%
72%
74%
76%
76%
< 1 grade/point
66%
64%
67%
difference
32%
69%
35%
74%
31%
68%
between
38%
72%
36%
75%
35%
68%
observers
s
t
1
Tob/e 2 shows the concordance rates of the two observers at baseline, I year and 2 years
follow-up for individual and combined scoring methods. For each moment perfect
concordance rates are low for all scoring methods.The concordance rates for the combined
SASSS methods are between 71% and 80%, accepting less than 6 points difference between
the 2 observers on a scale from 0-72. Accepting less than 2 grades difference the concordance
rates of BASRI-total (68-75%) are comparable with those of the combined SASSS methods
accepting less than 6 points difference. One grade change in BASRI-total represents 6.3% of
the maximum scoring range. One grade in the BASRI-total can be compared to 5 points in
the combined SASSS methods which represents 4.9% of the maximum range.
To visualize observer agreement over the complete range of observed scores, figure / ond
2 show Bland and Altman plots of baseline data and progression data of the modified SASSS.
Progression data are based onthe difference between baseline data and data of two year
follow up The Bland and Altman plot of baseline data of the modified SASSS shows a
maximum difference of 26 points between the two observers on a scoring range from 0-
72; the 95% limits of agreement of the difference between the two observers is ± 1.96 times
the SD (4.4) (figure /). Observer I scores systematically somewhat higher than observer 2.
The Bland and Altman plots of I and 2 year data are very similar to this baseline plot (data
not shown). Figure 2 concerning the progression data of the two observers over two years
figure /. Bland and Altman plot: Mean versus difference of 2 observers at baseline; SASSS-modified
(SASSS lumbar anterior and cervical anterior)
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figure 2. Bland and Altman plot: mean versus difference of the progression scores of the two
observers over 2 years; SASSS-modified (SASSS lumbar anterior and cervical anterior.
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Tbb/e 3. Summary statistics on the group level at baseline, after I year and 2
years follow-up.
s
I
Scoring method
(range)
SI SASSS
(0-4)
SI New York
(0-4)
BASRI-hip
(0-4)
BASRI-spine
(2-12)
BASRI-total
(2-16)
SASSS- total:
lumbar anterior and
posterior (0-72)
SASSS-modified:
lumbar and cervical
anterior (0-72)
baseline
3.1,0.8
3.0,0-4
3.1,0.8
3.0,0-4
0.7, 1.0
0.0,0-4
6.9,2.8
6.6,0-12
7.6, 3.4
7.1,0-16
11.5, 17.5
4.0,0-72
13.8, 16.4
6.7.0-72
average of the 2 observers'
mean, SD,
median, min-max
1 year
3.1,0.8
3.0,0-4
3.1,0.7
3.0,0-4
0.7, 1.0
0.0,0-4
6.8,2.7
6.5,0-12
7.5,3.3
- 7.1,0-16
12.2, 17.9
5.0,0-72
13.7, 16.3
6.7.0-72
2 years
3.1,0.8
3.0,0-4
3.1.0.8
3.0,0-4
0.6, 1.0
0.0,0-4
6.9,2.8
7.0,0-12
7.5,3.3
7.0,0-16
12.3, 18.0
4.5,0-72
15.0, 16.8
7.6,0-72
shows a maximum difference of 18 points between the observers with a 95% limits of
agreement of 7.45. Because the scores of BASRI are on categorical scales it is not allowed
to calculate SDD and Bland & Altman plots.
Change over time.
Overall, we found only little change over the course of 2 years. No difference was found in
mean, median and SD of the entire group for SI New York, SI SASSS, BASRI-hip score,
BASRI-s and BASRI-t (Tab/e 3). In case of SASSS (spine) there was little difference in mean,
median and SD on baseline, I year and 2 years (Tab/e 3). These differences did not reach
statistical significance.The distribution of (dis)agreement based on the minimum detectable
difference of I grade for data on graded scales or the SDD for data on a semi-continuous
scale is shown in Tob/e 4. (see page 90,) If a patient deteriorated or improved more than the
SDD or I grade, the change was judged as real. This is reported for the percentage of
patients that changed according to only one or according to two observers. For the graded
methods SI New York, SI SASSS and BASRI-hip 0.3-1.7% deteriorated a I grade according
to both observers (Tab/e 4). Although there was some change in mean, median and SD in
SASSS spine over this 2 year period only very few patients (0-1.1%) deteriorated more than
the SDD in the combined SASSS scores (Tob/e 4). Only BASRI-s and BASRI-t were able to
detect change over this 2 year period in a considerable number of patients, 7.5% and 7.4%
respectively. To avoid a possible ceiling effect we performed the same analysis excluding
maximum scores. For the graded scales we excluded grade 4 and for the BASRI combined
scores and SASSS scores we excluded all data above the 75* percentile from analysis.These
analysis did not influence the results (data not shown).
DISCUSSION
Scoring radiographs in AS remains very difficult. For most radiological scoring methods
developed for AS moderate to excellent intra- and interobserver reliability could be
reached by two well trained observers. However, only the combined BASRI scoring
methods (BASRI-s and BASRI-t) and especially the SASSS showed good to excellent
reliability. Even with a scoring interval of two years the interobserver reliability remained
very good. Because of this two year scoring interval intra-observer agreement was less high
in comparison with the interobserver agreement.The reliability of the relatively new scoring
method for the hips (BASRI-h) proved to be good.We found it to be more reliable than the
Larsen scoring method for the hips used in our first study"''. Hip involvement in AS often a-
shows as bony formations, which cannot be scored properly using the Larsen method.The «
BASRI-h seems to be more disease specific and the developers of the BASRI-h, also found ^
good to even excellent intra- and interobserver agreement using unweighted kappa's .^ In J
contrast to our first study and most other studies'"'*''* we used linear weighted kappa ©•
statistics instead of unweighted kappa statistics in this present study. In comparison the o§
value of unweighted kappa is lower than of weighted kappa because large and small K.
differences in assessments between observers are judged equally in unweighted kappa g
statistics. Furthermore, kappa indicates to what extent two observers are capable to 5"
perceive differences between radiographs. So kappa often turns out to be relatively low in 3
case of a homogeneous group where every single radiograph receives more or less the g.
same score. This could be an explanation for the relatively low intra-and interobserver o.
agreement of the SI scoring methods because patients were included if they fulfilled the
modified New York criteria. SI joints were at least scored grade 2 for both sites on a scale w
from 0 to 4. Measures that relate observed to expected agreement (such as kappa and ICC) »
are only of limited value in this situation because of high levels of expected agreement.This
Tab/e 4: Sensitivity to change of AS scoring methods (values are mean ± standard
deviation of the difference)
Method
Sl-joints
New-York
(left and right, 0-4)
Sl-joints
SASSS
(left and right. 0-4)
BASRI-hips
(left and right)
(0-4)
BASRI-S
lumbar- cervical
spine,
Si-New York (2-12)
BASRI-total
lumbar- cervical
spine,
Si-New York, hip (2-16)
SASSS-total
Iwk post + ant
(0-72)
'modified' SASSS
Iwk ant + cwk
(0-72)
Interobserver agreement' of change*
0-1 year
0.04 ± 0.32 P0 85.6%
a I grade change:
P- 0.3%, P+ 0.3%.
P(-) 7.2%, P(+) 6.6%
0.07 ± 0.17 P0 89.7%
a I grade change:
P- 0%, P+ 0%,
P(-) 5.6%, P(+) 4.5%
0.02 ± 0.24 P0 84.6%
a I grade change:
P- 0.3%, P+ 0.0%,
P(-) 8.2%, P(+) 1.6%
0.03 ± 1.28 P0 48.6%
& I grade change:
P- 5.6%, P+ 2.8%,
P(-) 22.5%, P(+) 8.5%
0.02 ± 0.59 P0 49.7%
a I grade change:
P- 5.6%, P+ 2.8%,
P(-) 28.2%, P(+) 1.5%
sdd 8.2 P0 89.9%
a sdd change:
P- 0.7%, P+ 0 %,
P(-) 8.6%, P(+) 0.7%
sdd 6.8 P0 89.9%
a sdd change:
P- 1. 3%, P+ 0 %,
1 -2 year
0.02 ± 0.24 P0 88.5%
a I grade change:
P- 0.3%, P+ 0.3%,
P(-) 5.2%, P(+) 5.7%
0.05 ± 0.14 P0 91.7%
a I grade change:
P- 0%, P+ 0 %,
P(-) 4.6%, P(+) 3.7%
0.02 ± 0.26 P0 84.6%
2 I grade change:
P- 0.9%, P+ 0.0%,
P(-) 7.4%, P(+) 6.8%
0.14 ± 1.0 P0 51.9%
2 I grade change:
P- 1.8%, P+ 1.2%,
P(-) 28.7%, P(+) 17.4%
0.1 I ± 0.86 P0 50.7%
2 I grade change:
P- 2.4%, P+ 0.6%,
P(-) 30.1%, P(+) 19.3%
sdd 6.8 P0 89.8%
2 sdd change:
P- 0%, P+ 0.7 %.
P(-) 4.4%, P(+) 5.8%
sdd 6.2 P0 89.4%
2 sdd change:
P-2.l%,P+0.7%,
P(-) 4.2%, P(+) 3.5%
0-2 years
0.03 ± 0.29 P0 88.8%
a I grade change:
P- 1.2%, P+ 0.6%,
P(-) 7.5%, P(+)3.7% -
0.01 ±O.I7PO9O.5%
2 I grade change:
P- 0.3%, P+ 0%,
P(-) 5.2%, P(+) 4.0%
0.0 ± 0.25 P0 85.3%
2 I grade change:
P- 0.3%, P+ 0.0%,
P(-) 7.3%, P(+) 7.3%
0.15 ± 1.22 P0 48.6%
2 I grade change:
P- 7.5%, P+ 1.9%,
P(-) 32.2%, P(+) 18.7%
0.1 I ± 0.73 P0 48.1 %
a I grade change:
P- 7.4%. P+ 1.8%,
P(-) 32.7%, P(+) 19.8%
sdd 9.8 P0 92.3%
2 sdd change:
P- 0%, P+ 0 %,
P(-) 6.2%, P(+) 1.5%
sdd 7.5 P0 92.1%
a sdd change:
P- 0.8%, P+ 0 %,
P(-) 4.7%, P(+) 2.4%
1
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' Mean and SD are calculated from the difference in scores of the 2 observers over two years.
Example: mean((score 2 years observer I - score baseline observer I) - (score two years
observer 2 - score baseline observer 2)).
* Level of reliability of at least I grade or SDD change.
P0: % of patients who did not change according to both observers.
P-: % of patients who deteriorated according to both observers.
P+: % of patients who improved according to both observers.
P(-): % of patients who deteriorated according to one observer.
P(+): % of patients who improved according to one observer.
is confirmed by the relatively low median scores for the SASSS-spine methods (Tob/e 3, see
page 95).The low prevalence of radiological damage in SASSS inflates the ICC statistics with
a tendency to overestimate the ICC.
We also decided to show perfect concordance rates as a measure of (complete) agreement
between the two observers not depending on statistical techniques used such as kappa and ICC.
For all scoring methods the perfect concordance rates for the 2 observers were rather low.
The developers of the BASRI method found good to excellent perfect concordance rates
for the hips between 78 and 95%*'°. They found good concordance rates (73-81%) for
BASRI applied on lumbar and cervical spine and they reached comparable concordance
rates for the SI New York method (78-86%)"°. Concordance rates for the SASSS method
were not reported by the developers. Visual presentation of a Bland and Altman method
adds to understanding the data especially because it visualizes the distribution of the data
and outliners over the entire range of observed data.Visual presentation of agreement using
the Bland and Altman method can only be applied reliably in scores with large ranges such
as the SASSS and not for the various BASRI scores.
In our present study only BASRI-s and BASRI-t were able to detect change in a considerable
number of patients over a two year period.This change could not be identified by the other
graded and detailed scoring methods. In case of BASRI-s and BASRI-t observers agreed in
up to 52% that no change occurred. Unfortunately we may still conclude that relevant
change occurred rarely because observers agreed in only 7.5% of cases that real change of
at least I grade occurred. A reason for this could be that observer variation or error can
not be distinguished from radiological progression. An important reason could be that we
followed an unselected group of patients, without a particular request for disease activity. In
a group of AS patients selected for high disease activity, the situation might be different with
a better signal to noise ratio. The developers of the BASRI-h found significant change after
I year using Wilcoxon signed rank test for nonparametric data (n=60)*. For BASRI-s they
found significant change after 2 years (n=3l) and after I year 30% of 20 cases showed
change of at least I grade but this was not significant'. In 1999 they reported the magnitude
of change for the BASRI-s was from 7.0 to 7.9 in 2 years and 42% of 3 I patients showed
change in BASRI-s score'°. In these studies change over time was not specified for BASRI-t.
These results are based on a small number of patients could be caused by a selection of
severe cases. The developers of the SASSS methods found significant change over a group
of 28 patients in I year using Mann-Whitney U test with a mean change of 4.1 points (range
0-72) in SASSS-total and a mean change of 1.02 grade in SASSS for the sacroiliac joints''. In
this study the order in which the radiographs were scored was known in contrast with our
study. This can markedly influence the results, as has been shown for rheumatoid arthritis
(RA) "•'*•". All these sensitivity to change studies report over a relatively small number of
patients.
Comparing all radiological AS studies available at the moment we recommend to use the
New York method for the Sl-joints because it is most widely used and the reliability is similar
to the SASSS score for SI joints. The BASRI-hip should be used because it is the only AS
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disease specific method for the hips available and it has good intra- and interobserver
reliability.To score the spine the choice is not unequivocal.The BASRI-s and BASRI-t can be
preferred above the SASSS methods by its feasibility. According to face validity, the BASRI
and modified SASSS score highest because both include the cervical spine in addition to the
lumbar spine. In our study the BASRI was the only method which showed change in a
considerable number of patients over a two year period. However, this might be misleading
information as we set a change of I grade arbitrarily as a cutoff. Looking at the concordance
rates within I grade difference, only in about 70% of the cases the observers agree. For the
SASSS the comparable data for concordance within 6 points is somewhat higher (in 78% of
the cases). However, the calculated SDD for the SASSS is higher (9.8 for SASSS and 7.5 for
modified SASSS). So the cutoff used for SASSS is very strict and that for BASRI is much
looser. This might be an important reason why we were unable to detect changes if we
applied the SASSS. Further study is needed with sets of radiographs in which progression of
damage is likely, e.g. sets with a 5 year interval or in a population with AS with a short
disease duration because these patients tend to show more radiological change or selected
for high disease activity. Additional studies where AS radiographs are scored in both random
and chronological order are warranted to assess the difference in methodology as was done
for RA"•"•". Given the conditions used in this study (paired reading without information on
sequence, average score of two observers, cut-off based on SDD on interobserver data,
unselected patient population) the scoring methods are unable to detect change over two
year time reliably in a considerable number of patients.
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Chapter 7 Radiological scoring methods - page 94
Chapter 8
SUMMARY AND GENERAL DISCUSSION
Summary and general discussion
To create more uniformity in studies concerning aspects of outcome and disease activity in
AS, the international working group on Assessments in Ankylosing Spondylitis (ASAS)
defined 'core sets' for the following three settings: disease controlling anti-rheumatic therapy
(DC-ART), symptom modifying anti-rheumatic drugs (SM-ARD)/physical therapy and clinical
record keeping' ^ . The domains for all three core sets are physical function, pain, spinal
mobility, spinal stiffness, patient global assessment and fatigue.The core sets for clinical record
keeping and DC-ART were extended with the domains acute phase reactants, peripheral
joints and enthesis and the core set of DC-ART includes also radiographs of spine and hip.
As a follow up of the work of the ASAS working group this thesis focuses on different
aspects of disease activity and outcome in AS. The first part of the thesis (chapter 2-5)
highlights aspects of disease activity and chapters 6 and 7 focus on outcome measures in
AS. Most of the results described and discussed in the chapters are derived from an
international observational multicenter project: the Outcome in Ankylosing Spondylitis
International Study (OASIS). A total of 217 consecutive outpatients with AS who satisfied
the modified New York criteria^ were included in OASIS.This cross sectional cohort of AS
patients is followed longitudinally and patients are derived from outpatient clinics of several
university hospitals and general hospitals in three European countries: 137 patients from the
university hospital Maastricht and the Maasland hospital Sittard (the Netherlands), 55
patients from the hospital Cochin, Paris (France) and 25 patients from the university hospital
Ghent (Belgium). These hospitals are secondary and tertiary referral centers.
Approximately two third of the OASIS patients are male, a distribution usually seen in AS
populations. At baseline of the study the mean age of the patients was 43 years (SD: 13 years)
and the mean disease duration since diagnosis was I I years (SD: 8 years). 27% of the patients
had peripheral arthritis diagnosed by their treating rheumatologist. In each country the
same trained person (2 rheumatologists and I research nurse) assessed all patients every
* six months according to a pre-specified protocol for a period of two years. All patients
§• were followed by their rheumatologist, independently of the evaluations of the
, researchers.
Comparison of two functional indexes in AS
Physical function is both related to disease activity and damage in AS. The ASAS working
group has also included physical function, assessed by the Dougados Functional Index (D-FI)*
or the Bath Ankylosing Spondylitis Functional Index (BASFI)*, in the core sets for all
settings'. In chapter 2, we compared these two widely applied and validated functional
indexes specific for AS. The main purpose of this cross-sectional study was to investigate
the relation of BASFI and D-FI to aspects of disease activity and damage, which are both
related to physical function. If one of the two indexes would perform better, this could be
selected as the preferred measure to assess physical function. The BASFI consists of 10
questions on a visual analogue scale (VAS), all questions deal with activities of daily living.
The final score is the average of the scores of the 10 items. The D-FI consists of twenty 5-
point Likert response items, assessing the ability to perform distinct daily activities.The total
score (ranging from 0-40) is calculated as the sum of the item scores. Because there is no
'gold standard' for disease activity in AS available we used three external criteria for disease
activity: both patient and physician assessment of disease activity on a VAS, (0-10) and the
Bath Ankylosing Spondylitis Disease Activity Index (BASDAI, range 0-10)'. A global and a
detailed radiological scoring system specific for AS: the Bath Ankylosng Spondyltis Radiology
Index-spine (BASRI-s, range 0-12)™' and the modified Stoke Ankylosing Spondylitis Spine
Score (SASSS, range 0-72)'°" were chosen as the external criterion for damage. In our
analyses we used the most contrasting groups of AS patients in which disease activity on
the three disease activity measures was defined as high (score a 6.0) or low disease activity
(score s 4.0). Furthermore, Receiver Operator Curves (ROC) were plotted for both
functional indexes with the three measures of disease activity.
Results of this study showed relatively low disease activity scores and functional scores in
our patient population. A total of 7 BASFI questionnaires showed one or more missing
answers versus 28 D-FI questionnaires. As expected both functional indexes were highly
correlated with each other (Spearman: 0.89). Correlation of BASFI and D-FI with the
disease activity measures were all comparable with the highest correlation for the BASDAI
(Spearman: 0.59, 0.57 resp.). ROC's of the two functional indexes and all three disease
activity measures showed the best curve with the highest sensitivity and specificity values
for both functional indexes and the BASDAI (BASFI: 94%, 87% resp. and D-FI: 93%, 79%
resp.). The cutoff values to determine high versus low disease activity were considerable
higher for the BASFI (_ 40% of the full scale) compared to D-FI (_ 20 % of full scale).
However, using these cutoff values showed that considerable percentages of patients were
misclassified (12-30%) as having high or low disease activity if solely based on their
functional scores. The proportion of misclassified patients was lowest for the BASFI cutoff a-
values in combination with disease activity measured with the BASDAI (12%). So, disease «
activity assessed with BASDAI comes most closely to the disease activity aspect of function ^,
assessed with BASFI. A reason for this may be that both BASDAI and BASFI are developed {f
by the same research group and completely patient reported. Physical function in AS is not |
solely based on disease activity therefore it could not be expected that all patients were 8j
correctly classified. Of the external criteria chosen for damage, BASRI-s appears to give a 8J
relatively higher median score for radiological damage than the modified SASSS method: 7.0 ^
(range 2-12) and 12.0 (range 0-72) respectively. Correlation of both functional indexes with 8
BASRI-s and SASSS were about similar, 0,42 and 0.36 respectively. K.
o
Although, in this cross-sectional study, BASFI seems to perform slightly better assessing the =
disease activity aspect and in feasibility (BASFI takes less time to complete and less missing -o
values were found) otherwise no definite choice can be made between BASFI and D-FI TS
based on these results. •>•
1The BASFI was developed several years after the D-FI and avoids some presumably
redundant items and items assessing symptoms instead of function'*. Furthermore the
BASFI included three items that improve content validity. For two of these items this was
proven in the development of the HAQ-s'^. In case of the third item, concerning physically
demanding activities, it was shown in rheumatoid arthritis''' and osteoarthritis'* that only
this item might discriminate for almost but not perfectly healthy patients who would not
score on any other item. At the other hand the BASFI comprises a few items reflecting
unusual tasks, and the DFI includes several items covering additional domains not included
in the BASFI. A literature review was published including all available studies comparing the
performance of BASFI and D-FI. The one study concerning a head to head comparison of
the two indexes showed that both instruments were able to discriminate inpatients from
outpatients, but only the BASFI could discriminate the effects of a 3 weeks intensive physical
therapy period'*. In four physical therapy trials the D-FI did not discriminate between the
treatment arms while the BASFI could discriminate between treatment arms in two other
physical therapy trials'*. A reason for this could be that the distribution of the D-FI scores
show a tendency towards normal scores in most studies where it was used. This may not
allow further measurement of improvement in patients with only mild disability.To improve
the sensitivity of the D-FI the authors proposed the 5 point Likert response scale instead
of the 3 point Likert response scale,
The D-FI discriminated well between treatment arms in all but one SMARD trial and in one
DC-ART trial between treatment arms'*. The BASFI did not discriminate between
treatment arms in one of the two SMARD trials where it was used'*.The one SMARD trial
concerning a head-to-head comparison of the two indexes showed that both instruments
discriminated equally well between placebo and treatment group'*. There is no DC-ART
study available which shows the results of a direct comparison of the two indexes.The only
study that evaluates a conventional DC-ART (salazopyrine) the D-FI was used and in three
other studies evaluating the effects of inhibition of tumor necrosis factor a only the BASFI
was u s e d ' * " " " . In all these studies the applied instrument discriminated between the
treatment arms. Based on all these results there is a slight preference for using the DIFI in
SMARD trials whereas the BASFI should be preferred in trials concerning physical therapy.
Given the efficacy of biological drugs in the treatment of AS direct comparison of both
instruments should be preformed in future DC-ART trials and should include calculation of
the effect sizes or standardized response mean of the instruments in these settings.
Acute phase reactants in AS
Both laboratory blood test, Erythrocyte Sedimentation Rate (ESR, mm/hr) and C-Reactive
Protein (CRP, mg/l), are frequently used to evaluate disease activity in patients with AS.
Assessments of acute phase reactants is also a recommended core set endpoint for DC-
ART and clinical record keeping by the ASAS Working Group' *. It is well known that the
mean values of these two acute phase reactants are considerably lower for patients with
AS in comparison with patients suffering from rheumatoid arthritis . Chapter 3 describes
a study which was conducted to determine whether ESR or CRP is more appropriate in
measuring disease activity in AS. Because there might exist differences with respect to ESR
and CRP in AS patients depending on the clinical disease presentation, we divided our
study population into two groups: patients with only spinal involvement (n=l49) and
patients with active peripheral arthritis and/or inflammatory bowel disease (n=42). Since
there is no 'gold standard' for disease activity in AS we studied the relationship of CRP and
ESR with three substitute clinical disease activity variables following the same
methodology and statistical approach as described in the previous study on the
comparison of BASFI and DFI. A second aim of this cross-sectional study was to determine
if elevated CRP or ESR reflect active disease defined by one of these three selected disease
activity variables.
The results showed that in the spinal group the majority of patients have normal values for
ESR and CRP whereas the majority of patients in the peripheral arthritis/IBD group have
slightly elevated levels for both acute phase reactants. Only for ESR this difference between
the two groups was statistically significant. Thirty percent of patients in both disease
subgroups showed either an elevated ESR with normal CRP or vice versa and in most of
these cases values just above normal were seen in case the acute phase reactant was
increased. Overa/f, re/ative/y fow disease activity scores were seen in both study groups.
Quite striking is the difference in judgement of disease activity between the physician at
one hand and both the patient derived measures (BASDAI and patient assessment of
disease activity) on the other hand. This is reflected in very different mean values at
baseline of physician assessment of disease activity versus BASDAI and patient assessment
of disease activity (for the spinal group: 1.5 versus 3.6/3.9 resp. and for the arthritis/IBD
group: 2.5 versus 4.3/4.1 resp.). Also in the spinal group only 3% of patients were classified
as having high disease activity according to the judgment of the physician. In contrast, the
percentage of patients in the spinal group with high disease activity defined by BASDAI and 3-
patient was I 1% and 21% resp.. Overall, the ROCs showed low cutoff values for ESR and "S
CRP in both groups. Based on these cutoff values sensitivity and specificity were reasonable ^
with the highest sensitivity for physician assessment of disease activity (100%). j f
Unfortunately the corresponding positive predictive values, which are of importance in §
clinical practice, were uniformly low with large percentages of misclassified patients. This 8j
cross-sectional study showed that neither ESR nor CRP are good reflections of active 8j
disease as defined in our study. So, no preference can be made to use either of these acute ^
phase reactants in the assessment of disease activity in AS based on these results.There 8
might be a difference between ESR and CRP in relation to the progression of damage in 8.
o
AS, which needs to be further evaluated. Other studies concerning a head-to-head =
comparison of ESR and CRP are difficult to interpret since different definitions of active -o
disease activity in AS were used. A literature review was published including all available *
studies comparing the performance of ESR and CRP . In five of these seven studies ESR 3
and CRP performed equally and two studies indicated that CRP is more closely related to
disease activity". There are two studies indicating that elevated ESR and CRP are more
likely in patients with peripheral manifestations of AS*°,
There is no SMARD trial available concerning a direct comparison of ESR an CRP. In the
available SMARD trials no discriminant capacity of the acute phase reactants was found™.
One of these SMARD trial also reports the standardized response mean for CRP which was
low . Nine DC-ART trials (one methotrexate trial and eight sulfazalazine trials) showed no
significant effect of the tested drugs and possibly therefore CRP or ESR did not discriminate
between therapy and placebo^.The two DC-ART trials allowing a direct comparison of the
two acute phase reactants provided opposite results™. In two other studies, evaluating the
effects of inhibition of tumor necrosis factor <t, both ESR and CRP discriminated between
treatment arms"" . Unfortunately the exact effect sizes or standardized response mean for
ESR and CRP were not given, although these were high for both (>3). Based on all these
results no definite decision can be made to use either ESR or CRP in all three clinical setting
defined for AS. Since the promising results of biological drugs in the treatment of AS direct
comparison of both acute phase reactants is possible and also calculation of the effect size
or standardized response mean is needed. Furthermore, the relation of CRP and ESR with
the progression of damage in AS should be investigated in future.
Patient self-assessed joint counts in AS
In chapter 4 a reliability study on patient self-assessed swollen and painful joints is
presented. In AS a minor part of the population has peripheral arthritis (± 25%).
Traditionally, either a physician or a well-trained healthcare professional is involved in the
clinical assessment of arthritis. If joint counts assessed by a physician could be replaced by
a patient self-assessed joint counts, this would be an advantage for rheumatologists in clinical
— practice and especially for researchers.The reliability of patient self-reported joint counts
8P in AS has never been studied. In rheumatoid arthritis, reliability of self-assessed joint counts
is studied extensively and the results found are both of good re l iab i l i t y " " " " " and poor
re l iab i l i ty"""^ . In our study, 217 AS patients were asked to mark their painful and swollen
joints on a mannequin designed after the method of Stewart" presenting 44 and 40 joints
respectively. At the same day, without knowledge of the patient assessment, three
"2 investigators (one person for each research center) assessed painful and swollen joints on
similar mannequins. Our results showed that, on a group level, there is a consistent
difference between the number of tender and swollen joints assessed by the patients and
by the physicians with only moderate agreement (Intraclass Correlation Coefficient
between 0.51 and 0.71) on the total number of joint counts and even poor to moderate
agreement (kappa between 0.23 and 0.64) on individual joint counts. Patients scored
consistently more tender joints and the physicians scored more swollen joints. Possible
explanations for these findings are: (I) AS patients can not differentiate between a tender
joint or pain caused by enthesitis since the entheses are located near the joint and (2) AS
patients are not trained to detect a swollen joint. The enthesis index of Mander was only
significantly correlated with the total number of swollen joints assessed by the physician. On
a patient level the results were even worse shown by visualizing our data with the Bland and
Altman method*'. Self assessed joint counts could still be valuable if patients could
differentiate between the absence of arthritis and the presence of mono-, oligo- or
polyarthritis. However, for these differentations, perfect concordance rates between
patients and physicians were also very low (17%, 17% and 22% resp.). The only good
concordance rate found was in case of absence of swollen joints (82%). Consequently, AS
patient can tell if their joints are not swollen but in case of swollen joints they are unable
to judge the extent of swelling even within the rough categories of mono-, oligo-, or
polyarthritis. We did not formally assess test-retest reliability in this study but the results
obtained at baseline and after one year follow up showed similar results. Based on the
results, joint scores derived by physicians cannot be replaced by patient self-assessed joint
counts in AS in general. Only information from patients that there are no swollen joints is
sufficiently reliable to be useful.
Disease activity in AS
Since there is extended variety in the clinical picture among different AS patients it is very
difficult to define disease activity in AS. Patients may experience axial involvement in all
degrees of severity, but may also have extra spinal manifestations.This clinical diversity, both
in severity and in localization, makes a high demand on instruments that are supposed to
measure disease activity in AS. Furthermore AS patients and rheumatologists seem to have
very different understandings about active disease". Chapter 5 describes on which criteria
AS patients and rheumatologists base their judgment on disease activity. Our goal was to
explore differences between the patient and the physician perspective of AS disease activity. 2
For this study, data of the OASIS patient cohort were used.The patients in this cohort may n
be considered to appropriately reflect the spectrum of AS patients seen by rheumatologists, •
since the patients were included irrespective of gender, age, disease duration, disease £
severity or disease activity, 3
In this study disease activity from patient perspective as well as from physician perspective ><
was analysed by dichotomising both patient and physician global disease activity score on a g^
VAS (VAS range: 0 not active and 10 extremely active) into 'high disease activity' (VAS a 6.0) 9:
and 'low disease activity' (VAS s 4.0).Various AS instruments selected by the ASAS working c
group were assessed every six months for two years. Data reduction of these instruments 5'
by principal components analysis (PCA) was performed and distinguished four factors •
capturing correlated instruments, therefore assumed to measure the same underlying "8
construct: spinal mobility, physician assessments, patient assessments and laboratory 2_
assessments (Cronbachs alpha between 0.52 and 0.81; explained variance 61%). —
"
Discriminant function analysis with the factor loadings was performed to discriminate
between the low- and high disease activity state for both patient and physician perspective.
This analysis showed that the factor patient assessments was most important (pooled
correlation: 0.84) in discriminating between low and high disease activity state as defined by
the patient. The other three factors contributed marginally (pooled correlation: <0.30). In
contrast, the three factors: physician assessments, spinal mobility and laboratory
assessments contributed most in discriminating between the two defined levels of disease
activity of the physician perspective (pooled correlation: 0.62, 0.48, 0.48 respectively). The
factor patient assessments did not contribute at all (pooled correlation: 0.05). The
discriminant function analysis of baseline data and the analyses of data from other time
points revealed similar information. Multiple regression analysis on the discriminant scores
was performed to prioritise the instruments with respect to their contribution to each
disease activity perspective. In case of the patient perspective disease activity was best
captured by the instruments: 'pain spine', 'BASFI', 'pain joints' and 'fatigue'. The physician
perspective was best captured by the instruments: 'cervical rotation', 'swollen joint count',
'CRP' and 'intermalleolar distance'.
According to our results AS patients and their physicians indeed have very different views
on what disease activity in AS means. AS patients seem to rate disease activity on the basis
of complaints while physicians rate disease activity on the basis of instruments assessing
inflammation and disease severity. There are a few more conclusions that can be derived
from this study. The BASFI, an index primarily designed to assess function in AS also
contributes to disease activity from the patient perspective. It also seems that AS patients
base part of their estimation of disease activity on what they are able to physically perform.
Overall, AS patients appear to properly distinguish disease activity (defined by them as
complaints) from disease severity. Disease activity from patient perspective is not captured
by acute phase reactants. The physician judgement of disease activity is based on a
combination of constructs including measures that combine information on disease activity
and severity. Remarkably, CRP was included as a variable while this information was not
available to the investigator at the time the judgement of disease activity was made. At the
moment fully patient derived instruments such as BASDAI are combined with physicians'
assessment of disease activity and/or elevated CRP are used as a 'gold standard' for the
assessment of disease activity in AS for including patients in clinical trials and for the start
of anti-TNF therapy in clinical practice. Furthermore, there is still lack of evidence that
"2 either patient- or physician derived assessments of disease activity are associated with long-
>, term outcome in AS. This important information is needed to be able to select the
p instruments that best reflect real disease activity leading to the final outcome.
I Since the options for drug therapy in AS are increasing it becomes more important to define
J* measures assessing a uniform construct of disease activity and outcome to be used in
k clinical trials.
Quality of life in AS
In chronic disabling conditions there is a growing interest in the assessment of quality of life
(QoL). Especially in studies designed to assess the impact of new pharmaceutical products or
to compare different treatment regimes it is becoming relatively common to measure QoL.
Disease specific instruments used to evaluate the course of AS focus predominantly on
physical impairment and/or physical functioning. Generic health status instruments are
available but currently no disease specific instrument exists for assessing quality of life (QoL)
in AS patients.
Chapter 6 describes the development of the Ankylosing Spondylitis Quality of Life
questionnaire (ASQoL). Our goal was to produce a valid and reliable AS-specific QoL
measure that would be relevant and acceptable to respondents.The ASQoL is a quality of
life instrument specific to AS and was developed in parallel in the United Kingdom and the
Netherlands. All included AS patients fulfilled the modified New York criteria. The
methodology used to develop the ASQoL combines the theoretical strengths of the needs-
based quality of life model" with the statistical and diagnostic power of the Rasch model".
The development of the questionnaire enclosed five stages. The first content of the
questionnaire was derived from interviews with 30 patients in the UK and 25 patients in
the Netherlands (stage I). Stage 2 concerned the selection of items and response format
which formed the first 41-item draft-questionnaire. To assess face and content validity 15
patient field-test interviews were done in both the UK and NL which lead to a 36-item
questionnaire (stage 3). Stage 4 concerned a postal survey in the UK (n = 121) to produce
a more efficient version of the ASQoL with Rasch analysis the number of questions was
reduced to 26 items. Rasch analysis of data from a final postal survey (UK: n = 164; NL: n =
154) was done to assess scaling properties, reliability, internal consistency and construct
validity in each country (stage 5). This analysis showed some item misfit, but showed that
items formed a hierarchical order and were stable over time.The problematic items were ^
removed resulting in the 18 items ASQoL. Both language versions of the ASQoL showed 2"
excellent internal consistency (Conbach's alpha: 0.89-0.91), test-retest reliability (intraclass f?
correlation coefficient: UK: 0.92: NL: 0.91), and validity.The ASQoL may serve a valuable tool •
in both clinical settings and research for assessing the impact of AS and its treatment on £
quality of life from the patients perspective. Independently of this study good reliability, 3
validity and responsiveness of the ASQoL was found in another study comparing disease -3
specific patient assessed measures of health outcome in AS". Since the development of the |_
ASQoL this instrument was also used in two trials. One study evaluates the effects of spa 9:
therapy and the two other study evaluates the effects of inhibition of tumor necrosis factor c
a and both studies show that ASQoL discriminated between treatment arms"" . The §•
standardized response mean (SRM) and effect size (ES) were only calculated in case of the •
spa therapy trial with moderate responsiveness scores (SRM: 0.24 and ES: 0.22) reflecting "8
the moderate treatment effect. In a study on the effect of etanercept there was a high 2.
responsiveness of the ASQoL and at least similar to that of the BASDAI". S
Radiological scoring methods in AS
Radiological damage is considered as an impor tan t ou tcome in AS. The evaluation of
radiological change proves t o be very difficult in AS. Changes o f the sacroiliac joints (SI) are
most frequently scored using the 5 grade N e w York cr i ter ia (0-4)* o r the nearly similar SI
score described by the Stoke group'".To evaluate the lumbar and cervical spine in AS there
are essentially t w o different scoring methods. The Bath Ankylosing Spondylitis Radiology
Index (BASRI) is a global graded scoring method, quick and easy t o per fo rm and developed
to score the lateral and anter ior-poster ior view of the lumbar spine (both views combined
(0-4), the lateral view of the cervical spine (0-4) ' and the hips (BASI-hip, 0 -4 ) " . The mean
score of the N e w York scoring method of the Sl-joints and the several BASRI scores are
also combined in t w o composite scores: BASRI-spine (2-12) and BASRI-total (2-16)*'-.The
SASSS for the spine is a more detailed scoring method assessing different features such as
squaring, sclerosis and erosions at various locations of each v e r t e b r a ' " " . T h i s method is
scored on the lateral v iew of the lumbar spine on both the anter ior and poster ior sites of
the vertebrae (0-72) .The 'modi f ied ' SASSS is scored on the lateral view of the lumbar spine
only at the anter ior site of the vertebrae and on the lateral view of the cervical spine also
at the anter ior site of the vertebrae (0-72)''°.
In c h a p t e r 7, we compared reliability and changes over one and t w o years of all these
available radiological scoring methods in AS. Two well trained observers scored sets of
radiographs f rom the OASIS coho r t at baseline, one and t w o years fo l low up. These sets
were scored viewing the radiographs simultaneously (paired) w i t hou t knowledge o f the
chronology and in random order. The sets of radiographs available for reliability analyses
varied f rom 136 t o 200 depending on the number of missing scores fo r the various scoring
methods.
O u r results showed good intra- and interobserver reliability fo r almost all radiological
scoring methods. For categorical data, observer agreement was analyzed w i th linear
weighted kappa statistics and in case of cont inuous data w i th the Intraclass Corre lat ion
Coeff icient ( ICC). The combined BASRI scoring methods (BASRI-s and BASRI-t) and
especially the SASSS showed excel lent reliability ( ICC 0.85-0.98). Even w i th a scoring
interval of t w o years the intraobserver reliability remained very good ( ICC 0.85-0.96).The
reliability of the relatively new scoring method fo r the hips (BASRI-h) proved t o be good
(kappa 0.59- 0.60). O f considerat ion is that kappa indicates t o what ex tent t w o observers
"2 are capable t o perceive differences between radiographs. So kappa often turns ou t t o be
>, relatively low in case of a homogeneous group where every single radiograph receives more
p o r less the same score. This could be an explanation for relatively low intra-and
| interobserver agreement found fo r the SI scoring methods (kappa 0.36-0.70). Fur thermore,
2 measures that relate observed t o expected agreement (such as kappa and ICC) are of
fe l imited value in this situation because of high levels of expected agreement. This is also
jj" confirmed by the relatively low median scores for the SASSS-spine scoring methods
O (median SASSS-total 17.5-18.0, median modified-SASSS 16.3-16.8, range 0-72). Furthermore,
the low prevalence of radiological damage in SASSS inflates the ICC statistics resulting in a
tendency to overestimate the ICC.
Because of these considerations concerning ICC and kappa statistics we also calculated
concordance rates.The results showed that the perfect concordance rates between the two
observers were overall low (21-76%). Also the visual presentation of a Bland and Altman
method^' adds to the understanding of continuous data (SASSS method) especially because
it visualizes the distribution of the data and outliners over the entire range of observed data.
These plots showed a maximum difference of 26 points (possible range 0-72) between both
observers.
In our study only BASRI-s and BASRI-t were able to detect change based on a binomial cut-
off in a small percentage of patients over a two year period (7.5% and 7.4% resp.). This
change could not be identified by the other graded and detailed scoring methods. In case of
BASRI-s and BASRI-t observers agreed in up to 52% that no change occurred. Unfortunately
we may still conclude that relevant change occurred rarely because observers agreed in only
7.5% of cases that real change of at least I grade occurred. However, this might be
misleading information as we set a change of I grade arbitrarily as a cut off.The calculated
smallest detectable difference (SDD) for the SASSS is relatively larger"". So the cut off used
for SASSS seems to be very strict in comparison to the cut off used for the BASRI.This
might be a reason why we were unable to detect changes if we applied the SASSS.
Furthermore it could be that observer variation or error cannot be distinguished from
radiological progression in our study. Moreover, the use of a binomial cut-off induces
considerable loss of information and consequently loss of power to detect differences.
Another consideration may be that we followed an unselected group of patients, without a
particular request for disease activity. In a group of AS patients selected for high disease
activity, the situation might be different.
In this study the reliability of AS scoring methods seems to be moderate till good.
Unfortunately the scoring methods were unable to detect change over two-year time _
reliably in a considerable number of patients under the given scoring conditions (paired 2"
reading without knowledge of chronology, results based on average score of two observers, i?
cut-off based on SDD, unselected AS population).
Resume and perspective
I
Since there was a great need to create more uniformity in different studies focusing on AS 9:
the international ASAS working group was formed and this working group defined domains c
jg
for three AS core sets (DC-ART, SM-ARD/physical therapy, clinical record keeping). In the 5"
past 5 years, as a follow up of the work of the ASAS working group, several study groups •
worldwide, which focus on disease activity and outcome in AS have done a lot of work. "S
Results presented in this thesis are derived from a large cohort of AS patients followed 2_
longitudinally (OASIS) and relate to both aspects of outcome and disease activity. Chapter wi
6 and 7 are focusing on outcome measures in AS. Chapter 6 describes the development of
a valid disease specific quality of life instrument (ASQoL). Chapter 7 describes the
comparison of available AS radiological scoring methods. These scoring methods prove to
be reliable but none of the methods showed considerable change in two year time. In
detecting structural change in AS the role of Magnetic Resonance Imaging (MRI) may be
become more clear in near future because with MRI it is possible to assess both features
of damage and disease activity of the spine and sacroiliac joints in AS'*'"-'". In case of
conventional radiography in AS the possible influence of aspects such as the knowledge of
the chronology of the radiographs on sensitivity to change are under investigation,
Chapter 2-5 highlights aspects of disease activity.The results presented in these chapters are
all confirming that measuring aspects of disease activity in AS remains very difficult.
Although there has been a lot of effort in studying disease activity in AS there is still no
uniform measure which reflects AS disease activity in all its aspects. The acute phase
reactants such as ESR and CRP are elevated in a minority of AS patients and of most
important consideration is that AS patients and their treating physicians seem to have very
different understandings about disease activity. Therefore, until now fully patient derived
instruments such as BASDAI in combination with physicians assessment of AS disease
activity and/or elevated CRP are used as a 'gold standard' to include patients in clinical trials
as well as establish anti TNF a therapy in clinical practice.The main reason for this is the
persistent lack of a valid tool which combines all aspects of disease activity in AS. Recently
more potent biological drugs such as anti TNF » have come available in the treatment of AS
and the effects of these drugs are very promising'""*. In future studies evaluating the
effects of these potent drugs can be used to validate and compare ASAS selected
instruments used in the follow-up of AS and hopefully these studies will finally lead to the
development of a disease activity measure which reflects AS disease activity in all its aspects.
I
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Chapter 9
* SAMENVATTING EN DISCUSSIE
Samenvatting en discussie
Een internationale werkgroep (Assessment in Ankylosing Spondylitis, ASAS) heeft sets met
kernpunten gedefinieerd voor wetenschappelijk onderzoek bij de ziekte van Bechterew
(ofwel spondylitis ankylopoetica) met als doel meer uniformiteit te scheppen in
wetenschappelijk onderzoek naar ziekte-activiteit en ziekte-uitkomst bij deze aandoening.
Deze sets met kernpunten werden gedefinieerd voor drie onderzoeksettings: therapie die
het beloop van de ziekte beinvloedt (disease controlling anti-rheumatic therapy, DC-ART),
medicatie en therapie die de symptomen van de ziekte beinvloeden (symptom modifying
anti-rheumatic drugs, SM-ARD/physical therapy) en reguliere behandeling (clinical record
keeping). De volgende domeinen werden voor alle drie onderzoeksettings geselecteerd:
lichamelijk functioneren, pijn, mobiliteit en stijfheid van de wervelkolom.globale indruk van
de patient tav ziekte en moeheid. De domeinen voor 'clinical record keeping' en 'DC-ART'
zijn uitgebreid met acute fase reacties, perifere gewrichten en peesaanhechtingen (enthesis),
'DC-ART bevat ook de domeinen: rontgen onderzoek van wervelkolom en heupen.
In navolging van het werk van de ASAS werkgroep heeft dit proefschrift vooral betrekking
op verschillende aspecten van ziekte-activiteit en ziekte-uitkomst bij de ziekte van
Bechterew. Het eerste deel van het proefschrift (hoofdstuk 2-5) gaat vooral over ziekte-
activiteit terwiji de hoofdstuken 6 en 7 zich met name richten op ziekte-uitkomst. Bijna alle
resultaten beschreven in dit proefschrift zijn afkomstig van een internationaal
observationeel 'multicenter' onderzoek: 'Outcome in Ankylosing Spondylitis International
Study' (OASIS). In deze studie werden 217 opeenvolgende poliklinische patienten met de
ziekte van Bechterew geincludeerd. Dit cross-sectioneel cohort van Bechterew patienten
voldeed aan de gemodificeerde 'New York' criteria en werd longitudinaal gevolgd in
verschillende academische- en perifere ziekenhuizen in Europa. Honderdzevenendertig
patienten zijn afkomstig uit het academisch ziekenhuis Maastricht en het Maasland
2 ziekenhuis in Sittard (Nederland), 55 patienten uit het Hopital Cochin in Parijs (Frankrijk)
t en 25 patienten uit het academisch ziekenhuis Gent (Belgie). Al deze ziekenhuizen zijnsecondaire en/of tertiaire referentie centra. Overeenkomstig met andere Bechterew
^ populaties is ongeveer twee derde van de OASIS patienten van het mannelijk geslacht. Aan
g het begin van de OASIS studie was de gemiddelde leeftijd van de patienten 43 jaar (SD 13
.& jaar) en hadden de patienten een gemiddelde ziekte duur van I I jaar (SD 8 jaar). Bij 27%
e van de patienten werd een perifere artritis vastgesteld door de behandelend reumatoloog.
gf In elk van de drie participerende landen werden de OASIS patienten ieder half jaar
gedurende 2 jaar onderzocht door steeds dezelfde getrainde persoon (2 reumatologen en
I onderzoeksverpleegkundige) volgens een vastgesteld protocol. Onafhankelijk van de
bevindingen van deze onderzoekers werden de patienten ook regulier gezien door de
behandelend reumatoloog.
De vergelijking van twee indexen voor fysiek functioneren bij de ziekte van
Bechterew
Fysiek functioneren is gerelateerd aan ziekte-activiteit en uiteindelijke schade aangericht
door de ziekte van Bechterew. De ASAS werkgroep selecteerde fysiek functioneren
gemeten met de'Dougados Functionele Index' (DFI) en de'Bath Ankyloserende Spondylitis
Functionele Index' (BASFI) voor de domeinen van alle drie de onderzoeksettings. In
hoofdstuk 2 werden deze twee veel gebruikte en gevalideerde ziekte specifieke
functionele indexen met elkaar vergeleken. Aangezien ziekte-activiteit en schade beide
gerelateerd zijn aan fysiek functioneren was het belangrijkste doel van deze cross-sectionele
studie om de relatie van BASFI en DFI met deze twee aspecten van de ziekte te
onderzoeken.Wanneer de resultaten van deze studie zouden laten zien dat een van deze
twee indexen beter zou presteren, dan zou die index uniform gebruikt kunnen worden voor
het meten van fysiek functioneren.
De BASFI bestaat uit 10 vragen op een visuele analoge schaal (VAS) en alle vragen betreffen
activiteiten uit het dagelijks leven. Het gemiddelde van de scores van de afzonderlijke 10
vragen vormt de uiteindelijke score. De DFI bestaat uit twintig 5 punts Likert respons
vragen over het in staat zijn om verschillende dagelijkse activiteiten uit te voeren. De totale
score (range van 0-40) wordt berekend door de som van de afzonderlijke vragen te
berekenen. Aangezien er geen 'gouden standaard' bestaat voor het meten van ziekte-
activiteit bij de ziekte van Bechterew hebben we voor ziekte-activiteit drie
meetinstrumenten gekozen: ziekte-activiteit aangegeven op een visuele analoge schaal (VAS,
0-10 cm) door de arts en de patient en de Bath Ankylosing Spondylitis Disease Activity
Index (BASDAI, range 0-10). Als meetinstrumenten voor schade werden een globale en een
gedetailleerde rontgen scoringsmethode specifiek voor het scoren van de wervelkolom bij
de ziekte van Bechterew gekozen: de Bath Ankylosing Spondylitis Radiology Index-spine
(BASRI-s, range 0-12) en de gemodificeerde Stoke Ankylosing Spondylitis Spine Score O
(SASSS, range 0-72). Voor de analyses hebben we de twee meest contrasterende groepen -8
patienten gebruikt: Bechterew patienten waarbij ziekte activiteit hoog (score a 6.0) en laag ™
(score s 4.0) was volgens de drie ziekte-activiteit instrumenten.Verder werden er Receiver to
Operator Curves (ROC) gemaakt voor beide functionele indexen versus de drie ziekte- 3
activiteit instrumenten. I
In onze patienten populatie werden relatief lage waarden voor de functionele indexen en §.
de ziekte-activiteit instrumenten gevonden. Er waren 7 BASFI vragenlijsten versus 28 DFI **
ft
vragenlijsten met een of meer niet ingevulde vragen. Zoals verwacht waren beide '
functionele indexen hoog met elkaar gecorreleerd (Spearman 0.89). De correlaties van de R
BASFI en DFI met de ziekte-activiteit instrumenten was vergelijkbaar voor beide indexen 8
S'
waarbij correlatie met de BASDAI het hoogst was (respectievelijk 0.59 en 0.57). ROC
curven voor elk van de twee functionele indexen met de drie ziekte- activiteit instrumenten "S
OQ
liet de beste curve met de hoogste sensitiviteit en specificiteit zien voor beide functionele **
indexen versus de BASDAI (BASFI: respectievelijk 94% en 87% en DFI: respectievelijk 93% w
en 79%) De afkappunten voor het onderscheiden van lage en hoge ziekte-activiteit waren
duidelijk hoger voor de BASFI (± 40% van de volledige schaal) in vergelijking met de DFI
(± 20 % van de volledige schaal). Wanneer we echter deze afkappunten gebruiken om
onderscheid te maken tussen hoge en lage ziekte-activiteit gebaseerd op de functioned
scores worden er behoorlijk hoge percentages patienten fout geclassificeerd (12-30%). Het
percentage fout geclassificeerde patienten was het laagste voor de BASFI afkappunten in
combinatie met ziekte-activiteit gemeten met de BASDAI (12%).
Ziekte-activiteit gemeten met de BASDAI komt dus het dichtst bij het ziekte-activiteit aspect
van de BASFI. Een reden hiervoor zou kunnen zijn dat beide indexen geheel door de patient
gerapporteerd worden en door dezelfde onderzoeksgroep ontwikkeld zijn. Aangezien fysiek
functioneren bij de ziekte van Bechterew niet alleen bepaald wordt door ziekte-activiteit kan
ook niet verwacht worden dat alle patienten goed geclassificeerd werden.Ten aanzien van de
instrumenten gekozen voor het bepalen van schade laat de BASRI-s een relatief hogere
mediaan score voor radiologische schade zien dan de gemodificeerde SASSS: respectievelijk
7.0 (range 2-12) en 12.0 (range 0-72). Correlaties van beide functionele indexen met BASRI-
s en gemodificeerde SASSS waren vergelijkbaar (respectievelijk 0.42 en 0.36).
In deze cross-sectionele studie lijkt de BASFI iets beter te presteren dan de DFI met
betrekking tot aspecten van ziekte-activiteit en uitvoerbaarheid (BASFI kost minder tijd om
in te vullen en er waren minder ontbrekende antwoorden). Op basis van de resultaten van
dit onderzoek is er anderszins geen voorkeur ten aanzien van BASFI en DFI uit te spreken.
De BASFI werd enkele jaren na de DFI ontwikkeld en vermijdt een aantal vermoedelijk
overtollige vragen en vragen met betrekking op symptomen in plaats van fysiek
functioneren.Verder bevat de BASFI drie vragen die de validiteit van de inhoud verbeteren.
Voor twee van deze vragen is dit bewezen bij de ontwikkeling van de HAQ-s. Bij patienten
met reumatoide artritis en artrose werd aangetoond dat alleen de derde van deze vragen,
betreffende fysiek belastende activiteiten, kon discrimineren tussen bijna maar niet geheel
gezonde patienten die niet scoorden op een van de andere vragen.
Aan de andere kant bevat de BASFI vragen over ongewone taken en de DFI bevat diverse
vragen met betrekking op verschillende aanvullende domeinen die niet in de BASFI
geincludeerd zijn. Er is een literatuur overzicht gepubliceerd van alle bestaande studies met
betrekking tot de vergelijking van de BASFI en DFI. De enige studie met een rechtstreekse
vergelijking van de twee functionele indexen liet zien dat beide indexen onderscheid konden
maken tussen poliklinische en klinische patienten maar alleen de BASFI kon de effecten van
een intensieve fysiotherapie gedurende drie weken aantonen. In zes studies met betrekking
tot fysiotherapie was de DFI vier maal niet in staat onderscheid te maken tussen de
verschillende behandelingen terwijl in de twee andere studies de BASFI wel kon
, discrimineren tussen de verschillende behandelingen. Een reden hiervoor kan zijn dat in de
* studies waar de DFI gebruikt werd de scores van de DFI vragen dicht bij de normale
k waarden lagen. Het gevolg hiervan kan zijn dat het niet mogelijk is verder te verbeteren
9" wanneer er sprake is van alleen milde invaliditeit. Om de sensitiviteit van de DFI te
O verbeteren stelden de auteurs voor de vragen om te zetten van een drie punt Likert
respons schaal naar een vijf punt Likert respons schaal.
De DFI discrimineerde goed tussen de verschillende behandelingen in op een na alle
SMARD trials en in een DC-ART studie waarbij deze index werd gebruikt. De BASFI
discrimineerde tussen de verschillende behandelingen in een van de twee SMARD trials
waarbij de index werd gebruikt. De enige SMARD trial waarbij een rechtstreekse
vergelijking van de twee indexen is gedaan liet zien dat beide indexen even goed
discrimineerden tussen placebo en behandelgroep. Er is geen DC-ART studie beschikbaar
die de BASFI en de DFI rechtstreeks vergelijkt. In de enige studie die een conventionele DC-
ART (sulfasalazine) evalueerde werd de DFI gebruikt en in drie andere studies waar de
effecten van anti tumor necrosis factor (TNF) a werden geevalueerd werd de BASFI
gebruikt. In al deze studies discrimineerde de gebruikte index goed tussen de verschillende
behandelarmen.
Samenvattend lijkt er een lichte voorkeur te bestaan om de DFI te gebruiken in SMARD
trials en de BASFI in trials met betrekking tot fysiotherapie. Gezien de goede effecten van
biologische geneesmiddelen zoals anti-TNF a bij de behandeling van de ziekte van
Bechterew is een rechtstreekse vergelijking van beide functioned indexen in toekomstige
DC-ART trials goed mogelijk; daarbij zullen dan ook'effect sizes' en/of'standardised reponse
mean' van beide indexen berekend moeten worden.
Bezinking (BSE) versus C-reactive protein (CRP) bij de ziekte van Bechterew
De acute fase bloed testen, BSE (mm/uur) en CRP (mg/l), worden beide regelmatig gebruikt
ter evaluatie van de ziekte activiteit bij Bechterew patienten. Het bepalen van acute fase
reacties is door de ASAS werkgroep voorgesteld als een domein voor de onderzoeksettings
DC-ART trial en reguliere behandeling. Het is bekend dat de gemiddelde waarde van deze
twee acute fase reacties laag zijn bij patienten met de ziekte van Bechterew in vergelijking O
met patienten met reumatoide artritis. -6
Hoofdstuk 3 van dit proefschrift beschrijft een onderzoek met als doel te bepalen of er •»
onderscheidt gemaakt kan worden tussen BSE en CRP voor het meten van ziekte-activiteit i/i
bij de ziekte van Bechterew. Gezien er verschillen kunnen bestaan in het klinisch beeld bij 3
Bechterew patienten ten aanzien van BSE en CRP is onze patienten populatie in twee <
groepen verdeeld: patienten met alleen spinale betrokkenheid (n=l49) en patienten met 3.
ook actieve perifere artritis en/of inflammatoire darmziekte (n=42). Zoals eerder werd "
aangegeven bestaat er geen 'gouden standaard' voor het meten van ziekte-activiteit bij de _^
ziekte van Bechterew. We bestudeerde daarom de relatie van BSE en CRP met drie S
vervangende klinische ziekte-activiteit instrumenten volgens dezelfde methodologie en 8
statische procedure als beschreven in de vorige studie met betrekking tot de vergelijking •
van BASFI en DFI. Een tweede doel van deze studie was na te gaan of hoge waarden voor "S
BSE en CRP de mate van ziekte-activiteit reflecteren gedefinieerd door de drie _
geselecteerde ziekte-activiteit instrumenten. 31
De resultaten lieten zien dat in de groep met alleen spinale betrokkenheid de meeste
patienten normale waarden voor BSE en CRP hadden. Daarentegen lieten de Bechterew
patienten met ook perifere artritis en/of inflammatoire darmziekte licht verhoogde waarden
voor BSE en CRP zien. Allen voor de BSE was dit verschil tussen de twee subgroepen
statistisch significant. Dertig procent van de patienten in beide subgroepen hadden een
verhoogde BSE en een normale CRP of vice versa en in de meeste van deze gevallen werden
waarden van net boven de normale grens gevonden als de acute fase reactie verhoogd was.
Over het algemeen werden er in beide subgroepen relatief lage scores voor de ziekte-
activiteit instrumenten gevonden. Opvallend is het verschil in beoordeling van ziekte-
activiteit door de arts (VAS) aan de ene kant en de twee op de patient gebaseerde
instrumenten aan de andere kant (BASDAI en ziekte-activiteit aangegeven op een VAS door
de patient). Aan het begin van de studie werd dit weergegeven in zeer verschillende
gemiddelde waarden van ziekte-activiteit aangegeven door de arts versus BASDAI en
ziekte-activiteit aangegeven door de patient (voor de groep met spinale betrokkenheid:
respectievelijk 1.5 versus 3.6 en 3.9 en voor de groep met perifere artritis en/of
inflammatoire darmziekte: respectievelijk 2.5 versus 4.3 en 4.1). In de groep met alleen
spinale betrokkenheid had maar 3% van de patienten hoge ziekte activiteit beoordeeld door
de arts in tegenstelling tot ziekte activiteit beoordeeld door de patient en BASDAI
(respectievelijk 21% en 11%). Over het algemeen lieten de ROC curven lage afkappunten
zien in beide subgroepen voor zowel BSE als CRP Gebaseerd op deze afkappunten waren
sensitiviteit en specificiteit redelijk met de hoogste sensitiviteit (100%) voor ziekte- activiteit
aangegeven op een VAS door de arts. Helaas waren de bijbehorende positief voorspellende
waarden, die belangrijk zijn in de klinische praktijk, laag met hoge percentages fout
geclassificeerde patienten. Deze cross-sectionele studie laat zien dat zowel BSE als CRP niet
overeenkomen met ziekte-activiteit zoals gedefinieerd in deze studie. Op basis van deze
resultaten kan er dus geen duidelijke voorkeur worden gegeven aan een van deze twee
acute fase reacties. In relatie met progressie van schade bij de ziekte van Bechterew zou er
wel een duidelijk verschil kunnen bestaan tussen BSE en CRP en dit zal in de toekomst ook
verder geevalueerd moeten worden.
Overige studies die een rechtstreekse vergelijking van BSE en CRP laten zien zijn moeilijk
te interpreteren doordat er steeds verschillende definities voor ziekte-activiteit worden
gebruikt. Er is een literatuuroverzicht gepubliceerd van alle bestaande studies met
betrekking tot de vergelijking van BSE en CRP bij de ziekte van Bechterew. In vijf van deze
zeven studies werd er geen verschil gevonden tussen BSE en CRP en de resultaten van de
twee andere studies geven aan dat CRP beter gerelateerd is aan ziekte activiteit dan BSE.
Twee studies geven aan dat verhoogde BSE en CRP vaker gezien worden in Bechterew
patienten met perifere manifestaties van de ziekte. BSE en CRP werden niet rechtstreeks
vergeleken in een SMARD trial. In de beschikbare SMARD trials werd geen onderscheidend
vermogen gevonden van BSE en CRP tussen de verschillende behandelingen. Een van deze
SMARD trials rapporteerde een lage 'standardised response mean' voor CRP. Negen DC-
ART trials (een methotrexaat trial en acht sulfasalazine trials) lieten geen significant effect
van de gebruikte medicatie zien en waarschijnlijk is hierdoor ook geen discriminerend
vermogen van BSE en CRP zichtbaar tussen de geteste medicatie en placebo. De twee DC-
ART trials met een rechtstreekse vergelijking van de twee acute fase reacties lieten
tegengestelde resultaten zien. In twee studies naar de effecten van anti-TNF a konden
zowel BSE als CRP erg goed onderscheid maken tussen de verschillende behandelingen.
Alhoewel de 'effect sizes' en 'standardised response mean'voor BSE en CRP hoog waren in
deze studies (>3) werden de exacte waarden hiervan helaas niet gerapporteerd. Op basis
van deze resultaten kan voor geen van de drie onderzoeksettings een definitieve keus
gemaakt worden tussen BSE en CRP. Gezien de veelbelovende resultaten van biologische
geneesmiddelen zoals anti-TNF alfa bij de behandeling van de ziekte van Bechterew is er
een rechtstreekse vergelijking van BSE en CRP mogelijk waarbij door berekening van 'effect
sizes' en/of standardised reponse mean' van beide acute fase reacties een betere vergelijking
mogelijk is. Tevens zal in de toekomst de relatie van BSE en CRP met de progressie van
schade bij de ziekte van Bechterew onderzocht moeten worden.
Patient gerapporteerde gewricht scores bij de ziekte van Bechterew
In hoofdstuk 4 wordt een studie gepresenteerd naar de betrouwbaarheid van het
rapporteren van pijnlijke en gezwollen gewrichten door de patient zelf. Een klein gedeelte
van de Bechterew patienten heeft een perifere artritis (± 25%). Normaal gesproken wordt
artritis klinisch gediagnostiseerd door een arts of een goed getrainde verpleegkundige.
Wanneer de gewrichtsscores aangetoond bij lichamelijk onderzoek door de arts vervangen
kunnen worden door gewrichtsscores door de patient zelf zou dit een groot voordeel
betekenen voor reumatologen en in het bijzonder klinisch onderzoekers. De
betrouwbaarheid van door de patienten zelf gerapporteerde gewrichtsscores bij de ziekte
van Bechterew is nooit eerder onderzocht. Bij patienten met reumatoTde artritis is de
betrouwbaarheid van patient gerapporteerde gewrichtsscores uitgebreid onderzocht en de
resultaten lieten zowel hoge als lage betrouwbaarheid zien. In onze studie werd aan 217
Bechterew patienten gevraagd hun pijnlijke en gezwollen gewrichten aan te kruisen op een
mannequin, ontwikkeld volgen de methode van Stewart waarop respectievelijk 44 en 40
gewrichten aangekruist kunnen worden. Op dezelfde dag maar zonder dat de resultaten van
de patienten bekend waren rapporteerden drie onderzoekers (een persoon voor elk
onderzoekscentrum) de pijnlijk en gezwollen gewrichten van deze patienten op
vergelijkbare mannequins. De resultaten lieten zien dat er op groepsniveau een consistent
verschil was tussen het aantal gerapporteerde pijnlijke en gezwollen gewrichten door
patienten en onderzoekers met een bijbehorende matige overeenstemming (Intraclass
Correlatie Coefficient tussen 0.51 en 0.71) van het totaal aantal pijnlijke en gezwollen
gewrichten en zelfs een slechte tot matige overeenstemming (kappa tussen 0.23 en 0.64)
van de individuele gewrichtsscores. Patienten scoorden consistent meer pijnlijke gewrichten
en de onderzoekers scoorden meer gezwollen gewrichten. Mogelijke verklaringen hiervoor
. zijn : (I) Bechterew patienten kunnen niet goed differentieren tussen een pijnlijk gewricht
X en pijn veroorzaakt door enthesitis gezien de aanhechtingen vlak bij het gewricht
, > gelokaliseerd zijn en (2) Bechterew patienten zijn niet getraind om gezwollen gewrichten te
1 detecteren. De enthesis index volgens Mander was alleen significant gecorreleerd met het
totaal aantal gezwollen gewrichten gerapporteerd door de onderzoekers. Op patientniveau
waren de resultaten zelfs nog slechter en dit is duidelijk zichtbaar gemaakt in Bland en
Altman plots. Door patient gerapporteerde gewrichtsscores kunnen nog steeds van waarde
zijn als patienten kunnen differentieren tussen de aanwezigheid van mono- oligo- en
polyartritis. Ook voor deze onderverdeling was volledige overeenstemming tussen
onderzoekers en patienten erg laag (respectievelijk 17%, 17% en 22%). Alleen wanneer er
geen sprake was van gezwollen gewrichten was de overeenstemming tussen onderzoekers
en patienten goed (82%). Bechterew patienten kunnen dus wel oordelen over de
afwezigheid van gezwollen gewrichten maar ze zijn niet in staat om om de aanwezigheid van
zwelling aan te geven zelfs niet in de grove categorieen van mono- oligo- en polyartritis. In
deze studie hebben we officieel geen test-retest betrouwbaarheid onderzocht maar de
resultaten verkregen met de baseline en I jaars data waren vergelijkbaar. Op basis van deze
resultaten kunnen gewrichtsscores gerapporteerd door onderzoekers/artsen dus niet
vervangen worden door gewrichtsscores gerapporteerd door de Bechterew patienten zelf.
Alleen informatie van de patienten ten aanzien van het afwezig zijn van gezwollen
gewrichten is voldoende betrouwbaar om bruikbaar te kunnen zijn.
Ziekte-activiteit bij de ziekte van Bechterew
Aangezien er een grote variatie bestaat in het klinische beeld tussen verschillende
Bechterew patienten is het erg moeilijk om ziekte-activiteit te definieren bij deze ziekte.
Patienten hebben axiale betrokkenheid in verschillende gradaties maar kunnen daarbij ook
verschillende extra-spinale manifestaties van de ziekte hebben. Deze klinische diversiteit in
zowel ernst als in lokalisatie zorgt ervoor dat instrumenten die gebruikt worden om ziekte-
activiteit te meten aan hoge eisen moeten voldoen.Verder hebben Bechterew patienten en
hun behandelend reumatologen zeer uiteenlopende inzichten ten aanzien van ziekte-
activiteit. Hoofdstuk 5 beschrijft op basis van welke criteria Bechterew patienten en
e reumatologen ziekte-activiteit beoordelen. Ons doel was om verschillen in inzicht ten
Bf> aanzien van ziekte-activiteit tussen patienten en reumatologen te verkennen. Voor deze
studie werden data van het OASIS cohort gebruikt. Aangenomen mag worden dat de
patienten uit dit cohort het hele klinische spectrum van Bechterew patienten omvat dat
normaal gesproken door reumatologen gezien worden. De patienten werden geincludeerd
onafhankelijk van geslacht, leeftijd, duur van de ziekte, ernst van de ziekte en mate van
ziekte-activiteit.
In deze studie werd ziekte-activiteit bestudeerd vanuit het perspectief van zowel de patient
als van de arts. Ziekte-activiteit door de arts en de patient aangegeven op een visuele
analoge schaal (VAS range: 0 = niet actief en 10 = zeer actief) werd onderverdeeld in 'hoge'
ziekte-activiteit (VAS a.6.0) en 'lage' ziekte-activiteit (VAS s 4.0). Meetinstrumenten die
door de ASAS werkgroep geselecteerd zijn voor gebruik bij de evaluatie van de ziekte van
Bechterew werden iedere zes maanden toegepast over een periode van twee jaar.
Datareductie van deze instrumenten werd verricht met behulp van factoranalyse. Dit
resulteerde in vier factoren met onderling correlerende meetinstrumenten: "metingen van
de mobiliteit van de wervelkolom', 'metingen door de arts','metingen door de patient' en
'laboratoriumbepalingen' (Cronbachs alpha tussen 0.52 en 0.81; verklaarde variantie 61%).
Er werd aangenomen dat de instrumenten binnen een factor hetzelfde onderliggende
construct bepalen. Een discriminantanalyse met de factorwaarden werd verricht om
onderscheid te kunnen maken tussen 'lage' en 'hoge' ziekte-activiteit voor zowel het
perspectief van de patient als dat van de arts. Deze analyse liet zien dat de factor,'metingen
door de patient', het meest bijdragend was (gezamenlijke (pooled) correlatie 0.84) in het
onderscheid maken tussen de twee niveaus van ziekte-activiteit gedefinieerd door de
patient. De bijdrage van de andere drie factoren was maar minimaal (pooled correlatie < 0.30).
Daarentegen droegen de drie factoren:'metingen door de arts','metingen van de mobiliteit
van de wervelkolom' en laboratoriumbepalingen' het meest bij in het discrimineren tussen
de twee niveaus van ziekte-activiteit gedefinieerd door de arts (pooled correlatie:
respectievelijk 0.62,0.48 en 0.48). De factor,'metingen door de patient', droeg in het geheel
niet bij (pooled correlatie 0.05). De discriminantanalyse verricht met baseline data en de
data van de andere momenten liet geen verschillen zien. De discriminantscores werden
gebruikt voor multipele regressie analyse om de prioriteit van de instrumenten te bepalen
ten aanzien van de bijdrage aan ieder perspectief van ziekte-activiteit. Het ziekte-activiteit
perspectief van de patient werd het beste verklaard door de instrumenten: 'pijn van de
wervelkolom','BASFI'.'gewrichtspijn', en 'moeheid'. Het perspectief van de arts kwam het
beste tot uiting met de instrumenten:'cervicale rotatie'.'aantal gezwollen gewrichten", CRP'
en 'intermalleolaire afstand'. Onze resultaten bevestigen dat patienten en artsen een heel O
ander zicht hebben op wat ziekte-activiteit bij de ziekte van Bechterew betekent. Bechterew -6
patienten beoordelen ziekte-activiteit op basis van klachten terwijl artsen ziekte-activiteit *
beoordelen op basis van instrumenten die ontsteking en ernst van de ziekte meten. M
Uit deze studie volgen nog een aantal andere conclusies. De BASFI, een index primair 3
ontworpen om fysiek functioneren bij Bechterew patienten te meten, sluit ook aan bij het
perspectief van ziekte-activiteit van de patient. Het lijkt er tevens op dat Bechterew
patienten hun inschatting van ziekte-activiteit gedeeltelijk maken op basis van wat ze •*
lichamelijk kunnen doen. Over het algemeen kunnen Bechterew patienten goed '
onderscheid maken tussen ziekte-activiteit (bepaald door klachten) en de ernst van de S
ziekte. Ziekte-activiteit vanuit het patienten perspectief wordt niet bepaald door acute fase jjj,
reacties. Het oordeel over ziekte-activiteit van de arts wordt gebaseerd op een combinatie •
van constructen met instrumenten die informatie over ziekte-activiteit en ernst van de "8
ziekte combineren. Opvallend is dat CRP als variabele werd geincludeerd aangezien de 2.
waarde hiervan niet bij de arts bekend was op het moment dat er een oordeel werd 3
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gegeven over ziekte-activiteit. Momenceel worden volledig op het oordeel van de patient
gebaseerde ziekte-activiteit instrumenten, zoals BASDAI, in combinatie met ziekte activiteit
aangegeven door de arts en/of verhoogde CRP gebruikt als 'gouden standaard' voor het
meten van ziekte-aciviteit bij de ziekte van Bechterew voor het includeren van patienten in
klinische trials en voor de besluitvorming rondom het starten van antiTNF « therapie in de
klinische praktijk. Er is echter nog steeds geen wetenschappelijk bewijs dat ziekte-activiteit
instrumenten gebaseerd op het oordeel van de patient of de arts geassocieerd zijn met
ziekte-uitkomst op de lange duur. Deze belangrijke informatie is nodig om instrumenten te
kunnen selecteren die zowel de ziekte-activiteit als de uitkomst van de ziekte het beste
weergeven. Aangezien de keuzes voor medicamenteuze behandeling van de ziekte van
Bechterew groter worden is het ook belangrijker om instrumenten te definieren die een
eenduidig construct van ziekte-activiteit en ziekte-uitkomst meten zodat deze gebruikt
kunnen worden in klinische trials.
Kwaliteit van leven bij de ziekte van Bechterew
Er is een groeiende belangstelling voor het meten van kwaliteit van leven (QoL) bij
chronische invaliderende aandoeningen. Met name in studies ontwikkeld om de impact van
nieuwe farmaceutische producten te meten of om verschillende behandelmethoden met
elkaar te vergelijken wordt steeds vaker kwaliteit van leven gemeten. Ziektespecifieke
instrumenten gebruikt om het beloop van de ziekte van Bechterew te evalueren richten zich
vooral op fysieke beperkingen en/of fysiek functioneren. Er zijn wel generieke instrumenten
die de algehele gezondheid meten maar er bestaat nog geen ziektespecifiek instrument voor
het meten van kwaliteit van leven bij de ziekte van Bechterew.
Hoofdstuk 6 beschrijft de ontwikkeling van de Ankylosing Spondylitis Quality of Life vragenlijst
(ASQoL). Ons doel was om een valide en betrouwbaar Bechterew specifiek kwaliteit van leven
instrument te ontwikkelen dat relevant en acceptabel is voor respondenten. De ASQoL is
gelijktijdig ontwikkeld in Engeland en Nederland. Alle geincludeerde Bechterew patienten
voldeden aan de gemodificeerde New York criteria. De methodologie gebruikt om de ASQoL
te ontwikkelen combineert de theoretische principes van het'needs-based' kwaliteit van leven
model met de statistische en diagnostische kracht van het Rasch-model.
De ontwikkeling van de vragenlijst bestaat uit vijf stadia. De inhoud van de eerste versie van
de vragenlijst was afkomstig van interviews met 30 patienten in Engeland en 25 patienten in
Nederland (stadium I). Stadium 2 betreft het selecteren van items en antwoord type
waarbij de eerste proef vragenlijst met 41 items werd gevormd. Er werden test interviews
gedaan met deze proef vragenlijst bij 15 patienten in Engeland en 15 patienten in Nederland
om informatie over validiteit van vorm en inhoud te verkrijgen. Hierbij ontstond een
vragenlijst met 36 items (stadium 3). Stadium 4 was een onderzoek per post in Engeland
(n= 121) met als doel een efficientere versie van de ASQoL te ontwikkelen. Met behulp van
Raschanalyse werd het aantal vragen verminderd tot 26 items. Raschanalyse van de data van
een laatste onderzoek per post werd in beide landen (Engeland: n=l64; Nederland: n=l54)
gedaan om eigenschappen van de schaal, betrouwbaarheid, interne consistentie en construct
validiteit te meten (stadium 5). Deze analyse liet enkele misplaatste items zien maar liet
tevens zien dat de items een hierarchische volgorde hadden en stabiel waren over de tijd.
De problematische items werden verwijderd hetgeen resulteerde in de definitieve ASQoL
met 18 items. Beide taal versies van de ASQoL hadden een uitstekende interne consistentie
(Cronbach's alfa: 0.89-0.91), test-retest betrouwbaarheid (Intraclass Correlatie Coefficient:
Engeland:0.92; Nederland: 0.91) en validiteit. De ASQol kan een waardevol instrument zijn
in zowel de klinische situatie als bij wetenschappelijk onderzoek wanneer de invloed van de
ziekte van Bechterew en bijbehorende behandeling op kwaliteit van leven gemeten wordt.
Onafhankelijk van deze studie werd een goede betrouwbaarheid, validiteit en respons van
de ASQoL gevonden in een studie waarbij door de patient bepaalde ziekte specifieke
instrumenten werden vergeleken. De ASQoL werd sinds de ontwikkeling gebruikt in twee
trials. Een studie evalueert het effect van kuurtherapie en de andere het effect van anti-TNF
a therapie. Beide studies laten zien dat de ASQol in staat is te discrimineren tussen de
verschillende behandelingen. De 'standardised reponse mean' (SRM) en 'effect size' (ES)
werden alleen berekend voor de kuurtherapie trial met matige respons scores (SRM: 0.24
en EF: 0.22) passend bij het matige behandeleffect. Er was een onderling vergelijkbaar hoge
respons van de ASQoL en de BASDAI in de studie naar het effect van etanercept.
Radiologische scoringsmethoden bij de ziekte van Bechterew
Radiologische schade is een belangrijke uitkomst maat bij de ziekte van Bechterew. Het is
erg moeilijk om deze radiologische schade te evalueren.Veranderingen van de sacroiliacale
gewrichten (SI) worden meestal gescoord door gebruik te maken van de New York criteria
of de bijna identieke scoringsmethode ontwikkeld door de Stoke groep. Beide SI Q
scoringsmethoden differentieren 5 graden (range 0-4 voor ieder SI gewricht). Er zijn twee -o
scoringsmethoden om de lumbale en cervicale wervelkolom te scoren. De'Bath Ankylosing i
Spondylitis Radiology Index' (BASRI) is een globale, snelle en makkelijke scoringsmethode wi
ontwikkeld voor het scoren van de voor-achterwaartse en de laterale opname van de 3
lumbale wervelkolom (range beide opnames gecombineerd 0-4), de laterale opname van de <
cervicale wervelkolom (range 0-4) en de heupen ( BASRI-h, range 0-4 voor iedere heup; 3
daarna gemiddelde rechter en linker heup). De gemiddelde score van de New York "
scoringsmethode voor de SI gewrichten gecombineerd met de verschillende BASRI ^
scoringsmethoden vormen twee samengestelde scoringsmethoden: BASRI-'spine' (range 2-
12) en BASRI-'total' (range 2-16). De SASSS methode voor de wervelkolom is een meer S.
gedetailleerde scoringsmethode die verschillende aspecten zoals 'squaring', sclerose en •
erosies op verschillende plaatsen van iedere wervel scoort. Deze methode wordt gescoord "8
op de laterale opname van de lumbale wervelkolom aan de voor- en achterzijde van iedere _^
wervel (SASSS, range 0-72). De 'gemodificeerde' SASSS wordt gescoord op de laterale —
;I
opname van zowel de lumbale als cervicale wervelkolom waarbij alleen de voorzijde van
iedere wervel gescoord wordt (range 0-72). In hoofdstuk 7, werd de betrouwbaarheid en
radiologische verandering na I en 2 jaar follow-up van al deze beschikbare radiologische
scoringsmethoden vergeleken. Twee goed getrainde 'observers' scoorden sets met
rbntgenfoto's van het OASIS cohort gemaakt op baseline, I en 2 jaar follow-up. De
rontgenfoto's van een set werden gelijktijdig (gepaard) gescoord zonder kennis van de
chronologische volgorde. De volgorde waarin alle sets werd gescoord was willekeurig.
Afhankelijk van het aantal missende scores voor iedere methode varieerde het aantal
beschikbare sets voor betrouwbaarheidsanalyse tussen de 100 en 136.
Onze resultaten lieten goede 'intra- en interobserver' betrouwbaarheid zien voor bijna alle
scoringsmethoden. 'Observer' betrouwbaarheid voor categoriale data werd geanalyseerd
met behulp van lineair gewogen kappa statistiek. Continue data werd geanalyseerd met
behulp van de Intraclass Correlatie Coefficient (ICC). De gecombineerde BASRI
scoringsmethoden (BASR-s) en BASRI-t ) en in het bijzonder de SASSS lieten een zeer
goede betrouwbaarheid zien (ICC 0.85-0.98). Zelfs met een scoringsinterval van twee jaar
was de 'intra-observer' betrouwbaarheid goed (ICC 0.85-0.96). De betrouwbaarheid van de
relatief nieuwe scoringsmethode voor de heupen (BASRI-h) bleek ook goed te zijn (kappa
0.59-0.60).
Kappa geeft aan in welke mate twee 'observers' verschillen tussen rontgenfoto's kunnen
waarnemen. Kappa is dus laag bij een homogene groep data waarbij iedere rontgenfoto dus
min of meet dezelfde score heeft gekregen. Dit zou een verklaring kunnen zijn voor de
relatief lage 'intra- en interobserver' betrouwbaarheid gevonden voor de SI
scoringsmethoden (kappa 0.36-0.70). In deze situatie zijn statistische methoden die de
geobserveerde overeenstemming relateren aan de verwachte overeenstemming (zoals
kappa en ICC) van beperkte waarde gezien de hoge mate van verwachte overeenstemming.
Dit wordt nog eens bevestigd door de relatief lage mediaan scores voor de SASSS
scoringsmethoden (mediaan SASSS-totaal 17.5-18.0, mediaan 'gemodificeerde' SASSS 16.3-
16.8, range 0-72).Verder geldt dat vanwege de lage prevalentie van radiologisch schade bij
de SASSS de ICC toeneemt met als gevolg overschatting van de ICC.
Vanwege deze overwegingen ten aanzien van kappa en ICC hebben we ook concordanties
berekend. De volledige concordantie tussen de twee 'observers' was over het algemeen laag
(2l-76%).Visuele presentatie van de continue data (SASSS scoringsmethoden) door middel
van een Bland and Altman plot geeft ook meer inzicht in de data zeker omdat deze plots
de verdeling van de data met'outliners' over de gehele range van geobserveerde data laat
zien. Deze plots lieten een maximaal verschil van 26 punten (range 0-72) tussen de twee
'observers' zien.
BASRI-s en BASRI-t waren de enige scoringsmethoden die verandering lieten zien bij een
klein aantal patienten na twee jaar follow-up (respectievelijk 7.5% en 7.4%) gebaseerd op
een binomiaal afkappunt. Deze verandering kon niet worden aangetoond met de andere
globale of gedetailleerde scoringsmethoden. De 'observers' kwamen in maximaal 52%
overeen dat er geen verandering in BASRI-s en BASRI-t score plaats vond.Toch moeten we
helaas concluderen dat er zelden sprake was van relevante verandering omdat de
'observers' maar in 7.5% van de patienten overeenstemde dat een significante verandering
van minimaal I graad had plaats gevonden. Dit laatste kan misleidend zijn aangezien de
definitie van I graad verandering een arbitrair afkappunt is. Het berekende kleinste
aantoonbare verschil (SDD) gedefinieerd als afkappunt voor de SASSS scoringsmethoden is
relatief groter. Het afkappunt gebruikt voor de SASSS methoden is dus strenger gedefinieerd
dan het afkappunt (Igraad verandering) gebruikt voor de BASRI methoden. Dit laatste zou
weer een reden kunnen zijn waarom we geen verandering hebben gevonden in SASSS
scores. Een mogelijke andere reden is dat 'observer variatie' of 'observer error' niet te
onderscheiden is van radiologische progressie in onze studie. Het gebruik van binomiale
afkappunten kan betekenen dat men informatie verliest en dat het daardoor niet meer
mogelijk is verschillen aan te tonen. Een andere overweging is dat we een niet geselecteerde
populatie Bechterew patienten gebruikt hebben zonder een gegarandeerde mate van ziekte
activiteit. In een groep Bechterew patienten met een hoge ziekte activiteit zouden de resultaten
wel eens anders kunnen zijn.
In onze studie is de betrouwbaarheid van de radiologische scoringsmethoden bij de ziekte van
Bechterew goed. Helaas waren de scoringsmethoden onder de gegeven scorings condities
(gepaard scoren met onbekende chronologische volgorde, resultaten gebaseerd op
gemiddelde scores van twee 'observers', binomiale afkappunten en een niet geselecteerde
patienten populatie) niet in staat om na twee jaar follow-up bij een groot aantal patienten
radiologische progressie of verandering aan te tonen.
Resume en perspectief
De ASAS we rkg roep is opger ich t vanwege gebrek aan un i fo rm i te i t op het gebied van z iekte-
act iv i tei t en z iek te-u i tkomst in wetenschappel i jke studies me t bet rekk ing t o t de ziekte van Q
Bechterew. Deze we rkg roep heeft verschi l lende domeinen gedef inieerd me t kernpunten •§!
voo r dr ie verschi l lende onderzoekset t ings bij de ziekte van Bechterew ( 'DC-ART ' , 'SM- i
ARDV'physical therapy 'en'clinical reco rd keeping'). In navolging op het w e r k van de ASAS (/)
werkgroep hebben were ldw i j d diverse onderzoeksgroepen de laatste vijf jaar veel w e r k 3
ft
verricht door zich voornamelijk te richten op aspecten van ziekte-activiteit en ziekte- <
uitkomst bij de ziekte van Bechterew. De resultaten in dit proefschrift zijn voor het grootste 3.
deel afkomstig van de gegevens van een groot cohort Bechterew patienten die longitudinaal •*
gevolgd zijn (OASIS). Deze resultaten zijn gericht op aspecten van zowel ziekte-activiteit als _^
ziekte-uitkomst. Hoofdstuk 6 en 7 gaan vooral over uitkomstmaten bij de ziekte van 8
Bechterew waarbij hoofdstuk 6 de ontwikkeling en validatie van een ziekte specifieke 8.
kwaliteit van leven vragenlijst (ASQoL) beschrijft. Hoofdstuk 7 beschrijft de vergelijking van
alle beschikbare radiologische scoringsmethoden bij de ziekte van Bechterew. De resultaten "S
w
van deze studie laten zien dat de methoden betrouwbaar zijn maar dat geen van de _
methoden in staat is bij een groot aantal patienten radiologische verandering aan te tonen w
over een periode van twee jaar. In de nabije toekomst wordt waarschijnlijk duidelijk welke
rol 'Magnetic Resonance Imaging' (MRI) gaat krijgen bij het aantonen van structurele
verandering bij de ziekte van Bechterew. Het is met behulp van de MRI mogelijk om
aspecten van schade en van ziekte-activiteit aan te tonen op het niveau van zowel de SI
gewrichten als van de wervelkolom. Het mogelijke effect van bijvoorbeeld een bekende
chronologische volgorde van rontgenfoto's op het aantonen van radiologische verandering
bij conventionele radiologie wordt nog onderzocht.
Hoofdstuk 2 tot en met 5 beschrijven aspecten van ziekte-activiteit en de resultaten
gepresenteerd in deze hoofdstukken bevestigen dat het meten van ziekte-activiteit bij de
ziekte van Bechterew erg moeilijk blijft. Hoewel wereldwijd veel werk is gedaan, is er nog
steeds geen uniforme maat die alle aspecten van ziekte-activiteit reflecteert. Acute fase
reacties gemeten met CRP en BSE zijn slechts bij een minderheid van de Bechterew
patienten verhoogd.Verder blijkt dat Bechterew patienten en hun behandeld artsen een heel
ander zicht op ziekte-activiteit hebben.Tot nu toe wordt om deze reden ziekte-activiteit
vanuit het patienten perspectief, zoals BASDAI, in combinatie met ziekte-activiteit vanuit het
perspectief van de arts en/of verhoogde CRP gebruikt als 'gouden standaard' voor het
includeren van patienten in klinische trials en voor de besluitvorming random het starten
van antiTNF u therapie in de klinische praktijk. AntiTNF a en andere nieuwe biologische
geneesmiddelen zijn recent beschikbaar gekomen bij de behandeling van de ziekte van
Bechterew en de effecten li/ken veelbelovend. In de toekomst zullen studies die de effecten
van deze potente geneesmiddelen evalueren gebruikt kunnen worden voor validatie en
vergelijking van de door de ASAS geselecteerde meetinstrumenten. Hopelijk leiden de
resultaten van deze studies uiteindelijk naar de ontwikkeling van een uniform en valide
meetinstrument dat alle aspecten van ziekte-activiteit bij de ziekte van Bechterew
reflecteert.
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bedanken voor de fijne samenwerking en hun gezelligheid.
Maarten Boers, jij hebt mij tijdens mijn co-schappen enthousiast gemaakt voor de
reumatologie en het wetenschappelijk onderzoek. Ik heb met heel veel plezier aan ons
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bijzonder ervaren.
Yolanda Soons, wat zouden ze zonder je moeten beginnen? Je was en bent de spil van de
organisatie van de werkgroep reumatologie in Maastricht.
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op je keuze om naast je werk als oncologisch chirurg ook een deel van de tijd voor Emma
en Sterre te zorgen met veel meer geduld dan ikzelf. Deze zorgtaak is binnen de chirurgie
zeker nog geen voor de hand liggende en alom gerespecteerde keuze .
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